No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519870 |
1. Apply sex-specific ruleNone |
519870 |
2. Check conditionsNone |
519870 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
3 out of 7 registries used, show all original rules. |
533 |
4. Check minimum number of eventsNone |
533 |
5. Include endpointsNone |
533 |
6. Filter based on genotype QC (FinnGen only) |
514 |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE
Extra metadata
- First used in FinnGen datafreeze
- DF12
Similar endpoints
↥List of similar endpoints to
Mantle cell lymphoma, including Hilmo
based on the number of shared cases.
Similar with more cases:
- Non-Hodgkin lymphoma, all, including Hilmo
- Primary_lymphoid and hematopoietic malignant neoplasms
- Liquid cancers
- Liquid cancers, including Hilmo
- Malignant neoplasm
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded (different definition than used in FinnGen).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 514 | 147 | 367 |
| Unadjusted period prevalence (%) | 0.14 | 0.05 | 0.17 |
| Median age at first event (years) | 68.62 | 66.60 | 69.43 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 533
- Matched controls
- 5330
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
C83.1
ICD-10 Finland
Mantle cell lymphoma
+∞
307.7
530
*
XW000
NOMESCO Finland
Bone marrow biopsy
83.9
307.7
267
63
WW500
NOMESCO Finland
Blood transfusion
82.3
307.7
198
38
A03FA01
ATC
metoclopramide; systemic, rectal
27.3
307.7
331
302
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
9246.0
307.7
452
*
JN4BD
NOMESCO Finland
Extensive body CT
31.7
304.4
226
121
H02AB02
ATC
dexamethasone; systemic
100.9
290.1
152
21
A04AA01
ATC
ondansetron; systemic, rectal
58.5
289.7
169
42
L03AA02
ATC
filgrastim; parenteral
4292.4
253.1
224
*
JN6AD
NOMESCO Finland
CT of torso and neck
129.3
252.8
128
13
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
244.1
215
*
M04AA01
ATC
allopurinol; systemic
15.5
236.5
341
548
WD405
NOMESCO Finland
Simple antiboidy therapy of methastized malignancy
1720.1
233.6
210
*
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
23.1
227.8
188
123
L03AA13
ATC
pegfilgrastim; parenteral
1563.8
218.8
198
*
R59.0
ICD-10 Finland
Localized enlarged lymph nodes
38.2
182.7
117
39
JN4AD
NOMESCO Finland
Body CT examination
15.5
182.7
189
182
R59.1
ICD-10 Finland
Generalized enlarged lymph nodes
89.8
181.5
96
13
C83.31
ICD-10 Finland
Diffuse lymphoma with large B cells
+∞
163.1
148
*
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
1026.4
160.3
149
*
ZX120
NOMESCO Finland
Intravenous
13.6
146.3
159
162
WD415
NOMESCO Finland
Demanding antibody therapy of methastized malignancy
905.9
145.2
136
*
A04AA02
ATC
granisetron; systemic, transdermal
+∞
139.9
128
*
A49.9
ICD-10 Finland
Bacterial infection, unspecified
9.0
128.4
210
360
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
23.9
126.6
95
48
9673/3-C42.1
ICD-O-3
Mantle cell lymphoma of bone marrow
+∞
119.4
110
*
TPH20
NOMESCO Finland
Insertion of central venous catheter through subclavian or brachiocephalic vein
24.7
111.7
82
39
ZX112
NOMESCO Finland
Subcutaneous
67.5
108.7
60
10
D70.82
ICD-10 Finland
Drug-induced neutropenia
434.7
107.4
104
*
Z51.5
ICD-10 Finland
Palliative care
12.0
106.6
120
126
R50.9
ICD-10 Finland
Fever, unspecified
7.3
105.3
208
428
WZC00
NOMESCO Finland
Treatment plan or consultation
5.9
93.7
284
858
WW300
NOMESCO Finland
Transfer of autologic stem cells
+∞
91.3
85
*
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
10.2
89.9
113
137
D69.6
ICD-10 Finland
Thrombocytopenia, unspecified
20.9
87.0
68
37
WD135
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
81.4
76
*
Z51.1
ICD-10 Finland
Chemotherapy session for neoplasm
+∞
81.4
76
*
PJA10
NOMESCO Finland
Exploration of lymph nodes
185.0
77.4
79
5
1XC02, ,
NOMESCO Finland
156.4
77.3
80
6
EN1BD
NOMESCO Finland
Very extensive CT examination of mouth and soft tissues of neck
37.6
76.4
48
14
XX3DW
NOMESCO Finland
Time consuming IT work
10.0
73.9
92
109
WD115
NOMESCO Finland
Multiple cystostatic therapy of methastized malignancy
+∞
73.7
69
*
DM1AA
NOMESCO Finland
Paranasal sinuses X-ray examination without contrast
13.7
73.5
72
60
L03AA14
ATC
lipegfilgrastim; parenteral
+∞
72.6
68
*
PJD41
NOMESCO Finland
Excision of cervical lymph nodes
101.4
72.2
78
9
C85.9
ICD-10 Finland
Non-Hodgkin lymphoma, unspecified
+∞
71.5
67
*
9673/3-C77.9
ICD-O-3
Mantle cell lymphoma of lymph node, NOS
+∞
71.5
67
*
WF049
NOMESCO Finland
Radiotherapy of metastasis
762.1
69.7
67
*
H02AB06
ATC
prednisolone; systemic
5.2
67.3
391
1853
J05AB11
ATC
valaciclovir; oral
5.4
65.8
164
402
C61
ICD-10 Finland
Malignant neoplasm of prostate
366.2
65.0
64
*
QAE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin in head or neck
9.8
62.2
77
90
J01MA12
ATC
levofloxacin; systemic
4.6
60.0
201
622
C83.9
ICD-10 Finland
Non-follicular (diffuse) lymphoma, unspecified
+∞
59.5
56
*
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
+∞
59.5
56
*
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
5.4
59.2
144
343
Z94.8
ICD-10 Finland
Other transplanted organ and tissue status
634.2
58.9
57
*
TGC00
NOMESCO Finland
Bronchial lavation
11.3
58.7
65
65
N02AA05
ATC
oxycodone; systemic
4.7
57.9
180
524
WF002
NOMESCO Finland
Radical radiotherapy
216.4
57.2
58
*
212
Kela drug reimbursment
Gout
11.4
56.5
62
61
9673/3-C77.8
ICD-O-3
Mantle cell lymphoma of lymph nodes of multiple regions
+∞
51.9
49
*
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
183.5
48.8
50
*
8090/3-C44.9
ICD-O-3
Basal cell carcinoma, NOS, of skin, NOS
+∞
48.7
46
*
JN6BD
NOMESCO Finland
Extensive CT of torso and neck
112.6
47.7
51
5
390
Kela drug reimbursment
Ibrutinib
+∞
47.6
45
*
WF004
NOMESCO Finland
Palliative radiotherapy
+∞
46.5
44
*
C85.1
ICD-10 Finland
B-cell lymphoma, unspecified
+∞
46.5
44
*
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
8.1
46.4
66
91
TNE25
NOMESCO Finland
Drill biopsy of bone marrow, pelvis
65.2
46.3
53
9
WZC30
NOMESCO Finland
Teaching
4.5
45.2
136
379
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
6.2
43.7
82
152
C44.31
ICD-10 Finland
Basocellular carcinoma of the skin on another or unspecified part of the face
87.8
43.7
48
6
R59.9
ICD-10 Finland
Enlarged lymph nodes, unspecified
58.4
41.2
48
9
C83.00
ICD-10 Finland
Lymphocytic lymphoma
+∞
40.1
38
*
TPX10
NOMESCO Finland
Implantation of vascular injection port
11.6
39.6
42
39
C82.1
ICD-10 Finland
Follicular lymphoma grade II
+∞
39.0
37
*
WD305
NOMESCO Finland
Simple therapy of methastized malignancy with biomodifiers
+∞
39.0
37
*
WW409
NOMESCO Finland
Other aferesis
+∞
39.0
37
*
1512
Kela drug reimbursment
Ibrutinib
+∞
39.0
37
*
UGC12
NOMESCO Finland
Flexible bronchoscopy
5.2
38.8
90
202
XZZ00
NOMESCO Finland
Active surveillance of a diagnosed cancer
393.5
37.5
37
*
PJD45
NOMESCO Finland
Excision of inguinal lymph nodes
393.5
37.5
37
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.3
37.0
356
2027
PJ2AT
NOMESCO Finland
Biopsy of lymphnode with ultrasound guidance
198.4
36.2
37
*
L01EL01
ATC
ibrutinib; oral
+∞
35.8
34
*
116
Kela drug reimbursment
Prostate cancer
+∞
34.8
33
*
JN4CD
NOMESCO Finland
Very extensive body CT
12.4
34.6
35
30
EP1AE
NOMESCO Finland
Neck ultrasound examination
6.9
34.5
56
89
WW402
NOMESCO Finland
Leucoferesis
+∞
32.6
31
*
C83.39
ICD-10 Finland
Diffuse non-Hodgkin's large cell lymphoma UNS
+∞
32.6
31
*
L01AA02
ATC
chlorambucil; oral
+∞
32.6
31
*
ZX108
NOMESCO Finland
Inhalation
46.6
32.3
39
9
JN4JR
NOMESCO Finland
Whole body extensive metabolic PET with CT
117.0
31.0
33
*
WF003
NOMESCO Finland
Adjuvant radiotherapy
+∞
30.5
29
*
A02BC02
ATC
pantoprazole; systemic
3.4
30.2
424
2845
D70.89
ICD-10 Finland
Neutropenic splenomegaly
53.3
29.7
35
7
WW200
NOMESCO Finland
Immunization
8.8
29.5
38
46
YNB10
NOMESCO Finland
Collection of stem cells for transplant
+∞
29.4
28
*
C83.3
ICD-10 Finland
Diffuse large B-cell lymphoma
+∞
28.4
27
*
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.7
27.8
233
1177
H02AB07
ATC
prednisone; oral
3.4
27.7
118
409
B01AB10
ATC
tinzaparin; parenteral
4.1
27.2
83
229
R91
ICD-10 Finland
Abnormal findings on diagnostic imaging of lung
3.7
26.3
94
290
C81.1
ICD-10 Finland
Nodular sclerosis classical Hodgkin lymphoma
+∞
26.3
25
*
R22.1
ICD-10 Finland
Localized swelling, mass and lump, neck
6.7
26.1
43
69
C91.1
ICD-10 Finland
Chronic lymphocytic leukaemia of B-cell type
98.4
25.9
28
*
PJ2AE
NOMESCO Finland
Lymphnode ultrasound examination
98.4
25.9
28
*
JN5DR
NOMESCO Finland
PET-CT of upper body metabolism
52.8
25.5
30
6
130
Kela drug reimbursment
Malignant tumour
+∞
25.2
24
*
C83.80
ICD-10 Finland
B-cell lymphoma in marginal zone
+∞
25.2
24
*
L02AE02
ATC
leuprorelin; implant, parenteral
73.6
25.0
28
*
J01MA14
ATC
moxifloxacin; systemic
3.8
25.0
85
253
GD1AD
NOMESCO Finland
Thorax CT examination
4.5
25.0
66
163
R06AE07
ATC
cetirizine; oral
2.6
24.6
238
1274
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
4.3
23.5
65
166
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.8
23.3
158
707
D69.5
ICD-10 Finland
Secondary thrombocytopenia
+∞
23.1
22
*
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
3.9
22.8
72
203
9680/3-C77.9
ICD-O-3
Diffuse large B-cell lymphoma, NOS, of lymph node, NOS
+∞
22.0
21
*
A04AA55
ATC
palonosetron, combinations; systemic
+∞
22.0
21
*
C83.01
ICD-10 Finland
Lymphoplasmacytic lymphoma
+∞
22.0
21
*
9673/3-C09.9
ICD-O-3
Mantle cell lymphoma of tonsil, NOS
+∞
22.0
21
*
D64.9
ICD-10 Finland
Anaemia, unspecified
3.1
22.0
110
416
YL1AD
NOMESCO Finland
CT examination of pelvis for dose design of radiotherapy
229.0
21.8
22
*
A07AA02
ATC
nystatin; oral
4.3
21.6
59
149
L02BB03
ATC
bicalutamide; oral
+∞
21.0
20
*
C44.51
ICD-10 Finland
Basocellular carcinoma of the skin on the torso
80.1
20.8
23
*
TDM10
NOMESCO Finland
Puncture of maxillary antrum
5.7
20.7
40
75
WD505
NOMESCO Finland
Simple enzyme inhibitor or similar therapy of methastized malignancy
+∞
19.9
19
*
1AA09, ,
NOMESCO Finland
+∞
19.9
19
*
J17.3*B59
ICD-10 Finland
Pneumonia due to Pneumocystis carinii
41.8
19.7
24
6
L01XE27
ATC
[U] ibrutinib
+∞
18.9
18
*
PJD42
NOMESCO Finland
Excision of axillary lymph nodes
103.7
18.7
20
*
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
3.8
18.2
59
169
HA1AA
NOMESCO Finland
X-ray mammography
7.0
18.0
28
42
ZX090
NOMESCO Finland
Other technic of radiotherapy
69.0
17.8
20
*
B72
ICPC
Hodgkin Lymphoma
+∞
17.8
17
*
C82.9
ICD-10 Finland
Follicular lymphoma, unspecified
+∞
17.8
17
*
WB113
NOMESCO Finland
Multiple adjuvant cytostatic therapy
+∞
17.8
17
*
QX2XE
NOMESCO Finland
Ultrsound examination of soft tissue not elsewhere classified
6.1
17.6
31
53
Y77
ICPC
Malignant neoplasm prostate
185.9
17.6
18
*
EMB10
NOMESCO Finland
Tonsillectomy
6.3
17.0
29
48
C83.89
ICD-10 Finland
Other types of diffuse non-Hodgkin's lymphoma
+∞
16.8
16
*
C81.9
ICD-10 Finland
Hodgkin lymphoma, unspecified
175.3
16.6
17
*
EMA10
NOMESCO Finland
Biopsy of tonsil
175.3
16.6
17
*
R22.0
ICD-10 Finland
Localized swelling, mass and lump, head
5.6
16.1
31
58
YL1BD
NOMESCO Finland
Extensive CT examination of pelvis for dose design of radiotherapy
+∞
15.7
15
*
YA1AD
NOMESCO Finland
CT examination of head and neck for dose design of radiotherapy
+∞
15.7
15
*
YNB00
NOMESCO Finland
Excision of bone marrow for transplantation
+∞
15.7
15
*
ZX070
NOMESCO Finland
Intensity modified radiotherapy
+∞
15.7
15
*
XX9CD
NOMESCO Finland
Very extensive complementary CT
+∞
15.7
15
*
PJA12
NOMESCO Finland
Sentinel node biopsy
+∞
15.7
15
*
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
+∞
15.7
15
*
EN1AD
NOMESCO Finland
CT examination of mouth and soft tissues of neck
20.0
15.7
23
12
TK800
NOMESCO Finland
Hemodialysis
6.5
15.6
26
42
J05AB01
ATC
aciclovir; systemic
2.4
15.6
132
643
YX9AD
NOMESCO Finland
Other CT eamination for dose design of radiotherapy
164.6
15.6
16
*
AA1BD
NOMESCO Finland
Extensive CT of head and brain
7.2
15.4
23
33
D72.8
ICD-10 Finland
Other specified disorders of white blood cells
24.2
15.2
21
9
A41.9
ICD-10 Finland
Sepsis, unspecified
4.3
15.2
40
98
NEA10
NOMESCO Finland
Exploration of soft tissue of pelvis, percutaneous
46.4
15.1
18
*
WX110
NOMESCO Finland
Infiltration anesthesia
2.1
14.8
366
2692
WZB00
NOMESCO Finland
Telephone prescription or other care instructions
2.2
14.8
154
818
GD1BD
NOMESCO Finland
Thorax extensive CT-examination
4.0
14.7
43
114
C44.32
ICD-10 Finland
Spinocellular carcinoma of the skin on another or unspecified part of the face
+∞
14.6
14
*
9591/3-C77.9
ICD-O-3
Malignant lymphoma, non-Hodgkin, NOS, of lymph node, NOS
+∞
14.6
14
*
Z51.0
ICD-10 Finland
Radiotherapy session
+∞
14.6
14
*
ZX080
NOMESCO Finland
Image guided radiotherapy
+∞
14.6
14
*
B02.9
ICD-10 Finland
Zoster without complication
3.2
14.5
63
217
ZXE00
NOMESCO Finland
One hour or less
2.1
14.3
217
1329
A04AD12
ATC
aprepitant; systemic
+∞
13.6
13
*
XW4XT
NOMESCO Finland
Biopsy of other inner organ with radiological guidance guidance
+∞
13.6
13
*
A79
ICPC
Malignancy NOS
143.5
13.5
14
*
J01CR02
ATC
amoxicillin and beta-lactamase inhibitor; systemic
2.0
13.5
274
1851
A41.8
ICD-10 Finland
Other specified sepsis
5.8
13.5
25
45
J01DB01
ATC
cefalexin; oral
2.4
13.4
437
3504
WZC10
NOMESCO Finland
Written specialist consultation based on a referral from a dentist or a physician
4.2
13.3
36
90
L57.0
ICD-10 Finland
Actinic keratosis
2.9
13.3
69
263
B01AB05
ATC
enoxaparin; parenteral
2.1
13.3
178
1036
WX408
NOMESCO Finland
General anesthesy, balanced
2.2
13.2
140
744
JN3AD
NOMESCO Finland
Abdominal CT examination
2.7
13.1
80
332
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
5.8
13.0
24
43
Z52.89
ICD-10 Finland
Donor of other organ or tissue
+∞
12.5
12
*
C81.3
ICD-10 Finland
Lymphocyte depleted classical Hodgkin lymphoma
+∞
12.5
12
*
C67.8
ICD-10 Finland
Malignant neoplasm: Overlapping lesion of bladder
+∞
12.5
12
*
115
Kela drug reimbursment
Breast cancer
+∞
12.5
12
*
YG1BD
NOMESCO Finland
Extensive CT examination of thorax for dose design of radiotherapy
133.0
12.5
13
*
ZXC50
NOMESCO Finland
Cryotherapy
5.3
12.3
25
49
EBA10
NOMESCO Finland
Operative extraction of tooth
2.9
12.2
63
239
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
2.1
12.0
142
785
TQW99
NOMESCO Finland
Other minor procedure on skin
4.0
11.9
35
93
QBE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin of trunk
4.0
11.9
35
93
XGX32
NOMESCO Finland
Bronchoscopic ultrasonography
47.8
11.9
14
*
TPH90
NOMESCO Finland
Removal of fixed intravenous catheter
15.1
11.9
19
13
EB1HA
NOMESCO Finland
Panorama tomography of teeth and jaws or similar X-ray examination
1.9
11.7
216
1393
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
2.6
11.7
77
331
ZXM00
NOMESCO Finland
Intraoperative use of ultrasonographic imaging
19.5
11.7
17
9
WB401
NOMESCO Finland
Simple antibody therapy of primary tumour
+∞
11.5
11
*
YG1AD
NOMESCO Finland
CT examination of thorax for dose design of radiotherapy
+∞
11.5
11
*
WD315
NOMESCO Finland
Multiple therapy of methastized malignancy with biomodifiers
+∞
11.5
11
*
WD325
NOMESCO Finland
Demanding therapy of methastized malignancy with biomodifiers
+∞
11.5
11
*
8090/3-C44.3
ICD-O-3
Basal cell carcinoma, NOS, of skin of other and unspecified parts of face
+∞
11.5
11
*
L01BC06
ATC
capecitabine; oral
+∞
11.5
11
*
WF029
NOMESCO Finland
Radiotherapy of local residive tumor
+∞
11.5
11
*
9680/3-C77.8
ICD-O-3
Diffuse large B-cell lymphoma, NOS, of lymph nodes of multiple regions
+∞
11.5
11
*
UJF32
NOMESCO Finland
Coloscopy
2.0
11.5
153
882
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.0
11.4
176
1068
127
Kela drug reimbursment
Transplant complication
13.1
11.2
19
15
GD1ED
NOMESCO Finland
Extensive high resolution CT examination of lungs
4.3
11.2
29
70
H02AB09
ATC
hydrocortisone; systemic
8.3
11.2
24
30
PH1AE
NOMESCO Finland
Ultrasound examination of upper extremity veins
8.9
11.1
23
27
TPH04
NOMESCO Finland
Cathetrisation of vein
2.1
11.0
134
746
J90
ICD-10 Finland
Pleural effusion, not elsewhere classified
3.9
10.9
32
85
J35.1
ICD-10 Finland
Hypertrophy of tonsils
15.9
10.9
17
11
J01MA02
ATC
ciprofloxacin; systemic
1.9
10.9
226
1507
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
5.1
10.8
23
47
ZZR00
NOMESCO Finland
Flap of skin
28.7
10.8
14
5
R50.8
ICD-10 Finland
Other specified fever
22.0
10.7
15
7
C03CA01
ATC
furosemide; systemic
1.9
10.7
221
1470
KE1AT
NOMESCO Finland
Biopsy of prostata with ultrasoudnguidance
4.2
10.5
28
69
HA1AE
NOMESCO Finland
Ultrasound examination of mammary glands
8.0
10.5
23
30
QDE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin in lower limb
5.6
10.5
20
37
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
1.9
10.5
173
1069
C50.41
ICD-10 Finland
Malignant tumor of the upper outer quadrant of the mammary gland, ductal tumor
+∞
10.4
10
*
C83.2
ICD-10 Finland
Mixed small and large cell (diffuse) non-Hodgkin's lymphoma
+∞
10.4
10
*
1CX01, ,
NOMESCO Finland
+∞
10.4
10
*
YA1BD
NOMESCO Finland
Extensive CT examination of head and neck for dose design of radiotherapy
+∞
10.4
10
*
KE3AT
NOMESCO Finland
Transrectal gold marker implantation in prostate under ultrasound guidance
+∞
10.4
10
*
C82.2
ICD-10 Finland
Follicular lymphoma grade III, unspecified
+∞
10.4
10
*
166
Kela drug reimbursment
Dalteparin and tinzaparin (treatment for more than 6 months)
+∞
10.4
10
*
C83.33
ICD-10 Finland
Primary medical lymphoma with large B cells
+∞
10.4
10
*
C82.00
ICD-10 Finland
Follicular nodular non-Hodgkin's lymphoma, ungraded
+∞
10.4
10
*
B03XA02
ATC
darbepoetin alfa; parenteral
7.7
10.3
23
31
DM1AI
NOMESCO Finland
Cone beam CT of paranasal sinus
5.4
10.2
20
38
ZXE10
NOMESCO Finland
More than one and less than three hours
1.9
10.0
190
1224
JN3BD
NOMESCO Finland
Extensive abdominal CT
2.6
9.9
58
235
TGD00
NOMESCO Finland
Needle biopsy of lung
101.8
9.4
10
*
ED1AA
NOMESCO Finland
Mandibular X-ray examination
30.6
9.4
12
*
D47.9
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour of lymphoid, haematopoietic and related tissue, unspecified
30.6
9.4
12
*
JN5JR
NOMESCO Finland
Extensive PET-CT of upper body metabolism (eyebrows to thighs)
30.6
9.4
12
*
FM1FN
NOMESCO Finland
Heart function isotope examination
+∞
9.4
9
*
2008X
ICD-9 Finland
Lymphosarcoma and reticulosarcoma, Other named variants
+∞
9.4
9
*
9673/3-C80.9
ICD-O-3
Mantle cell lymphoma of unknown primary site
+∞
9.4
9
*
C88.0
ICD-10 Finland
Waldenström macroglobulinaemia
+∞
9.4
9
*
9823/3-C42.1
ICD-O-3
B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma of bone marrow
+∞
9.4
9
*
8070/3-C44.9
ICD-O-3
Squamous cell carcinoma, NOS, of skin, NOS
+∞
9.4
9
*
OAA41
NOMESCO Finland
Health check based on individual needs
+∞
9.4
9
*
C83.0
ICD-10 Finland
Small cell B-cell lymphoma
+∞
9.4
9
*
GD1CT
NOMESCO Finland
Biopsy of the lung with CT guidance
22.2
9.4
13
6
A05AA02
ATC
ursodeoxycholic acid; oral
10.9
9.3
17
16
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
1.9
9.3
169
1069
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
2.2
9.2
80
388
U07.1
ICD-10 Finland
Emergency use of U07.1 | COVID-19, virus identified
2.2
9.2
89
451
B01AB04
ATC
dalteparin; parenteral
3.5
9.2
32
96
B99
ICD-10 Finland
Other and unspecified infectious diseases
4.7
9.1
21
46
D48.5
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Skin
3.2
9.0
35
113
QAA05
NOMESCO Finland
Incision for biopsy of skin of head or neck
8.2
8.9
19
24
N05CF01
ATC
zopiclone; oral
1.8
8.9
183
1201
FM1DE
NOMESCO Finland
Doppler ultrasound examination of heart
2.3
8.8
70
327
R16.1
ICD-10 Finland
Splenomegaly, not elsewhere classified
50.8
8.7
10
*
TPJ00
NOMESCO Finland
Biopsy of superficial lymph node
50.8
8.7
10
*
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
2.6
8.7
50
201
JN6DR
NOMESCO Finland
PET-CT of whole body metabolism
16.6
8.6
13
8
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
3.4
8.5
31
96
Z08.7
ICD-10 Finland
Follow-up examination after combined treatment for malignant neoplasm
91.5
8.4
9
*
D80.1
ICD-10 Finland
Nonfamilial hypogammaglobulinaemia
91.5
8.4
9
*
J01.0
ICD-10 Finland
Acute maxillary sinusitis
2.0
8.4
105
586
WE300
NOMESCO Finland
Profylactive therapy of malignancy with biomoidiers
+∞
8.4
8
*
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
+∞
8.4
8
*
8120/3-C67.9
ICD-O-3
Transitional cell carcinoma, NOS, of bladder, NOS
+∞
8.4
8
*
D80.8
ICD-10 Finland
Other immunodeficiencies with predominantly antibody defects
+∞
8.4
8
*
GEA20
NOMESCO Finland
Mediastinoscopy with excision of lesion
+∞
8.4
8
*
C91.9
ICD-10 Finland
Lymphoid leukaemia, unspecified
+∞
8.4
8
*
Z85.7
ICD-10 Finland
Personal history of other malignant neoplasms of lymphoid, haematopoietic and related tissues
+∞
8.4
8
*
C85.7
ICD-10 Finland
Other specified types of non-Hodgkin lymphoma
+∞
8.4
8
*
C82.01
ICD-10 Finland
Follicular nodular lymphoma, grade I
+∞
8.4
8
*
C88.9
ICD-10 Finland
Malignant immunoproliferative disease, unspecified
+∞
8.4
8
*
Z2221
NOMESCO Finland
Medical doctor
1.9
8.2
134
815
L04.0
ICD-10 Finland
Acute lymphadenitis of face, head and neck
14.8
8.2
13
9
SPAT1153
SPAT
Removal of sutures
1.8
8.2
169
1106
NK6AN
NOMESCO Finland
Total body bone isotope imaging
33.9
8.1
10
*
TPX15
NOMESCO Finland
Removal of vascular injection port
33.9
8.1
10
*
D10.4
ICD-10 Finland
Benign neoplasm: Tonsil
33.9
8.1
10
*
ZXD10
NOMESCO Finland
Scheduled procedure
1.7
8.1
193
1314
JJ2AT
NOMESCO Finland
Biopsy of liver with ultrasound guidance
10.3
8.1
15
15
ZXE30
NOMESCO Finland
More than five and less than seven hours
3.5
8.0
28
84
TAB00
NOMESCO Finland
Lumbar puncture
3.2
8.0
32
105
Z3231
NOMESCO Finland
Registered nurse
1.8
8.0
140
871
J02AC01
ATC
fluconazole; systemic
1.8
8.0
153
978
KA1AE
NOMESCO Finland
Kidney ultrasound examination
4.5
8.0
19
43
N02BE01
ATC
paracetamol; systemic, rectal
2.1
7.9
467
4092
Z03.1
ICD-10 Finland
Observation for suspected malignant neoplasm
8.6
7.9
16
19
QBA25
NOMESCO Finland
Destruction of lesion of skin of trunk
15.3
7.7
12
8
KCD02
NOMESCO Finland
Transurethral resection of bladder
15.3
7.7
12
8
C44.41
ICD-10 Finland
Basocellular carcinoma of the skin of the scalp and neck
45.7
7.7
9
*
B00.2
ICD-10 Finland
Herpesviral gingivostomatitis and pharyngotonsillitis
25.4
7.6
10
*
XX1AD
NOMESCO Finland
Other CT-examination
81.2
7.4
8
*
B74
ICPC
Malignant neoplasm blood other
+∞
7.3
7
*
PJD52
NOMESCO Finland
Block dissection of axillary lymph nodes
+∞
7.3
7
*
C83.59
ICD-10 Finland
Lymphoblastic lymphoma of indeterminate type
+∞
7.3
7
*
WB123
NOMESCO Finland
Demanding adjuvant cytostatic therapy
+∞
7.3
7
*
KEC00
NOMESCO Finland
Retropubic radical prostatectomy
+∞
7.3
7
*
C64.88
ICD-10 Finland
Other malignant neoplasm of kidney, except renal pelvis
+∞
7.3
7
*
C38.1
ICD-10 Finland
Malignant neoplasm: Anterior mediastinum
+∞
7.3
7
*
C78.7
ICD-10 Finland
Secondary malignant neoplasm of liver and intrahepatic bile duct
+∞
7.3
7
*
C90.0
ICD-10 Finland
Multiple myeloma
+∞
7.3
7
*
C44.61
ICD-10 Finland
Basocellular carcinoma of the skin of the upper extremity including the shoulder
+∞
7.3
7
*
HAC20
NOMESCO Finland
Total mastectomy
+∞
7.3
7
*
YN1AD
NOMESCO Finland
CT examination of extremities for dose design of radiotherapy
+∞
7.3
7
*
YX9AW, ,
NOMESCO Finland
+∞
7.3
7
*
R05
ICD-10 Finland
Cough
1.9
7.3
113
675
N02AX02
ATC
tramadol; systemic, rectal
1.6
7.2
227
1655
CBA10
NOMESCO Finland
Biopsy of eyelid
20.3
7.2
10
5
TPW99
NOMESCO Finland
Other minor surgical procedure on peripheral vessel or lymphatic system
8.1
7.1
15
19
J12.8
ICD-10 Finland
Other viral pneumonia
12.2
7.1
12
10
JN1DG
NOMESCO Finland
Very extensive MRI examination of upper part of abdomen with high intensity magnet
7.1
7.0
16
23
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
2.5
6.9
45
192
A04.7
ICD-10 Finland
Enterocolitis due to Clostridium difficile
3.5
6.9
23
67
I80.8
ICD-10 Finland
Phlebitis and thrombophlebitis of other sites
6.8
6.9
16
24
QXA25
NOMESCO Finland
Destruction of lesion of skin, site unspecified
4.4
6.8
17
40
N03AX16
ATC
[U] pregabalin
1.8
6.7
115
706
J01CA04
ATC
amoxicillin; systemic
1.7
6.7
399
3382
QX3HE
NOMESCO Finland
Ultrsound examination of lesion close to skin
7.0
6.6
15
22
UDH02
NOMESCO Finland
Rhinopharyngoscopy
2.5
6.5
40
166
T86.0
ICD-10 Finland
Bone-marrow transplant rejection
70.7
6.4
7
*
J06BA01
ATC
immunoglobulins, normal human, for extravascular adm.; systemic
70.7
6.4
7
*
JN4ED
NOMESCO Finland
Body CT examination with specail preparation
70.7
6.4
7
*
GA4YT
NOMESCO Finland
Puncture of pleura with ultrasound guidance
3.2
6.4
25
81
J32.0
ICD-10 Finland
Chronic maxillary sinusitis
2.5
6.4
41
174
UJF34
NOMESCO Finland
Left colonoscopy
18.3
6.3
9
5
C83.35
ICD-10 Finland
T-cell-rich B-cell lymphoma
+∞
6.3
6
*
9673/3-C16.9
ICD-O-3
Mantle cell lymphoma of stomach, NOS
+∞
6.3
6
*
C95.9
ICD-10 Finland
Leukaemia, unspecified
+∞
6.3
6
*
OAB38
NOMESCO Finland
Psychosocial guidance and counselling
+∞
6.3
6
*
L01CB01
ATC
etoposide; systemic
+∞
6.3
6
*
YJ1AD
NOMESCO Finland
CT examination of abdomen for dose design of radiotherapy
+∞
6.3
6
*
8500/3-C50.9
ICD-O-3
Infiltrating duct carcinoma, NOS, of breast, NOS
+∞
6.3
6
*
AAG00
NOMESCO Finland
Stereotactic intracranial biopsy
+∞
6.3
6
*
R59
ICD-10 Finland
Enlarged lymph nodes
+∞
6.3
6
*
C43.52
ICD-10 Finland
Malignant melanoma on the torso: 'superficial spreading' type
+∞
6.3
6
*
JAH21
NOMESCO Finland
Staging laparoscopy
+∞
6.3
6
*
9673/3-C77.3
ICD-O-3
Mantle cell lymphoma of lymph nodes of axilla or arm
+∞
6.3
6
*
Z51.3
ICD-10 Finland
Blood transfusion (without reported diagnosis)
+∞
6.3
6
*
3AA13, ,
NOMESCO Finland
+∞
6.3
6
*
8090/3-C44.5
ICD-O-3
Basal cell carcinoma, NOS, of skin of trunk
+∞
6.3
6
*
C81.0
ICD-10 Finland
Nodular lymphocyte predominant Hodgkin lymphoma
+∞
6.3
6
*
ZX050
NOMESCO Finland
Stereotactic radiotherapy
+∞
6.3
6
*
6BA02, ,
NOMESCO Finland
+∞
6.3
6
*
9673/3-C77.0
ICD-O-3
Mantle cell lymphoma of lymph nodes of head, face and neck
+∞
6.3
6
*
YX9BD
NOMESCO Finland
Other extensive CT eamination for dose design of radiotherapy
+∞
6.3
6
*
C18.00
ICD-10 Finland
Malignant tumor of the caecum without histology
+∞
6.3
6
*
9673/3-C77.4
ICD-O-3
Mantle cell lymphoma of lymph nodes of inguinal region or leg
+∞
6.3
6
*
C44.39
ICD-10 Finland
Malignant tumor of the skin on another or unspecified part of the face other or unspecified histology
+∞
6.3
6
*
D37.1
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Stomach
27.0
6.2
8
*
UKC02
NOMESCO Finland
Cystoscopy
1.8
6.2
96
571
AA1CD
NOMESCO Finland
Very extensive CT of head and brain
7.8
6.2
13
17
WX402
NOMESCO Finland
General anaesthesia
1.8
6.1
96
573
A41.5
ICD-10 Finland
Sepsis due to other Gram-negative organisms
3.0
6.1
27
94
J35.0
ICD-10 Finland
Chronic tonsillitis
4.2
6.1
16
39
G53.0
ICD-10 Finland
Postzoster neuralgia
12.7
6.1
10
8
R4110
NOMESCO Finland
Physiotherapy
1.7
6.0
136
902
TimeCodeWAS
↥TODO / Current known limitations:
- Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
- Legend / how to read the glyphs.
- Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
- Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
- Download CSV.
- No filters and sorters.
- Limited amount of endpoints (~400) having TimeCodeWAS data.
- Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Hematology
82 [38004501]
82 [38004501]
2.5e+00
3.8e+00
5.3e+00
1.0e+50
—
5.2e+00
4.6e+00
cases:7.13%
controls:0.60%
cases:13.51%
controls:0.34%
cases:15.57%
controls:0.09%
cases:14.26%
controls:0.00%
—
—
cases:41.72%
controls:0.38%
cases:36.05%
controls:0.58%
38
32
495
5298
72
18
461
5312
83
5
450
5325
76
0
457
5330
—
204
20
285
5175
137
26
243
4456
Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction
14804-9 [3022250]
14804-9 [3022250]
1.2e+00
2.4e+00
5.1e+00
1.0e+50
—
4.1e+00
3.1e+00
cases:4.32%
controls:1.39%
cases:8.44%
controls:0.83%
cases:15.76%
controls:0.11%
cases:3.75%
controls:0.00%
—
—
cases:32.92%
controls:0.85%
cases:38.16%
controls:2.77%
23
74
510
5256
45
44
488
5286
84
6
449
5324
20
0
513
5330
—
161
44
328
5151
145
124
235
4358
sulfamethoxazole and trimethoprim
J01EE01 [21602961]
J01EE01 [21602961]
2.0e+00
3.9e+00
—
—
1.0e+50
6.1e+00
3.7e+00
cases:2.25%
controls:0.32%
cases:5.44%
controls:0.11%
—
—
—
—
cases:10.65%
controls:0.00%
cases:44.38%
controls:0.17%
cases:22.89%
controls:0.71%
12
17
521
5313
29
6
504
5324
—
—
56
0
470
5315
217
9
272
5186
87
32
293
4450
Outpatient Visit
OP [9202]
OP [9202]
2.3e-01
8.3e-01
2.0e+00
4.4e+00
2.6e+00
2.9e+00
3.0e+00
cases:77.49%
controls:73.15%
cases:72.80%
controls:53.79%
cases:46.15%
controls:10.71%
cases:34.71%
controls:0.64%
cases:60.08%
controls:10.50%
cases:95.50%
controls:53.09%
cases:98.95%
controls:81.99%
413
3899
120
1431
388
2867
145
2463
246
571
287
4759
185
34
348
5296
316
558
210
4757
467
2758
22
2437
376
3675
4
807
Extensive body CT
JN4BD [2001310899]
JN4BD [2001310899]
2.1e+00
3.2e+00
1.0e+50
1.0e+50
1.0e+50
5.5e+00
4.8e+00
cases:3.38%
controls:0.43%
cases:4.13%
controls:0.17%
cases:4.69%
controls:0.00%
cases:1.50%
controls:0.00%
cases:6.46%
controls:0.00%
cases:24.95%
controls:0.13%
cases:29.47%
controls:0.36%
18
23
515
5307
22
9
511
5321
25
0
508
5330
8
0
525
5330
34
0
492
5315
122
7
367
5188
112
16
268
4466
Myelocytes/Leukocytes in Blood
26498-6 [3017181]
26498-6 [3017181]
9.0e-01
2.2e+00
3.7e+00
—
4.2e+00
3.3e+00
2.1e+00
cases:1.88%
controls:0.77%
cases:4.32%
controls:0.51%
cases:5.25%
controls:0.13%
—
—
cases:7.79%
controls:0.13%
cases:18.81%
controls:0.81%
cases:16.84%
controls:2.52%
10
41
523
5289
23
27
510
5303
28
7
505
5323
—
41
7
485
5308
92
42
397
5153
64
113
316
4369
Promyelocytes/Leukocytes in Blood
26524-9 [3021440]
26524-9 [3021440]
9.3e-01
2.1e+00
3.6e+00
—
4.0e+00
3.2e+00
2.1e+00
cases:1.88%
controls:0.75%
cases:3.94%
controls:0.51%
cases:4.50%
controls:0.13%
—
—
cases:6.46%
controls:0.13%
cases:16.97%
controls:0.81%
cases:16.05%
controls:2.39%
10
40
523
5290
21
27
512
5303
24
7
509
5323
—
34
7
492
5308
83
42
406
5153
61
107
319
4375
Metamyelocytes/Leukocytes in Blood
28541-1 [3002179]
28541-1 [3002179]
8.5e-01
2.1e+00
3.7e+00
—
3.9e+00
3.1e+00
2.1e+00
cases:1.69%
controls:0.73%
cases:3.56%
controls:0.43%
cases:4.88%
controls:0.13%
—
—
cases:5.89%
controls:0.13%
cases:14.11%
controls:0.71%
cases:15.79%
controls:2.30%
9
39
524
5291
19
23
514
5307
26
7
507
5323
—
31
7
495
5308
69
37
420
5158
60
103
320
4379
Blasts/Leukocytes in Blood
26446-5 [3025159]
26446-5 [3025159]
1.0e+00
1.9e+00
3.7e+00
—
3.9e+00
2.7e+00
2.0e+00
cases:1.88%
controls:0.68%
cases:3.19%
controls:0.51%
cases:5.07%
controls:0.13%
—
—
cases:5.89%
controls:0.13%
cases:11.04%
controls:0.85%
cases:15.00%
controls:2.37%
10
36
523
5294
17
27
516
5303
27
7
506
5323
—
31
7
495
5308
54
44
435
5151
57
106
323
4376
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
14631-6 [3006140]
2.6e-01
1.4e+00
3.7e+00
—
4.2e+00
2.8e+00
1.8e+00
cases:10.69%
controls:8.48%
cases:15.76%
controls:4.58%
cases:19.51%
controls:0.58%
—
—
cases:35.55%
controls:0.81%
cases:46.22%
controls:5.20%
cases:54.21%
controls:16.09%
57
452
476
4878
84
244
449
5086
104
31
429
5299
—
187
43
339
5272
226
270
263
4925
206
721
174
3761
Oncology Clinic/Center
261QX0200X [38004268]
261QX0200X [38004268]
4.7e+00
5.2e+00
1.0e+50
1.0e+50
—
—
3.7e+00
cases:15.20%
controls:0.17%
cases:16.89%
controls:0.11%
cases:5.44%
controls:0.00%
cases:56.29%
controls:0.00%
—
—
—
—
cases:14.74%
controls:0.42%
81
9
452
5321
90
6
443
5324
29
0
504
5330
300
0
233
5330
—
—
56
19
324
4463
CBC W Ordered Manual Differential panel - Blood
57782-5 [40760892]
57782-5 [40760892]
5.7e-01
1.8e+00
3.4e+00
1.0e+50
4.0e+00
2.3e+00
1.8e+00
cases:5.63%
controls:3.26%
cases:10.51%
controls:1.84%
cases:10.69%
controls:0.41%
cases:3.38%
controls:0.00%
cases:15.21%
controls:0.34%
cases:19.02%
controls:2.35%
cases:27.89%
controls:6.09%
30
174
503
5156
56
98
477
5232
57
22
476
5308
18
0
515
5330
80
18
446
5297
93
122
396
5073
106
273
274
4209
Urate [Moles/volume] in Serum or Plasma
14933-6 [3026493]
14933-6 [3026493]
1.4e-01
9.7e-01
3.7e+00
—
4.9e+00
2.5e+00
1.1e+00
cases:7.13%
controls:6.23%
cases:7.13%
controls:2.81%
cases:9.19%
controls:0.24%
—
—
cases:27.95%
controls:0.28%
cases:26.79%
controls:2.96%
cases:22.37%
controls:8.84%
38
332
495
4998
38
150
495
5180
49
13
484
5317
—
147
15
379
5300
131
154
358
5041
85
396
295
4086
Differential panel, method unspecified - Blood
69738-3 [42870588]
69738-3 [42870588]
1.7e-01
1.2e+00
3.6e+00
—
3.7e+00
2.5e+00
1.7e+00
cases:6.75%
controls:5.74%
cases:11.44%
controls:3.68%
cases:14.82%
controls:0.45%
—
—
cases:21.48%
controls:0.66%
cases:30.67%
controls:3.48%
cases:37.63%
controls:9.64%
36
306
497
5024
61
196
472
5134
79
24
454
5306
—
113
35
413
5280
150
181
339
5014
143
432
237
4050
Monocytes/Leukocytes in Blood
26485-3 [3019069]
26485-3 [3019069]
1.6e-01
1.2e+00
3.5e+00
—
3.7e+00
2.5e+00
1.9e+00
cases:10.32%
controls:8.95%
cases:15.95%
controls:5.29%
cases:20.64%
controls:0.79%
—
—
cases:28.33%
controls:1.02%
cases:41.92%
controls:5.37%
cases:52.11%
controls:14.30%
55
477
478
4853
85
282
448
5048
110
42
423
5288
—
149
54
377
5261
205
279
284
4916
198
641
182
3841
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
26450-7 [3006504]
1.9e-01
1.2e+00
3.5e+00
—
3.6e+00
2.5e+00
1.8e+00
cases:10.51%
controls:8.87%
cases:16.14%
controls:5.31%
cases:20.08%
controls:0.79%
—
—
cases:27.95%
controls:1.02%
cases:41.51%
controls:5.39%
cases:51.32%
controls:14.39%
56
473
477
4857
86
283
447
5047
107
42
426
5288
—
147
54
379
5261
203
280
286
4915
195
645
185
3837
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
26478-8 [3002030]
1.8e-01
1.2e+00
3.5e+00
—
3.6e+00
2.5e+00
1.8e+00
cases:10.51%
controls:8.93%
cases:16.14%
controls:5.38%
cases:20.64%
controls:0.79%
—
—
cases:28.33%
controls:1.05%
cases:41.72%
controls:5.58%
cases:52.37%
controls:14.77%
56
476
477
4854
86
287
447
5043
110
42
423
5288
—
149
56
377
5259
204
290
285
4905
199
662
181
3820
Basophils/Leukocytes in Blood
30180-4 [3022096]
30180-4 [3022096]
1.5e-01
1.2e+00
3.4e+00
—
3.6e+00
2.5e+00
1.8e+00
cases:10.13%
controls:8.87%
cases:15.95%
controls:5.31%
cases:19.51%
controls:0.81%
—
—
cases:27.57%
controls:1.02%
cases:41.10%
controls:5.41%
cases:51.05%
controls:14.35%
54
473
479
4857
85
283
448
5047
104
43
429
5287
—
145
54
381
5261
201
281
288
4914
194
643
186
3839
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Blood
47598-8 [3048816]
47598-8 [3048816]
7.7e-01
1.6e+00
3.2e+00
—
3.9e+00
2.4e+00
1.4e+00
cases:2.44%
controls:1.14%
cases:3.00%
controls:0.64%
cases:2.25%
controls:0.09%
—
—
cases:4.56%
controls:0.09%
cases:6.95%
controls:0.69%
cases:8.68%
controls:2.21%
13
61
520
5269
16
34
517
5296
12
5
521
5325
—
24
5
502
5310
34
36
455
5159
33
99
347
4383
Medical Oncology
90 [38004507]
90 [38004507]
4.9e+00
—
—
1.0e+50
1.0e+50
—
7.5e+00
cases:11.44%
controls:0.09%
—
—
—
—
cases:17.82%
controls:0.00%
cases:49.05%
controls:0.00%
—
—
cases:70.79%
controls:0.13%
61
5
472
5325
—
—
95
0
438
5330
258
0
268
5315
—
269
6
111
4476
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
751-8 [3013650]
2.5e-01
1.1e+00
3.1e+00
—
3.6e+00
2.6e+00
2.0e+00
cases:13.32%
controls:10.66%
cases:17.82%
controls:6.55%
cases:20.26%
controls:1.18%
—
—
cases:34.03%
controls:1.39%
cases:48.06%
controls:6.74%
cases:59.74%
controls:16.82%
71
568
462
4762
95
349
438
4981
108
63
425
5267
—
179
74
347
5241
235
350
254
4845
227
754
153
3728
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
4537-7 [3013707]
-9.5e-02
9.9e-01
2.9e+00
3.0e+00
3.2e+00
1.2e+00
9.8e-01
cases:16.70%
controls:18.07%
cases:22.89%
controls:9.96%
cases:19.14%
controls:1.28%
cases:1.88%
controls:0.09%
cases:25.48%
controls:1.39%
cases:28.02%
controls:10.64%
cases:49.74%
controls:27.02%
89
963
444
4367
122
531
411
4799
102
68
431
5262
10
5
523
5325
134
74
392
5241
137
553
352
4642
189
1211
191
3271
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
26511-6 [3018010]
1.7e-01
1.1e+00
3.3e+00
—
3.5e+00
2.4e+00
1.8e+00
cases:10.32%
controls:8.86%
cases:14.45%
controls:5.29%
cases:18.20%
controls:0.81%
—
—
cases:24.52%
controls:0.96%
cases:38.65%
controls:5.33%
cases:50.79%
controls:14.50%
55
472
478
4858
77
282
456
5048
97
43
436
5287
—
129
51
397
5264
189
277
300
4918
193
650
187
3832
Body CT examination
JN4AD [2001310897]
JN4AD [2001310897]
2.1e+00
3.1e+00
1.0e+50
—
1.0e+50
3.8e+00
3.2e+00
cases:2.25%
controls:0.28%
cases:3.19%
controls:0.15%
cases:3.19%
controls:0.00%
—
—
cases:2.47%
controls:0.00%
cases:10.63%
controls:0.27%
cases:18.16%
controls:0.94%
12
15
521
5315
17
8
516
5322
17
0
516
5330
—
13
0
513
5315
52
14
437
5181
69
42
311
4440
Monocytes [#/volume] in Blood
26484-6 [3001604]
26484-6 [3001604]
1.1e-01
1.2e+00
3.2e+00
—
3.5e+00
2.3e+00
1.9e+00
cases:10.32%
controls:9.36%
cases:16.32%
controls:5.74%
cases:17.26%
controls:0.84%
—
—
cases:26.43%
controls:1.05%
cases:40.08%
controls:6.01%
cases:53.95%
controls:15.48%
55
499
478
4831
87
306
446
5024
92
45
441
5285
—
139
56
387
5259
196
312
293
4883
205
694
175
3788
Eosinophils [#/volume] in Blood
26449-9 [3013115]
26449-9 [3013115]
1.1e-01
1.1e+00
3.3e+00
—
3.6e+00
2.3e+00
1.8e+00
cases:11.26%
controls:10.23%
cases:16.32%
controls:6.06%
cases:18.39%
controls:0.86%
—
—
cases:28.14%
controls:1.09%
cases:40.70%
controls:6.26%
cases:54.21%
controls:16.04%
60
545
473
4785
87
323
446
5007
98
46
435
5284
—
148
58
378
5257
199
325
290
4870
206
719
174
3763
Immunohistochemistry procedure
117617002 [4035726]
117617002 [4035726]
1.4e+00
2.5e+00
—
1.0e+50
—
4.7e+00
3.5e+00
cases:2.25%
controls:0.54%
cases:2.63%
controls:0.23%
—
—
cases:15.76%
controls:0.00%
—
—
cases:10.84%
controls:0.12%
cases:11.32%
controls:0.40%
12
29
521
5301
14
12
519
5318
—
84
0
449
5330
—
53
6
436
5189
43
18
337
4464
Basophils [#/volume] in Blood
26444-0 [3006315]
26444-0 [3006315]
1.1e-01
1.2e+00
3.2e+00
—
3.5e+00
2.3e+00
1.9e+00
cases:10.51%
controls:9.53%
cases:16.51%
controls:5.78%
cases:16.89%
controls:0.86%
—
—
cases:26.05%
controls:1.05%
cases:40.08%
controls:6.04%
cases:53.95%
controls:15.55%
56
508
477
4822
88
308
445
5022
90
46
443
5284
—
137
56
389
5259
196
314
293
4881
205
697
175
3785
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
26474-7 [3019198]
1.5e-01
1.1e+00
3.2e+00
—
3.5e+00
2.3e+00
1.8e+00
cases:11.26%
controls:9.83%
cases:16.70%
controls:5.98%
cases:17.82%
controls:0.88%
—
—
cases:27.00%
controls:1.09%
cases:39.88%
controls:6.20%
cases:54.21%
controls:16.09%
60
524
473
4806
89
319
444
5011
95
47
438
5283
—
142
58
384
5257
195
322
294
4873
206
721
174
3761
Teaching
WZC30 [2001310891]
WZC30 [2001310891]
4.5e-01
1.4e+00
2.5e+00
—
4.0e+00
2.2e+00
1.8e+00
cases:2.25%
controls:1.44%
cases:2.06%
controls:0.53%
cases:1.31%
controls:0.11%
—
—
cases:4.75%
controls:0.09%
cases:6.34%
controls:0.71%
cases:11.32%
controls:2.05%
12
77
521
5253
11
28
522
5302
7
6
526
5324
—
25
5
501
5310
31
37
458
5158
43
92
337
4390
Supplier / Service Provider
OMOP5117446 [33004]
OMOP5117446 [33004]
-4.4e-01
-5.1e-01
1.2e+00
—
4.0e+00
3.9e+00
3.2e+00
cases:14.63%
controls:21.03%
cases:4.50%
controls:7.28%
cases:2.63%
controls:0.81%
—
—
cases:4.75%
controls:0.09%
cases:17.59%
controls:0.42%
cases:22.37%
controls:1.20%
78
1121
455
4209
24
388
509
4942
14
43
519
5287
—
25
5
501
5310
86
22
403
5173
85
54
295
4428
metoclopramide; oral, parenteral, rectal
A03FA01 [21600484]
A03FA01 [21600484]
1.6e+00
3.1e+00
—
—
—
4.6e+00
2.5e+00
cases:6.57%
controls:1.44%
cases:8.82%
controls:0.45%
—
—
—
—
—
—
cases:31.70%
controls:0.46%
cases:17.63%
controls:1.70%
35
77
498
5253
47
24
486
5306
—
—
—
155
24
334
5171
67
76
313
4406
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
1988-5 [3020460]
-6.3e-02
6.5e-01
2.5e+00
3.2e+00
2.8e+00
1.4e+00
7.6e-01
cases:27.39%
controls:28.67%
cases:31.52%
controls:19.44%
cases:30.58%
controls:3.58%
cases:9.38%
controls:0.41%
cases:38.59%
controls:3.52%
cases:51.94%
controls:21.12%
cases:63.42%
controls:44.71%
146
1528
387
3802
168
1036
365
4294
163
191
370
5139
50
22
483
5308
203
187
323
5128
254
1097
235
4098
241
2004
139
2478
ABO and Rh group [Type] in Blood
882-1 [3003694]
882-1 [3003694]
-1.1e-01
1.3e+00
4.0e+00
—
4.0e+00
2.0e+00
2.4e-01
cases:3.19%
controls:3.55%
cases:5.07%
controls:1.41%
cases:4.88%
controls:0.09%
—
—
cases:6.46%
controls:0.13%
cases:8.79%
controls:1.23%
cases:6.58%
controls:5.24%
17
189
516
5141
27
75
506
5255
26
5
507
5325
—
34
7
492
5308
43
64
446
5131
25
235
355
4247
Medical doctor
Z2221 [2001311556]
Z2221 [2001311556]
3.0e-01
1.0e+00
2.4e+00
—
3.5e+00
2.5e+00
1.8e+00
cases:6.38%
controls:4.80%
cases:3.38%
controls:1.22%
cases:2.06%
controls:0.19%
—
—
cases:4.75%
controls:0.15%
cases:10.02%
controls:0.94%
cases:11.58%
controls:2.10%
34
256
499
5074
18
65
515
5265
11
10
522
5320
—
25
8
501
5307
49
49
440
5146
44
94
336
4388
Thorax X-ray examination
GD1AA [2001303617]
GD1AA [2001303617]
3.3e-01
1.3e+00
2.8e+00
—
2.8e+00
2.7e+00
1.6e+00
cases:13.13%
controls:9.79%
cases:11.26%
controls:3.49%
cases:5.44%
controls:0.36%
—
—
cases:6.08%
controls:0.40%
cases:33.95%
controls:3.33%
cases:38.95%
controls:11.42%
70
522
463
4808
60
186
473
5144
29
19
504
5311
—
32
21
494
5294
166
173
323
5022
148
512
232
3970
Bacterial infection, unspecified
A49.9 [45590816]
A49.9 [45590816]
7.4e-01
2.1e+00
—
—
3.2e+00
3.7e+00
2.1e+00
cases:2.06%
controls:0.99%
cases:3.00%
controls:0.39%
—
—
—
—
cases:2.28%
controls:0.09%
cases:21.27%
controls:0.65%
cases:12.63%
controls:1.81%
11
53
522
5277
16
21
517
5309
—
—
12
5
514
5310
104
34
385
5161
48
81
332
4401
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
6768-6 [3035995]
1.8e-01
9.1e-01
3.1e+00
—
3.5e+00
2.1e+00
1.4e+00
cases:19.70%
controls:17.07%
cases:22.33%
controls:10.38%
cases:25.33%
controls:1.46%
—
—
cases:36.50%
controls:1.69%
cases:48.88%
controls:10.80%
cases:61.05%
controls:27.78%
105
910
428
4420
119
553
414
4777
135
78
398
5252
—
192
90
334
5225
239
561
250
4634
232
1245
148
3237
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
1751-7 [3024561]
5.7e-02
9.3e-01
2.7e+00
—
4.0e+00
2.2e+00
1.1e+00
cases:8.82%
controls:8.37%
cases:11.63%
controls:4.92%
cases:10.88%
controls:0.84%
—
—
cases:27.76%
controls:0.68%
cases:32.92%
controls:5.02%
cases:31.84%
controls:13.54%
47
446
486
4884
62
262
471
5068
58
45
475
5285
—
146
36
380
5279
161
261
328
4934
121
607
259
3875
Outpatient Hospital
22 [8756]
22 [8756]
2.6e-01
1.1e+00
2.9e+00
—
3.4e+00
2.5e+00
1.0e+00
cases:31.89%
controls:26.60%
cases:21.01%
controls:7.95%
cases:14.45%
controls:0.96%
—
—
cases:22.24%
controls:0.94%
cases:45.81%
controls:6.49%
cases:36.32%
controls:17.02%
170
1418
363
3912
112
424
421
4906
77
51
456
5279
—
117
50
409
5265
224
337
265
4858
138
763
242
3719
pH of Serum or Plasma
2753-2 [3018418]
2753-2 [3018418]
2.2e-02
9.6e-01
3.2e+00
1.0e+50
3.2e+00
2.3e+00
1.1e+00
cases:5.44%
controls:5.33%
cases:7.50%
controls:3.02%
cases:7.32%
controls:0.32%
cases:1.69%
controls:0.00%
cases:11.60%
controls:0.51%
cases:22.90%
controls:2.91%
cases:24.47%
controls:9.37%
29
284
504
5046
40
161
493
5169
39
17
494
5313
9
0
524
5330
61
27
465
5288
112
151
377
5044
93
420
287
4062
Otolaryngology
4 [38004449]
4 [38004449]
4.6e-01
1.2e+00
3.2e+00
—
3.2e+00
1.4e+00
1.4e+00
cases:17.26%
controls:11.61%
cases:12.57%
controls:4.24%
cases:13.32%
controls:0.62%
—
—
cases:14.07%
controls:0.70%
cases:14.52%
controls:3.95%
cases:36.05%
controls:12.41%
92
619
441
4711
67
226
466
5104
71
33
462
5297
—
74
37
452
5278
71
205
418
4990
137
556
243
3926
Blood type and Crossmatch panel - Blood
34531-4 [3044640]
34531-4 [3044640]
2.7e-02
1.1e+00
2.8e+00
1.0e+50
3.4e+00
2.4e+00
1.1e+00
cases:5.25%
controls:5.12%
cases:6.19%
controls:2.18%
cases:5.82%
controls:0.36%
cases:2.25%
controls:0.00%
cases:5.70%
controls:0.21%
cases:19.63%
controls:2.25%
cases:17.89%
controls:7.03%
28
273
505
5057
33
116
500
5214
31
19
502
5311
12
0
521
5330
30
11
496
5304
96
117
393
5078
68
315
312
4167
Blood group antibody screen [Presence] in Serum or Plasma
890-4 [3001079]
890-4 [3001079]
3.3e-02
1.0e+00
3.2e+00
—
3.5e+00
2.2e+00
7.3e-01
cases:7.50%
controls:7.28%
cases:8.82%
controls:3.40%
cases:8.63%
controls:0.39%
—
—
cases:9.89%
controls:0.34%
cases:23.31%
controls:3.33%
cases:20.53%
controls:11.02%
40
388
493
4942
47
181
486
5149
46
21
487
5309
—
52
18
474
5297
114
173
375
5022
78
494
302
3988
Office Visit
OMOP4822458 [581477]
OMOP4822458 [581477]
4.5e-01
1.4e+00
2.6e+00
1.0e+50
2.9e+00
2.4e+00
1.3e+00
cases:12.38%
controls:8.24%
cases:8.63%
controls:2.36%
cases:4.32%
controls:0.34%
cases:1.50%
controls:0.00%
cases:6.84%
controls:0.40%
cases:17.79%
controls:1.96%
cases:20.00%
controls:6.34%
66
439
467
4891
46
126
487
5204
23
18
510
5312
8
0
525
5330
36
21
490
5294
87
102
402
5093
76
284
304
4198
Calcium [Moles/volume] corrected for albumin in Serum or Plasma
29265-6 [3020059]
29265-6 [3020059]
-4.1e-01
5.8e-01
2.9e+00
—
4.3e+00
2.3e+00
1.0e+00
cases:2.06%
controls:3.08%
cases:3.19%
controls:1.82%
cases:3.19%
controls:0.19%
—
—
cases:12.17%
controls:0.19%
cases:15.75%
controls:1.75%
cases:12.89%
controls:5.00%
11
164
522
5166
17
97
516
5233
17
10
516
5320
—
64
10
462
5305
77
91
412
5104
49
224
331
4258
ABO and Rh group [Type] in Blood by Confirmatory method
77397-8 [46236098]
77397-8 [46236098]
9.9e-02
9.9e-01
2.9e+00
—
3.2e+00
2.3e+00
1.1e+00
cases:3.94%
controls:3.58%
cases:3.94%
controls:1.50%
cases:4.69%
controls:0.28%
—
—
cases:4.18%
controls:0.17%
cases:14.52%
controls:1.75%
cases:14.47%
controls:5.11%
21
191
512
5139
21
80
512
5250
25
15
508
5315
—
22
9
504
5306
71
91
418
5104
55
229
325
4253
Reticulocytes/Erythrocytes in Blood
4679-7 [3027945]
4679-7 [3027945]
4.5e-01
2.2e+00
4.1e+00
1.0e+50
—
2.8e+00
1.4e+00
cases:2.81%
controls:1.82%
cases:6.00%
controls:0.73%
cases:7.69%
controls:0.13%
cases:3.94%
controls:0.00%
—
—
cases:15.34%
controls:1.14%
cases:14.47%
controls:3.95%
15
97
518
5233
32
39
501
5291
41
7
492
5323
21
0
512
5330
—
75
59
414
5136
55
177
325
4305
Inpatient Visit
IP [9201]
IP [9201]
3.1e-01
1.1e+00
2.3e+00
1.0e+50
4.0e+00
2.3e+00
6.5e-01
cases:5.82%
controls:4.32%
cases:6.75%
controls:2.27%
cases:2.81%
controls:0.30%
cases:3.94%
controls:0.00%
cases:11.41%
controls:0.23%
cases:20.25%
controls:2.39%
cases:17.11%
controls:9.71%
31
230
502
5100
36
121
497
5209
15
16
518
5314
21
0
512
5330
60
12
466
5303
99
124
390
5071
65
435
315
4047
Reticulocytes [#/volume] in Blood
14196-0 [3023520]
14196-0 [3023520]
4.7e-01
2.0e+00
3.9e+00
1.0e+50
—
2.9e+00
1.5e+00
cases:2.06%
controls:1.29%
cases:4.50%
controls:0.62%
cases:5.25%
controls:0.11%
cases:3.38%
controls:0.00%
—
—
cases:13.29%
controls:0.81%
cases:12.11%
controls:2.95%
11
69
522
5261
24
33
509
5297
28
6
505
5324
18
0
515
5330
—
65
42
424
5153
46
132
334
4350
Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]
2601-3 [3012095]
-3.0e-02
1.1e+00
—
—
4.6e+00
3.0e+00
1.7e+00
cases:1.88%
controls:1.93%
cases:3.00%
controls:1.07%
—
—
—
—
cases:8.94%
controls:0.09%
cases:21.68%
controls:1.39%
cases:16.58%
controls:3.64%
10
103
523
5227
16
57
517
5273
—
—
47
5
479
5310
106
72
383
5123
63
163
317
4319
Inpatient Hospital
21 [8717]
21 [8717]
8.2e-02
9.9e-01
2.6e+00
—
3.4e+00
2.3e+00
1.0e+00
cases:35.65%
controls:33.79%
cases:25.89%
controls:11.46%
cases:18.57%
controls:1.73%
—
—
cases:33.46%
controls:1.60%
cases:55.62%
controls:10.90%
cases:45.53%
controls:23.29%
190
1801
343
3529
138
611
395
4719
99
92
434
5238
—
176
85
350
5230
272
566
217
4629
173
1044
207
3438
Short blood count panel - Blood
55429-5 [40758558]
55429-5 [40758558]
3.5e-01
9.1e-01
2.8e+00
1.0e+50
3.2e+00
2.0e+00
1.4e+00
cases:5.63%
controls:4.02%
cases:6.57%
controls:2.74%
cases:6.75%
controls:0.45%
cases:2.44%
controls:0.00%
cases:11.41%
controls:0.51%
cases:17.79%
controls:2.79%
cases:22.89%
controls:6.89%
30
214
503
5116
35
146
498
5184
36
24
497
5306
13
0
520
5330
60
27
466
5288
87
145
402
5050
87
309
293
4173
Calcium [Moles/volume] in Serum or Plasma
2000-8 [3015377]
2000-8 [3015377]
-1.4e-01
5.7e-01
2.6e+00
—
4.1e+00
2.3e+00
1.2e+00
cases:4.69%
controls:5.35%
cases:5.07%
controls:2.93%
cases:6.00%
controls:0.47%
—
—
cases:14.26%
controls:0.26%
cases:24.74%
controls:3.12%
cases:22.89%
controls:8.48%
25
285
508
5045
27
156
506
5174
32
25
501
5305
—
75
14
451
5301
121
162
368
5033
87
380
293
4102
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
19072-8 [3016431]
3.6e-02
9.5e-01
2.8e+00
—
3.5e+00
2.0e+00
9.7e-01
cases:9.94%
controls:9.62%
cases:13.32%
controls:5.63%
cases:12.01%
controls:0.81%
—
—
cases:19.96%
controls:0.77%
cases:31.90%
controls:5.81%
cases:36.05%
controls:17.60%
53
513
480
4817
71
300
462
5030
64
43
469
5287
—
105
41
421
5274
156
302
333
4893
137
789
243
3693
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
1995-0 [3021347]
2.1e-02
8.1e-01
3.0e+00
1.0e+50
3.3e+00
2.1e+00
1.0e+00
cases:8.82%
controls:8.65%
cases:10.69%
controls:5.05%
cases:10.51%
controls:0.60%
cases:3.19%
controls:0.00%
cases:17.11%
controls:0.73%
cases:28.83%
controls:4.79%
cases:32.63%
controls:14.66%
47
461
486
4869
57
269
476
5061
56
32
477
5298
17
0
516
5330
90
39
436
5276
141
249
348
4946
124
657
256
3825
prednisone; oral
H02AB07 [21602735]
H02AB07 [21602735]
6.9e-01
1.1e+00
2.5e+00
—
3.4e+00
2.8e+00
1.4e+00
cases:3.75%
controls:1.91%
cases:2.25%
controls:0.75%
cases:1.31%
controls:0.11%
—
—
cases:3.99%
controls:0.13%
cases:9.82%
controls:0.67%
cases:5.26%
controls:1.36%
20
102
513
5228
12
40
521
5290
7
6
526
5324
—
21
7
505
5308
48
35
441
5160
20
61
360
4421
prednisone
A07EA03 [21600655]
A07EA03 [21600655]
6.9e-01
1.1e+00
2.5e+00
—
3.4e+00
2.8e+00
1.4e+00
cases:3.75%
controls:1.91%
cases:2.25%
controls:0.75%
cases:1.31%
controls:0.11%
—
—
cases:3.99%
controls:0.13%
cases:9.82%
controls:0.67%
cases:5.26%
controls:1.36%
20
102
513
5228
12
40
521
5290
7
6
526
5324
—
21
7
505
5308
48
35
441
5160
20
61
360
4421
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
30385-9 [3002385]
8.3e-02
3.5e-01
2.2e+00
3.7e+00
2.4e+00
9.1e-01
5.3e-01
cases:24.58%
controls:23.08%
cases:25.70%
controls:19.55%
cases:26.83%
controls:4.07%
cases:11.07%
controls:0.30%
cases:30.99%
controls:3.93%
cases:40.08%
controls:21.14%
cases:52.11%
controls:38.96%
131
1230
402
4100
137
1042
396
4288
143
217
390
5113
59
16
474
5314
163
209
363
5106
196
1098
293
4097
198
1746
182
2736
enoxaparin; parenteral
B01AB05 [21600976]
B01AB05 [21600976]
3.1e-01
9.8e-01
2.7e+00
—
3.3e+00
2.1e+00
9.2e-01
cases:6.38%
controls:4.75%
cases:3.38%
controls:1.29%
cases:2.25%
controls:0.15%
—
—
cases:4.37%
controls:0.17%
cases:11.45%
controls:1.58%
cases:10.79%
controls:4.62%
34
253
499
5077
18
69
515
5261
12
8
521
5322
—
23
9
503
5306
56
82
433
5113
41
207
339
4275
Chloride [Moles/volume] in Serum or Plasma
2075-0 [3014576]
2075-0 [3014576]
3.5e-01
1.3e+00
2.6e+00
1.0e+50
2.9e+00
2.3e+00
7.7e-01
cases:2.44%
controls:1.73%
cases:3.00%
controls:0.81%
cases:1.50%
controls:0.11%
cases:0.94%
controls:0.00%
cases:2.09%
controls:0.11%
cases:8.79%
controls:0.94%
cases:9.47%
controls:4.62%
13
92
520
5238
16
43
517
5287
8
6
525
5324
5
0
528
5330
11
6
515
5309
43
49
446
5146
36
207
344
4275
Intravenous
ZX120 [2001311495]
ZX120 [2001311495]
9.0e-01
2.6e+00
—
1.0e+50
—
4.3e+00
3.0e+00
cases:1.88%
controls:0.77%
cases:3.56%
controls:0.28%
—
—
cases:1.31%
controls:0.00%
—
—
cases:19.22%
controls:0.31%
cases:13.42%
controls:0.74%
10
41
523
5289
19
15
514
5315
—
7
0
526
5330
—
94
16
395
5179
51
33
329
4449
IgG [Mass/volume] in Serum or Plasma
2465-3 [3005719]
2465-3 [3005719]
1.3e+00
2.4e+00
—
—
1.0e+50
3.2e+00
3.0e+00
cases:2.06%
controls:0.58%
cases:3.56%
controls:0.34%
—
—
—
—
cases:9.51%
controls:0.00%
cases:11.04%
controls:0.48%
cases:22.89%
controls:1.49%
11
31
522
5299
19
18
514
5312
—
—
50
0
476
5315
54
25
435
5170
87
67
293
4415
Bacteria identified in Blood by Culture
600-7 [3023368]
600-7 [3023368]
-1.5e-01
8.3e-01
2.7e+00
—
2.7e+00
2.4e+00
1.3e+00
cases:4.13%
controls:4.77%
cases:5.44%
controls:2.46%
cases:3.75%
controls:0.26%
—
—
cases:5.70%
controls:0.41%
cases:26.38%
controls:3.21%
cases:27.37%
controls:9.50%
22
254
511
5076
29
131
504
5199
20
14
513
5316
—
30
22
496
5293
129
167
360
5028
104
426
276
4056
Esophagoscopy, gastroscopy and duodenoscopy
UJD10 [2001304788]
UJD10 [2001304788]
-1.2e-01
8.6e-01
3.5e+00
—
3.1e+00
1.9e+00
1.4e+00
cases:4.32%
controls:4.86%
cases:3.38%
controls:1.46%
cases:3.00%
controls:0.09%
—
—
cases:2.47%
controls:0.11%
cases:7.57%
controls:1.25%
cases:15.00%
controls:4.28%
23
259
510
5071
18
78
515
5252
16
5
517
5325
—
13
6
513
5309
37
65
452
5130
57
192
323
4290
One hour or less
ZXE00 [2001311394]
ZXE00 [2001311394]
7.3e-01
6.2e-01
2.5e+00
1.0e+50
2.7e+00
2.8e+00
1.2e+00
cases:11.44%
controls:5.85%
cases:3.00%
controls:1.63%
cases:2.63%
controls:0.23%
cases:4.32%
controls:0.00%
cases:2.09%
controls:0.15%
cases:14.72%
controls:1.08%
cases:10.00%
controls:3.37%
61
312
472
5018
16
87
517
5243
14
12
519
5318
23
0
510
5330
11
8
515
5307
72
56
417
5139
38
151
342
4331
Internal Medicine
11 [38004456]
11 [38004456]
3.8e-03
1.1e+00
2.7e+00
—
2.7e+00
2.1e+00
9.9e-01
cases:26.64%
controls:26.57%
cases:25.33%
controls:9.98%
cases:17.82%
controls:1.44%
—
—
cases:16.92%
controls:1.34%
cases:47.65%
controls:9.86%
cases:44.47%
controls:22.98%
142
1416
391
3914
135
532
398
4798
95
77
438
5253
—
89
71
437
5244
233
512
256
4683
169
1030
211
3452
Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection
40987-0 [3043924]
40987-0 [3043924]
-1.7e-02
1.3e+00
2.3e+00
—
2.2e+00
2.5e+00
1.3e+00
cases:1.13%
controls:1.14%
cases:2.44%
controls:0.68%
cases:1.31%
controls:0.13%
—
—
cases:1.90%
controls:0.21%
cases:12.47%
controls:1.15%
cases:14.21%
controls:4.46%
6
61
527
5269
13
36
520
5294
7
7
526
5323
—
10
11
516
5304
61
60
428
5135
54
200
326
4282
Tissue Pathology biopsy report
66121-5 [40768804]
66121-5 [40768804]
6.0e-01
1.0e+00
2.6e+00
—
2.6e+00
1.5e+00
1.2e+00
cases:9.38%
controls:5.38%
cases:5.82%
controls:2.16%
cases:2.06%
controls:0.15%
—
—
cases:3.23%
controls:0.24%
cases:7.57%
controls:1.83%
cases:18.68%
controls:6.27%
50
287
483
5043
31
115
502
5215
11
8
522
5322
—
17
13
509
5302
37
95
452
5100
71
281
309
4201
allopurinol; oral, parenteral
M04AA01 [21604131]
M04AA01 [21604131]
5.8e-01
1.3e+00
1.3e+00
—
3.5e+00
2.3e+00
1.2e+00
cases:7.13%
controls:4.11%
cases:11.44%
controls:3.26%
cases:3.00%
controls:0.86%
—
—
cases:23.00%
controls:0.92%
cases:27.20%
controls:3.70%
cases:15.26%
controls:5.13%
38
219
495
5111
61
174
472
5156
16
46
517
5284
—
121
49
405
5266
133
192
356
5003
58
230
322
4252
oxycodone; oral, parenteral
N02AA05 [21604260]
N02AA05 [21604260]
4.3e-01
1.3e+00
2.2e+00
—
2.3e+00
2.7e+00
1.0e+00
cases:2.06%
controls:1.35%
cases:3.56%
controls:0.96%
cases:2.25%
controls:0.26%
—
—
cases:3.23%
controls:0.34%
cases:11.86%
controls:0.92%
cases:8.42%
controls:3.21%
11
72
522
5258
19
51
514
5279
12
14
521
5316
—
17
18
509
5297
58
48
431
5147
32
144
348
4338
prednisolone; oral, parenteral
H02AB06 [21602734]
H02AB06 [21602734]
2.8e-01
1.1e+00
1.7e+00
—
3.1e+00
2.3e+00
1.2e+00
cases:15.38%
controls:12.08%
cases:14.82%
controls:5.59%
cases:6.00%
controls:1.16%
—
—
cases:17.49%
controls:0.94%
cases:35.58%
controls:5.00%
cases:31.32%
controls:12.27%
82
644
451
4686
79
298
454
5032
32
62
501
5268
—
92
50
434
5265
174
260
315
4935
119
550
261
3932
prednisolone
A07EA01 [21600653]
A07EA01 [21600653]
2.9e-01
1.1e+00
1.7e+00
—
3.1e+00
2.3e+00
1.2e+00
cases:15.57%
controls:12.12%
cases:15.01%
controls:5.59%
cases:6.00%
controls:1.16%
—
—
cases:17.49%
controls:0.94%
cases:35.58%
controls:5.08%
cases:31.32%
controls:12.29%
83
646
450
4684
80
298
453
5032
32
62
501
5268
—
92
50
434
5265
174
264
315
4931
119
551
261
3931
Normoblasts [#/volume] in Blood
715-3 [3021589]
715-3 [3021589]
2.2e-01
8.9e-01
2.8e+00
—
2.9e+00
1.6e+00
1.2e+00
cases:8.82%
controls:7.22%
cases:13.32%
controls:5.93%
cases:15.76%
controls:1.16%
—
—
cases:19.77%
controls:1.32%
cases:26.58%
controls:6.58%
cases:37.11%
controls:15.48%
47
385
486
4945
71
316
462
5014
84
62
449
5268
—
104
70
422
5245
130
342
359
4853
141
694
239
3788
Localized enlarged lymph nodes
R59.0 [45534459]
R59.0 [45534459]
2.5e+00
3.9e+00
—
1.0e+50
1.0e+50
—
2.9e+00
cases:1.13%
controls:0.09%
cases:4.50%
controls:0.09%
—
—
cases:8.07%
controls:0.00%
cases:6.27%
controls:0.00%
—
—
cases:2.89%
controls:0.16%
6
5
527
5325
24
5
509
5325
—
43
0
490
5330
33
0
493
5315
—
11
7
369
4475
Fever, unspecified
R50.9 [45582716]
R50.9 [45582716]
1.0e+00
2.4e+00
—
—
—
3.8e+00
2.2e+00
cases:3.19%
controls:1.20%
cases:3.38%
controls:0.32%
—
—
—
—
—
—
cases:18.20%
controls:0.52%
cases:17.37%
controls:2.28%
17
64
516
5266
18
17
515
5313
—
—
—
89
27
400
5168
66
102
314
4380
levofloxacin; inhalant, oral, parenteral
J01MA12 [21603019]
J01MA12 [21603019]
5.8e-01
1.7e+00
2.5e+00
—
—
3.3e+00
1.8e+00
cases:4.32%
controls:2.46%
cases:3.56%
controls:0.68%
cases:1.31%
controls:0.11%
—
—
—
—
cases:16.77%
controls:0.77%
cases:15.26%
controls:2.83%
23
131
510
5199
19
36
514
5294
7
6
526
5324
—
—
82
40
407
5155
58
127
322
4355
Upper gastrointestinal surgery
106 [44777669]
106 [44777669]
2.4e-01
1.3e+00
3.2e+00
—
2.7e+00
1.2e+00
8.2e-01
cases:10.88%
controls:8.76%
cases:9.76%
controls:3.00%
cases:8.44%
controls:0.38%
—
—
cases:8.17%
controls:0.62%
cases:9.82%
controls:3.10%
cases:18.68%
controls:9.17%
58
467
475
4863
52
160
481
5170
45
20
488
5310
—
43
33
483
5282
48
161
441
5034
71
411
309
4071
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
1742-6 [3006923]
2.8e-02
3.6e-01
2.2e+00
3.0e+00
2.6e+00
9.6e-01
2.7e-01
cases:35.27%
controls:34.63%
cases:34.71%
controls:26.98%
cases:27.20%
controls:4.02%
cases:5.63%
controls:0.28%
cases:37.83%
controls:4.37%
cases:50.72%
controls:28.33%
cases:62.11%
controls:55.47%
188
1846
345
3484
185
1438
348
3892
145
214
388
5116
30
15
503
5315
199
232
327
5083
248
1472
241
3723
236
2486
144
1996
Hepatitis B virus core Ab [Presence] in Serum
16933-4 [3021879]
16933-4 [3021879]
1.1e+00
2.7e+00
—
1.0e+50
1.0e+50
4.3e+00
2.1e+00
cases:1.50%
controls:0.49%
cases:3.56%
controls:0.24%
—
—
cases:1.50%
controls:0.00%
cases:20.91%
controls:0.00%
cases:18.00%
controls:0.31%
cases:7.37%
controls:1.00%
8
26
525
5304
19
13
514
5317
—
8
0
525
5330
110
0
416
5315
88
16
401
5179
28
45
352
4437
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
62238-1 [40764999]
5.3e-02
3.4e-01
2.1e+00
3.2e+00
2.4e+00
8.8e-01
4.7e-01
cases:23.64%
controls:22.70%
cases:27.02%
controls:20.79%
cases:26.45%
controls:4.22%
cases:7.69%
controls:0.34%
cases:31.94%
controls:4.21%
cases:41.10%
controls:22.48%
cases:54.74%
controls:43.04%
126
1210
407
4120
144
1108
389
4222
141
225
392
5105
41
18
492
5312
168
224
358
5091
201
1168
288
4027
208
1929
172
2553
Protein electrophoresis panel - Serum or Plasma
24351-9 [3004588]
24351-9 [3004588]
2.1e-01
2.3e+00
—
—
4.0e+00
1.7e+00
9.3e-01
cases:1.50%
controls:1.22%
cases:3.56%
controls:0.38%
—
—
—
—
cases:6.08%
controls:0.11%
cases:2.86%
controls:0.52%
cases:4.47%
controls:1.81%
8
65
525
5265
19
20
514
5310
—
—
32
6
494
5309
14
27
475
5168
17
81
363
4401
Scheduled procedure
ZXD10 [2001311387]
ZXD10 [2001311387]
5.0e-01
8.9e-01
2.0e+00
1.0e+50
2.7e+00
2.2e+00
1.2e+00
cases:9.38%
controls:5.91%
cases:3.75%
controls:1.58%
cases:1.69%
controls:0.23%
cases:3.56%
controls:0.00%
cases:1.33%
controls:0.09%
cases:9.82%
controls:1.19%
cases:8.68%
controls:2.86%
50
315
483
5015
20
84
513
5246
9
12
524
5318
19
0
514
5330
7
5
519
5310
48
62
441
5133
33
128
347
4354
Abdominal ultrasound examination
JN3AE [2001305555]
JN3AE [2001305555]
1.2e+00
2.2e+00
—
1.0e+50
—
3.2e+00
2.4e+00
cases:3.75%
controls:1.13%
cases:3.00%
controls:0.36%
—
—
cases:0.94%
controls:0.00%
—
—
cases:6.34%
controls:0.29%
cases:13.42%
controls:1.38%
20
60
513
5270
16
19
517
5311
—
5
0
528
5330
—
31
15
458
5180
51
62
329
4420
Influenza virus B RNA [Presence] in Specimen by NAA with probe detection
40982-1 [3038288]
40982-1 [3038288]
-1.7e-02
1.1e+00
2.5e+00
—
2.3e+00
2.6e+00
1.4e+00
cases:1.13%
controls:1.14%
cases:2.06%
controls:0.69%
cases:1.31%
controls:0.11%
—
—
cases:1.90%
controls:0.19%
cases:13.29%
controls:1.12%
cases:15.53%
controls:4.33%
6
61
527
5269
11
37
522
5293
7
6
526
5324
—
10
10
516
5305
65
58
424
5137
59
194
321
4288
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
5894-1 [3033658]
1.3e-02
9.5e-01
2.9e+00
1.0e+50
1.9e+00
2.1e+00
9.7e-01
cases:4.50%
controls:4.45%
cases:5.82%
controls:2.33%
cases:6.19%
controls:0.38%
cases:2.25%
controls:0.00%
cases:2.66%
controls:0.40%
cases:13.70%
controls:1.94%
cases:15.00%
controls:6.25%
24
237
509
5093
31
124
502
5206
33
20
500
5310
12
0
521
5330
14
21
512
5294
67
101
422
5094
57
280
323
4202
Cathetrisation of vein
TPH04 [2001309597]
TPH04 [2001309597]
-2.2e-01
1.4e+00
2.2e+00
1.0e+50
2.1e+00
2.1e+00
9.9e-01
cases:2.25%
controls:2.78%
cases:3.56%
controls:0.92%
cases:1.31%
controls:0.15%
cases:2.06%
controls:0.00%
cases:1.52%
controls:0.19%
cases:6.95%
controls:0.90%
cases:9.47%
controls:3.75%
12
148
521
5182
19
49
514
5281
7
8
526
5322
11
0
522
5330
8
10
518
5305
34
47
455
5148
36
168
344
4314
Platelets [#/volume] in Blood
26515-7 [3007461]
26515-7 [3007461]
7.7e-02
2.7e-01
2.2e+00
3.5e+00
2.3e+00
6.9e-01
1.9e-01
cases:40.90%
controls:39.06%
cases:40.15%
controls:33.81%
cases:39.02%
controls:6.59%
cases:15.38%
controls:0.53%
cases:42.21%
controls:6.94%
cases:52.76%
controls:36.02%
cases:64.21%
controls:59.82%
218
2082
315
3248
214
1802
319
3528
208
351
325
4979
82
28
451
5302
222
369
304
4946
258
1871
231
3324
244
2681
136
1801
MCH [Entitic mass]
28539-5 [3035941]
28539-5 [3035941]
7.2e-02
2.8e-01
2.2e+00
3.5e+00
2.3e+00
6.9e-01
1.8e-01
cases:40.90%
controls:39.17%
cases:40.34%
controls:33.77%
cases:39.02%
controls:6.59%
cases:15.38%
controls:0.53%
cases:42.21%
controls:6.94%
cases:52.76%
controls:36.02%
cases:64.21%
controls:59.95%
218
2088
315
3242
215
1800
318
3530
208
351
325
4979
82
28
451
5302
222
369
304
4946
258
1871
231
3324
244
2687
136
1795
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
718-7 [3000963]
7.8e-02
2.8e-01
2.2e+00
3.5e+00
2.3e+00
6.8e-01
1.8e-01
cases:41.09%
controls:39.21%
cases:40.53%
controls:33.88%
cases:39.02%
controls:6.59%
cases:15.38%
controls:0.53%
cases:42.40%
controls:6.98%
cases:52.76%
controls:36.07%
cases:64.21%
controls:60.04%
219
2090
314
3240
216
1806
317
3524
208
351
325
4979
82
28
451
5302
223
371
303
4944
258
1874
231
3321
244
2691
136
1791
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
30428-7 [3024731]
7.8e-02
2.9e-01
2.2e+00
3.5e+00
2.3e+00
6.8e-01
1.8e-01
cases:41.09%
controls:39.21%
cases:40.53%
controls:33.83%
cases:39.02%
controls:6.59%
cases:15.38%
controls:0.53%
cases:42.21%
controls:6.94%
cases:52.76%
controls:36.07%
cases:64.21%
controls:60.00%
219
2090
314
3240
216
1803
317
3527
208
351
325
4979
82
28
451
5302
222
369
304
4946
258
1874
231
3321
244
2689
136
1793
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
26453-1 [3026361]
7.8e-02
2.9e-01
2.2e+00
3.5e+00
2.3e+00
6.8e-01
1.8e-01
cases:41.09%
controls:39.21%
cases:40.53%
controls:33.86%
cases:39.02%
controls:6.59%
cases:15.38%
controls:0.53%
cases:42.21%
controls:6.94%
cases:52.76%
controls:36.09%
cases:64.21%
controls:60.00%
219
2090
314
3240
216
1805
317
3525
208
351
325
4979
82
28
451
5302
222
369
304
4946
258
1875
231
3320
244
2689
136
1793
Leukocytes [#/volume] in Blood
26464-8 [3010813]
26464-8 [3010813]
7.7e-02
2.8e-01
2.2e+00
3.5e+00
2.3e+00
6.8e-01
1.7e-01
cases:41.09%
controls:39.25%
cases:40.53%
controls:33.88%
cases:39.02%
controls:6.60%
cases:15.38%
controls:0.53%
cases:42.21%
controls:6.94%
cases:52.76%
controls:36.11%
cases:63.95%
controls:60.04%
219
2092
314
3238
216
1806
317
3524
208
352
325
4978
82
28
451
5302
222
369
304
4946
258
1876
231
3319
243
2691
137
1791
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
20570-8 [3009542]
7.7e-02
2.9e-01
2.2e+00
3.5e+00
2.3e+00
6.8e-01
1.8e-01
cases:41.09%
controls:39.23%
cases:40.53%
controls:33.83%
cases:39.02%
controls:6.62%
cases:15.38%
controls:0.53%
cases:42.21%
controls:6.96%
cases:52.76%
controls:36.03%
cases:64.21%
controls:60.02%
219
2091
314
3239
216
1803
317
3527
208
353
325
4977
82
28
451
5302
222
370
304
4945
258
1872
231
3323
244
2690
136
1792
dexamethasone; oral, parenteral
H02AB02 [21602730]
H02AB02 [21602730]
1.1e+00
2.2e+00
—
—
—
3.7e+00
1.8e+00
cases:3.19%
controls:1.05%
cases:3.75%
controls:0.45%
—
—
—
—
—
—
cases:10.63%
controls:0.31%
cases:8.68%
controls:1.61%
17
56
516
5274
20
24
513
5306
—
—
—
52
16
437
5179
33
72
347
4410
Emergency Room Visit
ER [9203]
ER [9203]
1.9e-01
8.0e-01
2.5e+00
—
2.4e+00
1.9e+00
1.0e+00
cases:40.71%
controls:36.19%
cases:24.39%
controls:12.63%
cases:14.63%
controls:1.43%
—
—
cases:14.45%
controls:1.54%
cases:49.49%
controls:12.63%
cases:55.79%
controls:30.86%
217
1929
316
3401
130
673
403
4657
78
76
455
5254
—
76
82
450
5233
242
656
247
4539
212
1383
168
3099
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
2951-2 [3019550]
2.6e-02
2.9e-01
2.1e+00
3.2e+00
2.4e+00
8.6e-01
2.8e-01
cases:35.83%
controls:35.23%
cases:35.65%
controls:29.32%
cases:31.14%
controls:5.31%
cases:10.32%
controls:0.45%
cases:39.73%
controls:5.55%
cases:51.53%
controls:30.99%
cases:61.58%
controls:54.66%
191
1878
342
3452
190
1563
343
3767
166
283
367
5047
55
24
478
5306
209
295
317
5020
252
1610
237
3585
234
2450
146
2032
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
2823-3 [3023103]
8.2e-03
2.7e-01
2.1e+00
3.2e+00
2.4e+00
8.4e-01
2.8e-01
cases:35.83%
controls:35.65%
cases:35.65%
controls:29.72%
cases:31.33%
controls:5.48%
cases:10.32%
controls:0.47%
cases:39.92%
controls:5.59%
cases:51.53%
controls:31.57%
cases:61.84%
controls:55.13%
191
1900
342
3430
190
1584
343
3746
167
292
366
5038
55
25
478
5305
210
297
316
5018
252
1640
237
3555
235
2471
145
2011
ondansetron; oral, parenteral, rectal
A04AA01 [21600493]
A04AA01 [21600493]
—
—
—
—
1.0e+50
5.5e+00
3.0e+00
—
—
—
—
—
—
—
—
cases:8.37%
controls:0.00%
cases:18.61%
controls:0.10%
cases:4.74%
controls:0.25%
—
—
—
—
44
0
482
5315
91
5
398
5190
18
11
362
4471
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
14682-9 [3020564]
8.0e-03
2.4e-01
2.1e+00
3.2e+00
2.4e+00
7.6e-01
2.4e-01
cases:37.71%
controls:37.52%
cases:37.71%
controls:32.20%
cases:36.21%
controls:6.45%
cases:11.26%
controls:0.51%
cases:42.02%
controls:6.32%
cases:53.17%
controls:34.63%
cases:63.95%
controls:58.30%
201
2000
332
3330
201
1716
332
3614
193
344
340
4986
60
27
473
5303
221
336
305
4979
260
1799
229
3396
243
2613
137
1869
Protein [Mass/volume] in Serum or Plasma
2885-2 [3020630]
2885-2 [3020630]
1.2e-01
2.0e+00
—
—
3.7e+00
1.7e+00
1.0e+00
cases:1.50%
controls:1.33%
cases:3.75%
controls:0.53%
—
—
—
—
cases:3.80%
controls:0.09%
cases:3.48%
controls:0.65%
cases:5.79%
controls:2.16%
8
71
525
5259
20
28
513
5302
—
—
20
5
506
5310
17
34
472
5161
22
97
358
4385
Forced vital capacity [Volume] Respiratory system
19870-5 [3020158]
19870-5 [3020158]
1.1e+00
1.0e+00
—
—
2.5e+00
2.7e+00
1.9e+00
cases:4.13%
controls:1.48%
cases:1.50%
controls:0.54%
—
—
—
—
cases:1.14%
controls:0.09%
cases:5.93%
controls:0.42%
cases:7.89%
controls:1.20%
22
79
511
5251
8
29
525
5301
—
—
6
5
520
5310
29
22
460
5173
30
54
350
4428
FEV1/FVC
19926-5 [3011505]
19926-5 [3011505]
1.1e+00
1.0e+00
—
—
2.5e+00
2.7e+00
1.9e+00
cases:4.13%
controls:1.48%
cases:1.50%
controls:0.54%
—
—
—
—
cases:1.14%
controls:0.09%
cases:5.93%
controls:0.42%
cases:7.89%
controls:1.20%
22
79
511
5251
8
29
525
5301
—
—
6
5
520
5310
29
22
460
5173
30
54
350
4428
FEV1
20150-9 [3024653]
20150-9 [3024653]
1.1e+00
1.0e+00
—
—
2.5e+00
2.7e+00
1.9e+00
cases:4.13%
controls:1.48%
cases:1.50%
controls:0.54%
—
—
—
—
cases:1.14%
controls:0.09%
cases:5.93%
controls:0.42%
cases:7.89%
controls:1.20%
22
79
511
5251
8
29
525
5301
—
—
6
5
520
5310
29
22
460
5173
30
54
350
4428
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
207NI0002X [38003841]
6.5e-01
1.4e+00
1.8e+00
—
1.9e+00
1.2e+00
1.1e+00
cases:10.13%
controls:5.57%
cases:8.26%
controls:2.18%
cases:2.25%
controls:0.38%
—
—
cases:2.47%
controls:0.38%
cases:7.57%
controls:2.33%
cases:16.58%
controls:6.14%
54
297
479
5033
44
116
489
5214
12
20
521
5310
—
13
20
513
5295
37
121
452
5074
63
275
317
4207
Laboratory Visit
OMOP4822461 [32036]
OMOP4822461 [32036]
9.9e-03
2.1e-01
1.7e+00
4.0e+00
1.8e+00
4.8e-01
9.1e-02
cases:43.15%
controls:42.91%
cases:45.40%
controls:40.36%
cases:43.71%
controls:12.53%
cases:35.08%
controls:0.96%
cases:46.39%
controls:12.51%
cases:55.21%
controls:43.39%
cases:65.53%
controls:63.45%
230
2287
303
3043
242
2151
291
3179
233
668
300
4662
187
51
346
5279
244
665
282
4650
270
2254
219
2941
249
2844
131
1638
Influenza virus A RNA [Presence] in Specimen by NAA with probe detection
34487-9 [3044938]
34487-9 [3044938]
0.0e+00
7.9e-01
2.0e+00
—
1.9e+00
2.6e+00
1.5e+00
cases:1.88%
controls:1.88%
cases:2.25%
controls:1.03%
cases:1.50%
controls:0.21%
—
—
cases:1.71%
controls:0.26%
cases:18.00%
controls:1.60%
cases:21.05%
controls:5.64%
10
100
523
5230
12
55
521
5275
8
11
525
5319
—
9
14
517
5301
88
83
401
5112
80
253
300
4229
tinzaparin; parenteral
B01AB10 [21600981]
B01AB10 [21600981]
1.7e+00
1.7e+00
—
—
—
2.9e+00
1.6e+00
cases:1.88%
controls:0.36%
cases:1.50%
controls:0.28%
—
—
—
—
—
—
cases:5.32%
controls:0.31%
cases:4.47%
controls:0.89%
10
19
523
5311
8
15
525
5315
—
—
—
26
16
463
5179
17
40
363
4442
Hepatitis B virus surface Ag [Presence] in Serum
5195-3 [3019284]
5195-3 [3019284]
6.4e-01
2.2e+00
—
1.0e+50
—
3.8e+00
1.8e+00
cases:1.69%
controls:0.90%
cases:4.32%
controls:0.49%
—
—
cases:1.88%
controls:0.00%
—
—
cases:18.61%
controls:0.50%
cases:9.47%
controls:1.70%
9
48
524
5282
23
26
510
5304
—
10
0
523
5330
—
91
26
398
5169
36
76
344
4406
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
28540-3 [3003338]
-9.6e-02
1.3e-01
1.9e+00
3.5e+00
2.0e+00
4.7e-01
-6.5e-02
cases:27.58%
controls:29.53%
cases:26.64%
controls:24.15%
cases:24.02%
controls:4.65%
cases:10.69%
controls:0.36%
cases:25.86%
controls:4.57%
cases:34.97%
controls:25.22%
cases:43.16%
controls:44.76%
147
1574
386
3756
142
1287
391
4043
128
248
405
5082
57
19
476
5311
136
243
390
5072
171
1310
318
3885
164
2006
216
2476
Human bocavirus DNA [Presence] in Specimen by NAA with probe detection
62424-7 [40765161]
62424-7 [40765161]
—
—
—
—
—
4.5e+00
3.3e+00
—
—
—
—
—
—
—
—
—
—
cases:7.77%
controls:0.10%
cases:9.74%
controls:0.38%
—
—
—
—
—
38
5
451
5190
37
17
343
4465
IgM [Mass/volume] in Serum or Plasma
2472-9 [3028026]
2472-9 [3028026]
1.3e+00
2.4e+00
—
—
1.0e+50
3.0e+00
2.4e+00
cases:1.50%
controls:0.41%
cases:2.44%
controls:0.23%
—
—
—
—
cases:6.84%
controls:0.00%
cases:5.93%
controls:0.33%
cases:10.00%
controls:0.98%
8
22
525
5308
13
12
520
5318
—
—
36
0
490
5315
29
17
460
5178
38
44
342
4438
Reticulocyte production index
31111-8 [3000012]
31111-8 [3000012]
—
2.5e+00
—
—
1.0e+50
3.3e+00
2.0e+00
—
—
cases:1.31%
controls:0.11%
—
—
—
—
cases:3.04%
controls:0.00%
cases:4.91%
controls:0.19%
cases:3.16%
controls:0.45%
—
7
6
526
5324
—
—
16
0
510
5315
24
10
465
5185
12
20
368
4462
INR in Blood by Coagulation assay
34714-6 [3032080]
34714-6 [3032080]
5.6e-02
5.1e-01
1.4e+00
2.7e+00
1.2e+00
1.2e+00
6.7e-01
cases:12.95%
controls:12.33%
cases:12.20%
controls:7.69%
cases:10.69%
controls:2.81%
cases:3.00%
controls:0.21%
cases:9.13%
controls:2.92%
cases:22.09%
controls:8.01%
cases:30.79%
controls:18.50%
69
657
464
4673
65
410
468
4920
57
150
476
5180
16
11
517
5319
48
155
478
5160
108
416
381
4779
117
829
263
3653
valaciclovir; oral
J05AB11 [21603137]
J05AB11 [21603137]
8.4e-01
1.6e+00
—
—
—
3.0e+00
2.2e+00
cases:3.94%
controls:1.74%
cases:2.63%
controls:0.53%
—
—
—
—
—
—
cases:15.34%
controls:0.87%
cases:13.16%
controls:1.67%
21
93
512
5237
14
28
519
5302
—
—
—
75
45
414
5150
50
75
330
4407
pH of Specimen
17433-4 [3019225]
17433-4 [3019225]
-2.2e-01
2.1e-01
2.6e+00
—
3.5e+00
1.5e+00
7.5e-01
cases:1.69%
controls:2.10%
cases:1.50%
controls:1.22%
cases:2.25%
controls:0.17%
—
—
cases:4.94%
controls:0.15%
cases:5.32%
controls:1.21%
cases:5.53%
controls:2.70%
9
112
524
5218
8
65
525
5265
12
9
521
5321
—
26
8
500
5307
26
63
463
5132
21
121
359
4361
Iron [Moles/volume] in Serum or Plasma
14798-3 [3022948]
14798-3 [3022948]
3.4e-01
1.1e+00
2.2e+00
—
2.1e+00
1.3e+00
8.0e-01
cases:3.00%
controls:2.16%
cases:3.56%
controls:1.16%
cases:2.25%
controls:0.24%
—
—
cases:1.71%
controls:0.21%
cases:5.93%
controls:1.67%
cases:10.53%
controls:5.02%
16
115
517
5215
19
62
514
5268
12
13
521
5317
—
9
11
517
5304
29
87
460
5108
40
225
340
4257
CBC panel - Blood by Automated count
58410-2 [40761511]
58410-2 [40761511]
1.7e-01
2.4e-01
1.9e+00
3.2e+00
1.9e+00
6.7e-01
1.6e-01
cases:36.02%
controls:32.12%
cases:27.58%
controls:23.10%
cases:20.83%
controls:3.86%
cases:6.75%
controls:0.30%
cases:22.81%
controls:4.25%
cases:38.45%
controls:24.23%
cases:51.05%
controls:46.94%
192
1712
341
3618
147
1231
386
4099
111
206
422
5124
36
16
497
5314
120
226
406
5089
188
1259
301
3936
194
2104
186
2378
nystatin; oral
A07AA02 [21600604]
A07AA02 [21600604]
8.5e-01
2.6e+00
—
—
—
2.9e+00
2.1e+00
cases:1.31%
controls:0.56%
cases:1.69%
controls:0.13%
—
—
—
—
—
—
cases:5.52%
controls:0.31%
cases:5.79%
controls:0.76%
7
30
526
5300
9
7
524
5323
—
—
—
27
16
462
5179
22
34
358
4448
Hepatitis C virus Ab [Presence] in Serum
16128-1 [3017143]
16128-1 [3017143]
5.8e-01
2.2e+00
—
1.0e+50
—
3.6e+00
1.7e+00
cases:1.69%
controls:0.96%
cases:4.32%
controls:0.49%
—
—
cases:1.69%
controls:0.00%
—
—
cases:18.20%
controls:0.58%
cases:8.16%
controls:1.58%
9
51
524
5279
23
26
510
5304
—
9
0
524
5330
—
89
30
400
5165
31
71
349
4411
Bilirubin.conjugated [Moles/volume] in Serum or Plasma
29760-6 [3005772]
29760-6 [3005772]
2.9e-01
1.7e+00
—
—
2.0e+00
2.5e+00
1.3e+00
cases:2.06%
controls:1.56%
cases:3.38%
controls:0.62%
—
—
—
—
cases:1.14%
controls:0.15%
cases:7.57%
controls:0.64%
cases:7.63%
controls:2.30%
11
83
522
5247
18
33
515
5297
—
—
6
8
520
5307
37
33
452
5162
29
103
351
4379
Gastroenterology
10 [38004455]
10 [38004455]
2.6e-01
6.7e-01
2.4e+00
—
2.3e+00
1.6e+00
1.2e+00
cases:6.38%
controls:4.99%
cases:4.32%
controls:2.25%
cases:2.81%
controls:0.26%
—
—
cases:4.18%
controls:0.43%
cases:10.22%
controls:2.18%
cases:17.89%
controls:6.29%
34
266
499
5064
23
120
510
5210
15
14
518
5316
—
22
23
504
5292
50
113
439
5082
68
282
312
4200
Insertion of central venous catheter through external or internal jugular vein
TPH15 [2001309600]
TPH15 [2001309600]
—
—
—
—
—
5.3e+00
2.2e+00
—
—
—
—
—
—
—
—
—
—
cases:16.16%
controls:0.10%
cases:3.68%
controls:0.42%
—
—
—
—
—
79
5
410
5190
14
19
366
4463
Iron/Transferrin [Ratio] in Serum or Plasma
60517-0 [40763571]
60517-0 [40763571]
4.5e-01
1.2e+00
2.0e+00
—
2.1e+00
1.3e+00
7.8e-01
cases:2.81%
controls:1.82%
cases:3.38%
controls:0.99%
cases:1.69%
controls:0.23%
—
—
cases:1.71%
controls:0.21%
cases:5.11%
controls:1.46%
cases:8.95%
controls:4.33%
15
97
518
5233
18
53
515
5277
9
12
524
5318
—
9
11
517
5304
25
76
464
5119
34
194
346
4288
Transferrin [Mass/volume] in Serum or Plasma
3034-6 [3004789]
3034-6 [3004789]
3.6e-01
1.2e+00
2.3e+00
—
1.8e+00
1.4e+00
7.2e-01
cases:2.81%
controls:1.99%
cases:3.75%
controls:1.16%
cases:2.25%
controls:0.23%
—
—
cases:1.52%
controls:0.26%
cases:5.93%
controls:1.56%
cases:9.21%
controls:4.71%
15
106
518
5224
20
62
513
5268
12
12
521
5318
—
8
14
518
5301
29
81
460
5114
35
211
345
4271
Dentistry
C5 [903277]
C5 [903277]
3.9e-01
1.2e+00
—
—
3.2e+00
2.8e+00
1.3e+00
cases:2.81%
controls:1.91%
cases:1.69%
controls:0.53%
—
—
—
—
cases:2.28%
controls:0.09%
cases:9.20%
controls:0.60%
cases:6.58%
controls:1.83%
15
102
518
5228
9
28
524
5302
—
—
12
5
514
5310
45
31
444
5164
25
82
355
4400
HIV 1 and 2 tests - Meaningful Use set
75622-1 [46235355]
75622-1 [46235355]
5.5e-01
2.1e+00
—
1.0e+50
—
3.7e+00
1.6e+00
cases:2.25%
controls:1.31%
cases:5.63%
controls:0.73%
—
—
cases:2.06%
controls:0.00%
—
—
cases:18.81%
controls:0.60%
cases:11.05%
controls:2.54%
12
70
521
5260
30
39
503
5291
—
11
0
522
5330
—
92
31
397
5164
42
114
338
4368
Gas panel - Venous blood
24339-4 [3000991]
24339-4 [3000991]
—
1.2e+00
2.3e+00
—
—
2.8e+00
9.5e-01
—
—
cases:2.44%
controls:0.71%
cases:1.13%
controls:0.11%
—
—
—
—
cases:7.16%
controls:0.48%
cases:6.58%
controls:2.66%
—
13
38
520
5292
6
6
527
5324
—
—
35
25
454
5170
25
119
355
4363
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
14749-6 [3013826]
-1.2e-01
4.5e-01
2.5e+00
—
2.5e+00
1.5e+00
7.3e-01
cases:11.44%
controls:12.68%
cases:11.07%
controls:7.37%
cases:10.69%
controls:0.94%
—
—
cases:10.84%
controls:1.00%
cases:25.97%
controls:7.20%
cases:37.11%
controls:22.22%
61
676
472
4654
59
393
474
4937
57
50
476
5280
—
57
53
469
5262
127
374
362
4821
141
996
239
3486
Abnormal findings on diagnostic imaging of lung
R91 [45548995]
R91 [45548995]
1.4e+00
2.0e+00
—
—
—
2.0e+00
1.9e+00
cases:3.94%
controls:1.03%
cases:3.00%
controls:0.43%
—
—
—
—
—
—
cases:3.07%
controls:0.42%
cases:8.42%
controls:1.34%
21
55
512
5275
16
23
517
5307
—
—
—
15
22
474
5173
32
60
348
4422
Flexible bronchoscopy
UGC12 [2001303610]
UGC12 [2001303610]
5.2e-01
2.1e+00
—
—
—
2.8e+00
2.4e+00
cases:1.50%
controls:0.90%
cases:1.31%
controls:0.17%
—
—
—
—
—
—
cases:2.66%
controls:0.17%
cases:7.37%
controls:0.71%
8
48
525
5282
7
9
526
5321
—
—
—
13
9
476
5186
28
32
352
4450
Bone marrow biopsy
XW000 [2001310618]
XW000 [2001310618]
2.6e+00
—
1.0e+50
1.0e+50
1.0e+50
—
4.6e+00
cases:2.81%
controls:0.23%
—
—
cases:3.56%
controls:0.00%
cases:5.07%
controls:0.00%
cases:12.36%
controls:0.00%
—
—
cases:19.74%
controls:0.25%
15
12
518
5318
—
19
0
514
5330
27
0
506
5330
65
0
461
5315
—
75
11
305
4471
Adenovirus DNA [Identifier] in Specimen by NAA with probe detection
40976-3 [3040853]
40976-3 [3040853]
-1.0e+50
—
—
—
—
4.1e+00
3.0e+00
cases:0.00%
controls:0.11%
—
—
—
—
—
—
—
—
cases:9.61%
controls:0.17%
cases:11.32%
controls:0.62%
0
6
533
5324
—
—
—
—
47
9
442
5186
43
28
337
4454
Emergency Room and Inpatient Visit
ERIP [262]
ERIP [262]
-9.9e-02
6.4e-01
2.6e+00
1.0e+50
2.3e+00
1.6e+00
6.0e-01
cases:3.94%
controls:4.33%
cases:4.88%
controls:2.63%
cases:4.69%
controls:0.38%
cases:2.44%
controls:0.00%
cases:4.18%
controls:0.43%
cases:15.75%
controls:3.54%
cases:21.32%
controls:12.99%
21
231
512
5099
26
140
507
5190
25
20
508
5310
13
0
520
5330
22
23
504
5292
77
184
412
5011
81
582
299
3900
Legionella pneumophila DNA [Presence] in Specimen by NAA with probe detection
21363-7 [3020565]
21363-7 [3020565]
—
—
—
—
—
3.9e+00
3.2e+00
—
—
—
—
—
—
—
—
—
—
cases:4.50%
controls:0.10%
cases:7.37%
controls:0.33%
—
—
—
—
—
22
5
467
5190
28
15
352
4467
Essential (primary) hypertension
I10 [45591453]
I10 [45591453]
1.6e-02
3.5e-01
1.2e+00
3.7e+00
1.5e+00
6.1e-01
-1.1e-01
cases:24.39%
controls:24.09%
cases:16.70%
controls:12.40%
cases:6.00%
controls:1.89%
cases:4.88%
controls:0.13%
cases:8.17%
controls:1.86%
cases:19.84%
controls:11.86%
cases:28.68%
controls:31.01%
130
1284
403
4046
89
661
444
4669
32
101
501
5229
26
7
507
5323
43
99
483
5216
97
616
392
4579
109
1390
271
3092
Human metapneumovirus RNA [Presence] in Specimen by NAA with probe detection
38917-1 [3042194]
38917-1 [3042194]
-1.0e+50
—
—
—
1.0e+50
4.0e+00
2.9e+00
cases:0.00%
controls:0.11%
—
—
—
—
—
—
cases:0.95%
controls:0.00%
cases:9.82%
controls:0.19%
cases:10.79%
controls:0.67%
0
6
533
5324
—
—
—
5
0
521
5315
48
10
441
5185
41
30
339
4452
Mycoplasma pneumoniae DNA [Presence] in Specimen by NAA with probe detection
29257-3 [3002482]
29257-3 [3002482]
-1.0e+50
—
—
—
—
3.9e+00
3.0e+00
cases:0.00%
controls:0.11%
—
—
—
—
—
—
—
—
cases:5.52%
controls:0.12%
cases:8.95%
controls:0.49%
0
6
533
5324
—
—
—
—
27
6
462
5189
34
22
346
4460
Respiratory virus DNA+RNA [Identifier] in Specimen by NAA with probe detection
50548-7 [3030692]
50548-7 [3030692]
—
—
—
—
—
3.7e+00
3.2e+00
—
—
—
—
—
—
—
—
—
—
cases:4.29%
controls:0.12%
cases:7.37%
controls:0.33%
—
—
—
—
—
21
6
468
5189
28
15
352
4467
Bacteria [Presence] in Urine
87829-8 [36304419]
87829-8 [36304419]
-4.4e-02
9.0e-01
1.8e+00
1.0e+50
1.7e+00
1.7e+00
6.7e-01
cases:4.88%
controls:5.08%
cases:6.00%
controls:2.53%
cases:2.25%
controls:0.38%
cases:0.94%
controls:0.00%
cases:2.28%
controls:0.41%
cases:13.50%
controls:2.91%
cases:15.53%
controls:8.57%
26
271
507
5059
32
135
501
5195
12
20
521
5310
5
0
528
5330
12
22
514
5293
66
151
423
5044
59
384
321
4098
Chlamydophila pneumoniae DNA [Presence] in Specimen by NAA with probe detection
34645-2 [3031478]
34645-2 [3031478]
—
—
—
—
—
3.8e+00
3.0e+00
—
—
—
—
—
—
—
—
—
—
cases:4.70%
controls:0.12%
cases:8.68%
controls:0.47%
—
—
—
—
—
23
6
466
5189
33
21
347
4461
Bordetella pertussis DNA [Presence] in Specimen by NAA with probe detection
23826-1 [3012477]
23826-1 [3012477]
—
—
—
—
—
3.6e+00
3.0e+00
—
—
—
—
—
—
—
—
—
—
cases:4.91%
controls:0.13%
cases:7.63%
controls:0.42%
—
—
—
—
—
24
7
465
5188
29
19
351
4463
General Surgery
2 [38004447]
2 [38004447]
2.7e-01
9.2e-01
2.6e+00
—
2.4e+00
7.0e-01
3.6e-01
cases:22.14%
controls:17.79%
cases:12.57%
controls:5.44%
cases:6.94%
controls:0.54%
—
—
cases:5.89%
controls:0.58%
cases:9.20%
controls:4.79%
cases:18.95%
controls:14.08%
118
948
415
4382
67
290
466
5040
37
29
496
5301
—
31
31
495
5284
45
249
444
4946
72
631
308
3851
Thorax X-ray examination outside radiological department
GD1UA [2001303652]
GD1UA [2001303652]
-1.6e-01
9.5e-01
2.5e+00
—
—
3.0e+00
1.0e+00
cases:2.06%
controls:2.40%
cases:1.88%
controls:0.73%
cases:1.13%
controls:0.09%
—
—
—
—
cases:15.95%
controls:0.90%
cases:7.37%
controls:2.74%
11
128
522
5202
10
39
523
5291
6
5
527
5325
—
—
78
47
411
5148
28
123
352
4359
Plastic And Reconstructive Surgery
24 [38004467]
24 [38004467]
5.5e-01
1.3e+00
—
1.0e+50
2.4e+00
1.4e+00
1.3e+00
cases:3.19%
controls:1.86%
cases:2.06%
controls:0.56%
—
—
cases:1.69%
controls:0.00%
cases:1.71%
controls:0.15%
cases:2.25%
controls:0.54%
cases:6.32%
controls:1.74%
17
99
516
5231
11
30
522
5300
—
9
0
524
5330
9
8
517
5307
11
28
478
5167
24
78
356
4404
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 [3013721]
1920-8 [3013721]
3.5e-01
8.7e-01
2.7e+00
1.0e+50
2.0e+00
9.3e-01
3.4e-01
cases:7.50%
controls:5.38%
cases:6.38%
controls:2.78%
cases:4.69%
controls:0.34%
cases:0.94%
controls:0.00%
cases:2.85%
controls:0.38%
cases:8.18%
controls:3.41%
cases:13.42%
controls:9.95%
40
287
493
5043
34
148
499
5182
25
18
508
5312
5
0
528
5330
15
20
511
5295
40
177
449
5018
51
446
329
4036
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
51483-6 [3030467]
-9.3e-02
8.7e-01
1.7e+00
—
1.7e+00
1.6e+00
6.2e-01
cases:4.88%
controls:5.33%
cases:6.38%
controls:2.78%
cases:2.44%
controls:0.45%
—
—
cases:2.85%
controls:0.51%
cases:13.70%
controls:3.18%
cases:15.79%
controls:9.19%
26
284
507
5046
34
148
499
5182
13
24
520
5306
—
15
27
511
5288
67
165
422
5030
60
412
320
4070
Human coronavirus RNA [Presence] in Specimen by NAA with probe detection
41001-9 [3042596]
41001-9 [3042596]
—
—
—
—
—
3.7e+00
2.8e+00
—
—
—
—
—
—
—
—
—
—
cases:3.89%
controls:0.10%
cases:5.79%
controls:0.38%
—
—
—
—
—
19
5
470
5190
22
17
358
4465
Treatment plan or consultation
WZC00 [2001310885]
WZC00 [2001310885]
7.6e-01
1.2e+00
—
—
—
2.9e+00
1.7e+00
cases:7.32%
controls:3.55%
cases:4.50%
controls:1.44%
—
—
—
—
—
—
cases:19.84%
controls:1.39%
cases:21.05%
controls:4.71%
39
189
494
5141
24
77
509
5253
—
—
—
97
72
392
5123
80
211
300
4271
Lactate [Moles/volume] in Serum or Plasma
2524-7 [3014111]
2524-7 [3014111]
—
1.2e+00
2.8e+00
—
—
2.9e+00
8.1e-01
—
—
cases:2.06%
controls:0.62%
cases:1.50%
controls:0.09%
—
—
—
—
cases:7.36%
controls:0.44%
cases:6.32%
controls:2.92%
—
11
33
522
5297
8
5
525
5325
—
—
36
23
453
5172
24
131
356
4351
aciclovir; oral, parenteral
J05AB01 [21603131]
J05AB01 [21603131]
-2.1e-01
9.8e-01
—
—
2.5e+00
2.3e+00
1.7e+00
cases:2.25%
controls:2.76%
cases:2.06%
controls:0.79%
—
—
—
—
cases:1.33%
controls:0.11%
cases:8.38%
controls:0.89%
cases:11.84%
controls:2.48%
12
147
521
5183
11
42
522
5288
—
—
7
6
519
5309
41
46
448
5149
45
111
335
4371
Pharmacy visit
OMOP4822462 [581458]
OMOP4822462 [581458]
2.0e-01
6.2e-01
5.7e-01
1.2e+00
1.3e+00
9.2e-01
1.9e+00
cases:96.06%
controls:95.22%
cases:93.62%
controls:88.80%
cases:67.92%
controls:54.43%
cases:8.63%
controls:2.72%
cases:80.42%
controls:53.94%
cases:95.30%
controls:89.01%
cases:99.47%
controls:96.68%
512
5075
21
255
499
4733
34
597
362
2901
171
2429
46
145
487
5185
423
2867
103
2448
466
4624
23
571
378
4333
2
149
Transferrin receptor.soluble [Mass/volume] in Serum or Plasma
30248-9 [3015399]
30248-9 [3015399]
-3.6e-02
1.1e+00
2.4e+00
—
2.2e+00
7.4e-01
4.7e-01
cases:4.32%
controls:4.47%
cases:6.94%
controls:2.51%
cases:3.19%
controls:0.30%
—
—
cases:2.09%
controls:0.23%
cases:5.93%
controls:2.91%
cases:13.42%
controls:8.84%
23
238
510
5092
37
134
496
5196
17
16
516
5314
—
11
12
515
5303
29
151
460
5044
51
396
329
4086
cefalexin; oral
J01DB01 [21602870]
J01DB01 [21602870]
2.1e-01
9.2e-01
1.5e+00
—
1.9e+00
1.4e+00
6.6e-01
cases:31.89%
controls:27.43%
cases:19.70%
controls:8.87%
cases:4.13%
controls:0.92%
—
—
cases:5.70%
controls:0.92%
cases:28.02%
controls:8.37%
cases:40.00%
controls:25.61%
170
1462
363
3868
105
473
428
4857
22
49
511
5281
—
30
49
496
5266
137
435
352
4760
152
1148
228
3334
Case Management Agency
251B00000X [38004193]
251B00000X [38004193]
1.6e-01
3.9e-01
1.0e+00
2.8e+00
1.5e+00
7.2e-01
1.7e-01
cases:69.61%
controls:66.21%
cases:66.98%
controls:57.80%
cases:44.84%
controls:22.35%
cases:20.45%
controls:1.52%
cases:54.75%
controls:22.11%
cases:75.87%
controls:60.52%
cases:83.42%
controls:80.92%
371
3529
162
1801
357
3081
176
2249
239
1191
294
4139
109
81
424
5249
288
1175
238
4140
371
3144
118
2051
317
3627
63
855
Extensive MRI examination of brain with high intensity magnet
AA1CG [2001300116]
AA1CG [2001300116]
—
2.0e+00
1.0e+50
—
—
2.2e+00
2.1e+00
—
—
cases:1.13%
controls:0.15%
cases:1.31%
controls:0.00%
—
—
—
—
cases:1.43%
controls:0.15%
cases:5.53%
controls:0.69%
—
6
8
527
5322
7
0
526
5330
—
—
7
8
482
5187
21
31
359
4451
Epithelial cells [#/volume] in Urine
30383-4 [3000850]
30383-4 [3000850]
2.2e-02
8.9e-01
1.6e+00
—
1.6e+00
1.6e+00
7.0e-01
cases:4.50%
controls:4.41%
cases:4.69%
controls:1.99%
cases:2.06%
controls:0.43%
—
—
cases:1.71%
controls:0.34%
cases:10.22%
controls:2.33%
cases:11.58%
controls:6.09%
24
235
509
5095
25
106
508
5224
11
23
522
5307
—
9
18
517
5297
50
121
439
5074
44
273
336
4209
Biopsy of skin and subcutaneous tissue
TQX10 [2001310152]
TQX10 [2001310152]
1.5e+00
1.8e+00
—
—
—
2.7e+00
2.2e+00
cases:2.81%
controls:0.66%
cases:1.13%
controls:0.19%
—
—
—
—
—
—
cases:2.25%
controls:0.15%
cases:4.74%
controls:0.56%
15
35
518
5295
6
10
527
5320
—
—
—
11
8
478
5187
18
25
362
4457
Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture
13317-3 [3019902]
13317-3 [3019902]
5.4e-01
4.6e-01
3.1e+00
—
—
1.9e+00
1.3e+00
cases:3.00%
controls:1.76%
cases:1.69%
controls:1.07%
cases:2.44%
controls:0.11%
—
—
—
—
cases:7.77%
controls:1.21%
cases:9.74%
controls:2.79%
16
94
517
5236
9
57
524
5273
13
6
520
5324
—
—
38
63
451
5132
37
125
343
4357
Granulocytes/Leukocytes in Blood
30395-8 [3035933]
30395-8 [3035933]
1.3e+00
2.0e+00
—
—
—
3.5e+00
2.8e+00
cases:1.13%
controls:0.32%
cases:0.94%
controls:0.13%
—
—
—
—
—
—
cases:5.52%
controls:0.17%
cases:4.47%
controls:0.29%
6
17
527
5313
5
7
528
5323
—
—
—
27
9
462
5186
17
13
363
4469
Phosphate [Moles/volume] in Serum or Plasma
14879-1 [3003458]
14879-1 [3003458]
-5.5e-01
6.6e-01
1.4e+00
—
2.8e+00
2.4e+00
1.1e+00
cases:1.31%
controls:2.25%
cases:3.00%
controls:1.58%
cases:1.69%
controls:0.43%
—
—
cases:4.75%
controls:0.30%
cases:16.77%
controls:1.79%
cases:10.53%
controls:3.95%
7
120
526
5210
16
84
517
5246
9
23
524
5307
—
25
16
501
5299
82
93
407
5102
40
177
340
4305
Bacteria identified in Isolate by Culture
43409-2 [3042936]
43409-2 [3042936]
-7.5e-01
5.0e-01
—
—
2.3e+00
2.5e+00
1.3e+00
cases:1.13%
controls:2.35%
cases:1.88%
controls:1.14%
—
—
—
—
cases:1.52%
controls:0.15%
cases:11.66%
controls:1.02%
cases:12.37%
controls:3.55%
6
125
527
5205
10
61
523
5269
—
—
8
8
518
5307
57
53
432
5142
47
159
333
4323
Herpes simplex virus 1+2 DNA [Presence] in Specimen by NAA with probe detection
20444-6 [3028369]
20444-6 [3028369]
—
—
—
—
—
3.3e+00
2.9e+00
—
—
—
—
—
—
—
—
—
—
cases:2.66%
controls:0.10%
cases:3.42%
controls:0.20%
—
—
—
—
—
13
5
476
5190
13
9
367
4473
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
50554-5 [3029287]
-1.2e-01
6.6e-01
1.7e+00
—
1.7e+00
1.5e+00
6.2e-01
cases:6.75%
controls:7.54%
cases:7.50%
controls:4.03%
cases:3.56%
controls:0.66%
—
—
cases:3.23%
controls:0.62%
cases:17.18%
controls:4.52%
cases:20.26%
controls:12.00%
36
402
497
4928
40
215
493
5115
19
35
514
5295
—
17
33
509
5282
84
235
405
4960
77
538
303
3944
Extensive abdominal CT
JN3BD [2001305556]
JN3BD [2001305556]
3.1e-01
1.8e+00
—
—
—
2.6e+00
1.7e+00
cases:1.50%
controls:1.11%
cases:1.50%
controls:0.24%
—
—
—
—
—
—
cases:3.27%
controls:0.25%
cases:2.89%
controls:0.54%
8
59
525
5271
8
13
525
5317
—
—
—
16
13
473
5182
11
24
369
4458
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
30391-7 [3002582]
-1.2e-01
7.1e-01
1.6e+00
—
1.7e+00
1.5e+00
6.4e-01
cases:5.82%
controls:6.51%
cases:6.57%
controls:3.34%
cases:2.63%
controls:0.56%
—
—
cases:2.85%
controls:0.55%
cases:15.54%
controls:3.81%
cases:18.95%
controls:10.98%
31
347
502
4983
35
178
498
5152
14
30
519
5300
—
15
29
511
5286
76
198
413
4997
72
492
308
3990
Extensive structural and functional ultrasound examination of heart
FM1EE [2001303307]
FM1EE [2001303307]
3.3e-01
5.2e-01
1.4e+00
—
3.1e+00
2.0e+00
7.5e-01
cases:6.19%
controls:4.52%
cases:3.56%
controls:2.16%
cases:0.94%
controls:0.24%
—
—
cases:4.18%
controls:0.19%
cases:13.09%
controls:1.91%
cases:12.11%
controls:6.09%
33
241
500
5089
19
115
514
5215
5
13
528
5317
—
22
10
504
5305
64
99
425
5096
46
273
334
4209
High resolution CT examination of lungs
GD1DD [2001303632]
GD1DD [2001303632]
7.3e-01
1.8e+00
—
—
—
3.3e+00
2.6e+00
cases:1.13%
controls:0.54%
cases:1.13%
controls:0.19%
—
—
—
—
—
—
cases:2.45%
controls:0.10%
cases:7.63%
controls:0.58%
6
29
527
5301
6
10
527
5320
—
—
—
12
5
477
5190
29
26
351
4456
Anaemia, unspecified
D64.9 [45600610]
D64.9 [45600610]
2.9e-01
1.9e+00
—
—
—
3.1e+00
9.0e-01
cases:2.06%
controls:1.56%
cases:3.75%
controls:0.56%
—
—
—
—
—
—
cases:8.79%
controls:0.44%
cases:5.00%
controls:2.10%
11
83
522
5247
20
30
513
5300
—
—
—
43
23
446
5172
19
94
361
4388
Standard cardiac ultrasound examination
FM1AE [2001303278]
FM1AE [2001303278]
-7.9e-02
6.3e-01
—
—
2.8e+00
1.9e+00
1.2e+00
cases:3.56%
controls:3.85%
cases:2.81%
controls:1.52%
—
—
—
—
cases:2.09%
controls:0.13%
cases:8.79%
controls:1.41%
cases:10.26%
controls:3.32%
19
205
514
5125
15
81
518
5249
—
—
11
7
515
5308
43
73
446
5122
39
149
341
4333
Excision of other lesion extending through all layers of skin in head or neck
QAE10 [2001309784]
QAE10 [2001309784]
2.8e+00
—
—
—
—
—
3.1e+00
cases:2.44%
controls:0.15%
—
—
—
—
—
—
—
—
—
—
cases:6.32%
controls:0.31%
13
8
520
5322
—
—
—
—
—
24
14
356
4468
Hemoglobin [Entitic mass] in Reticulocytes
42810-2 [3029080]
42810-2 [3029080]
—
—
—
—
1.0e+50
3.6e+00
2.3e+00
—
—
—
—
—
—
—
—
cases:3.04%
controls:0.00%
cases:4.70%
controls:0.13%
cases:3.16%
controls:0.33%
—
—
—
—
16
0
510
5315
23
7
466
5188
12
15
368
4467
Leukocytes [#/volume] in Urine
30405-5 [3018095]
30405-5 [3018095]
-2.1e-02
7.1e-01
1.3e+00
—
1.7e+00
1.5e+00
6.0e-01
cases:6.75%
controls:6.89%
cases:7.32%
controls:3.73%
cases:2.63%
controls:0.69%
—
—
cases:3.23%
controls:0.62%
cases:16.36%
controls:4.37%
cases:20.53%
controls:12.45%
36
367
497
4963
39
199
494
5131
14
37
519
5293
—
17
33
509
5282
80
227
409
4968
78
558
302
3924
Base excess in Venous blood by calculation
1927-3 [3002032]
1927-3 [3002032]
-4.0e-01
8.2e-01
—
—
3.2e+00
2.6e+00
6.3e-01
cases:0.94%
controls:1.39%
cases:2.06%
controls:0.92%
—
—
—
—
cases:2.28%
controls:0.09%
cases:8.59%
controls:0.71%
cases:6.84%
controls:3.77%
5
74
528
5256
11
49
522
5281
—
—
12
5
514
5310
42
37
447
5158
26
169
354
4313
Carbon dioxide [Partial pressure] in Venous blood
2021-4 [3021447]
2021-4 [3021447]
-4.2e-01
8.2e-01
—
—
3.2e+00
2.6e+00
5.6e-01
cases:0.94%
controls:1.43%
cases:2.06%
controls:0.92%
—
—
—
—
cases:2.28%
controls:0.09%
cases:9.00%
controls:0.75%
cases:6.58%
controls:3.88%
5
76
528
5254
11
49
522
5281
—
—
12
5
514
5310
44
39
445
5156
25
174
355
4308
Paranasal sinuses X-ray examination in one projection
DM1QA [2001301761]
DM1QA [2001301761]
1.2e+00
2.5e+00
—
—
—
—
3.3e+00
cases:0.94%
controls:0.28%
cases:1.31%
controls:0.11%
—
—
—
—
—
—
—
—
cases:5.79%
controls:0.22%
5
15
528
5315
7
6
526
5324
—
—
—
—
22
10
358
4472
Urology
34 [38004474]
34 [38004474]
3.2e-01
7.6e-01
1.7e+00
—
1.4e+00
1.1e+00
8.2e-01
cases:10.32%
controls:7.69%
cases:6.75%
controls:3.26%
cases:2.63%
controls:0.51%
—
—
cases:2.09%
controls:0.51%
cases:7.98%
controls:2.83%
cases:16.84%
controls:8.21%
55
410
478
4920
36
174
497
5156
14
27
519
5303
—
11
27
515
5288
39
147
450
5048
64
368
316
4114
Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma
33762-6 [3029187]
33762-6 [3029187]
1.9e-01
5.0e-01
1.8e+00
—
2.1e+00
1.3e+00
5.3e-01
cases:6.94%
controls:5.82%
cases:5.82%
controls:3.62%
cases:2.81%
controls:0.47%
—
—
cases:4.18%
controls:0.51%
cases:13.09%
controls:4.02%
cases:20.00%
controls:12.83%
37
310
496
5020
31
193
502
5137
15
25
518
5305
—
22
27
504
5288
64
209
425
4986
76
575
304
3907
cetirizine; oral
R06AE07 [21603497]
R06AE07 [21603497]
2.4e-01
8.4e-01
9.3e-01
—
1.8e+00
1.9e+00
1.2e+00
cases:8.63%
controls:6.94%
cases:7.32%
controls:3.28%
cases:1.50%
controls:0.60%
—
—
cases:3.99%
controls:0.68%
cases:18.40%
controls:3.27%
cases:18.16%
controls:6.38%
46
370
487
4960
39
175
494
5155
8
32
525
5298
—
21
36
505
5279
90
170
399
5025
69
286
311
4196
aPTT in Platelet poor plasma by Coagulation assay
14979-9 [3018677]
14979-9 [3018677]
-2.2e-02
9.7e-01
2.4e+00
—
—
2.5e+00
8.4e-01
cases:2.63%
controls:2.68%
cases:2.81%
controls:1.09%
cases:1.69%
controls:0.15%
—
—
—
—
cases:11.25%
controls:1.08%
cases:9.21%
controls:4.19%
14
143
519
5187
15
58
518
5272
9
8
524
5322
—
—
55
56
434
5139
35
188
345
4294
Actinic keratosis
L57.0 [45591640]
L57.0 [45591640]
1.2e+00
1.5e+00
—
—
—
1.5e+00
1.4e+00
cases:3.19%
controls:0.94%
cases:1.88%
controls:0.41%
—
—
—
—
—
—
cases:2.04%
controls:0.46%
cases:6.32%
controls:1.58%
17
50
516
5280
10
22
523
5308
—
—
—
10
24
479
5171
24
71
356
4411
Clinic/Center
261Q00000X [38004207]
261Q00000X [38004207]
—
—
—
—
—
3.8e+00
1.9e+00
—
—
—
—
—
—
—
—
—
—
cases:5.73%
controls:0.13%
cases:4.74%
controls:0.74%
—
—
—
—
—
28
7
461
5188
18
33
362
4449
12 lead EKG panel
34534-8 [3044889]
34534-8 [3044889]
1.1e-01
2.2e-01
2.1e+00
—
2.6e+00
9.8e-01
1.1e-01
cases:21.76%
controls:19.98%
cases:14.26%
controls:11.82%
cases:8.82%
controls:1.18%
—
—
cases:13.31%
controls:1.13%
cases:25.36%
controls:11.36%
cases:31.32%
controls:28.94%
116
1065
417
4265
76
630
457
4700
47
63
486
5267
—
70
60
456
5255
124
590
365
4605
119
1297
261
3185
Ferritin [Mass/volume] in Serum or Plasma
2276-4 [3001122]
2276-4 [3001122]
1.2e-01
9.2e-01
2.2e+00
—
1.7e+00
8.3e-01
4.0e-01
cases:6.38%
controls:5.70%
cases:9.01%
controls:3.81%
cases:4.13%
controls:0.47%
—
—
cases:3.04%
controls:0.58%
cases:9.20%
controls:4.22%
cases:18.68%
controls:13.30%
34
304
499
5026
48
203
485
5127
22
25
511
5305
—
16
31
510
5284
45
219
444
4976
71
596
309
3886
Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
2324-2 [3026910]
2324-2 [3026910]
1.6e-01
3.9e-01
2.7e+00
—
2.3e+00
6.6e-01
1.9e-01
cases:14.82%
controls:12.91%
cases:9.38%
controls:6.53%
cases:6.75%
controls:0.51%
—
—
cases:6.65%
controls:0.73%
cases:12.68%
controls:6.95%
cases:24.74%
controls:21.44%
79
688
454
4642
50
348
483
4982
36
27
497
5303
—
35
39
491
5276
62
361
427
4834
94
961
286
3521
Sepsis, unspecified
A41.9 [45585911]
A41.9 [45585911]
-1.0e+50
—
—
—
—
2.9e+00
2.6e+00
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
cases:2.45%
controls:0.13%
cases:3.16%
controls:0.25%
0
19
533
5311
—
—
—
—
12
7
477
5188
12
11
368
4471
Pulmonary Disease
29 [38004472]
29 [38004472]
5.7e-02
4.8e-01
1.7e+00
—
1.7e+00
1.1e+00
1.1e+00
cases:11.44%
controls:10.88%
cases:9.01%
controls:5.76%
cases:5.82%
controls:1.14%
—
—
cases:5.32%
controls:1.02%
cases:14.11%
controls:5.33%
cases:27.89%
controls:11.85%
61
580
472
4750
48
307
485
5023
31
61
502
5269
—
28
54
498
5261
69
277
420
4918
106
531
274
3951
Panorama tomography of teeth and jaws or similar X-ray examination
EB1HA [2001301913]
EB1HA [2001301913]
1.4e-01
4.5e-01
1.7e+00
1.0e+50
2.9e+00
1.8e+00
7.6e-01
cases:7.69%
controls:6.74%
cases:3.56%
controls:2.31%
cases:0.94%
controls:0.17%
cases:1.13%
controls:0.00%
cases:3.42%
controls:0.19%
cases:9.61%
controls:1.81%
cases:14.21%
controls:7.16%
41
359
492
4971
19
123
514
5207
5
9
528
5321
6
0
527
5330
18
10
508
5305
47
94
442
5101
54
321
326
4161
X-ray mammography
HA1AA [2001303884]
HA1AA [2001303884]
2.7e+00
—
—
—
—
—
2.7e+00
cases:1.69%
controls:0.11%
—
—
—
—
—
—
—
—
—
—
cases:2.63%
controls:0.18%
9
6
524
5324
—
—
—
—
—
10
8
370
4474
Extended examination of mouth
SAA03 [2001310276]
SAA03 [2001310276]
-7.8e-02
5.0e-01
—
—
2.9e+00
1.6e+00
9.5e-01
cases:6.75%
controls:7.26%
cases:2.63%
controls:1.61%
—
—
—
—
cases:1.71%
controls:0.09%
cases:6.75%
controls:1.48%
cases:12.63%
controls:5.31%
36
387
497
4943
14
86
519
5244
—
—
9
5
517
5310
33
77
456
5118
48
238
332
4244
omeprazole; oral, parenteral
A02BC01 [21600096]
A02BC01 [21600096]
3.1e-01
9.2e-01
1.3e+00
—
2.0e+00
1.6e+00
8.9e-01
cases:5.25%
controls:3.92%
cases:4.50%
controls:1.84%
cases:1.50%
controls:0.39%
—
—
cases:2.85%
controls:0.40%
cases:8.59%
controls:1.83%
cases:7.63%
controls:3.28%
28
209
505
5121
24
98
509
5232
8
21
525
5309
—
15
21
511
5294
42
95
447
5100
29
147
351
4335
Other and unspecified abdominal pain
R10.4 [45568113]
R10.4 [45568113]
7.3e-02
1.2e+00
3.2e+00
—
—
1.0e+00
1.3e-01
cases:5.63%
controls:5.25%
cases:4.13%
controls:1.26%
cases:2.25%
controls:0.09%
—
—
—
—
cases:3.89%
controls:1.44%
cases:5.79%
controls:5.11%
30
280
503
5050
22
67
511
5263
12
5
521
5325
—
—
19
75
470
5120
22
229
358
4253
pH of Venous blood
2746-6 [3012544]
2746-6 [3012544]
-4.5e-01
7.4e-01
—
—
2.8e+00
2.6e+00
5.1e-01
cases:0.94%
controls:1.46%
cases:1.88%
controls:0.90%
—
—
—
—
cases:1.90%
controls:0.11%
cases:9.00%
controls:0.75%
cases:6.58%
controls:4.04%
5
78
528
5252
10
48
523
5282
—
—
10
6
516
5309
44
39
445
5156
25
181
355
4301
Infiltration anesthesia
WX110 [2001310767]
WX110 [2001310767]
1.8e-01
4.8e-01
1.3e+00
—
2.0e+00
1.4e+00
6.4e-01
cases:19.32%
controls:16.72%
cases:10.69%
controls:6.92%
cases:3.38%
controls:0.90%
—
—
cases:4.75%
controls:0.70%
cases:22.90%
controls:6.68%
cases:32.89%
controls:20.55%
103
891
430
4439
57
369
476
4961
18
48
515
5282
—
25
37
501
5278
112
347
377
4848
125
921
255
3561
Mycobacterium tuberculosis DNA [Presence] in Specimen by NAA with probe detection
13956-8 [3014162]
13956-8 [3014162]
—
—
—
1.0e+50
—
2.9e+00
2.4e+00
—
—
—
—
—
—
cases:1.13%
controls:0.00%
—
—
cases:3.48%
controls:0.19%
cases:8.95%
controls:0.85%
—
—
—
6
0
527
5330
—
17
10
472
5185
34
38
346
4444
Removal of sutures
SPAT1153 [2001700254]
SPAT1153 [2001700254]
5.4e-01
8.5e-01
—
—
3.1e+00
1.9e-01
7.8e-01
cases:10.13%
controls:6.17%
cases:4.13%
controls:1.80%
—
—
—
—
cases:4.18%
controls:0.19%
cases:1.84%
controls:1.52%
cases:10.79%
controls:5.27%
54
329
479
5001
22
96
511
5234
—
—
22
10
504
5305
9
79
480
5116
41
236
339
4246
Cytology report of Tissue fine needle aspirate Cyto stain
33718-8 [3043109]
33718-8 [3043109]
1.3e+00
3.1e+00
1.0e+50
—
—
—
2.2e+00
cases:0.94%
controls:0.26%
cases:2.06%
controls:0.09%
cases:1.13%
controls:0.00%
—
—
—
—
—
—
cases:2.11%
controls:0.25%
5
14
528
5316
11
5
522
5325
6
0
527
5330
—
—
—
8
11
372
4471
Troponin T.cardiac [Mass/volume] in Serum or Plasma
6598-7 [3019800]
6598-7 [3019800]
-8.3e-02
2.8e-01
1.5e+00
—
2.4e+00
8.9e-01
4.6e-01
cases:8.07%
controls:8.71%
cases:5.44%
controls:4.18%
cases:3.00%
controls:0.69%
—
—
cases:6.65%
controls:0.62%
cases:11.04%
controls:4.85%
cases:22.11%
controls:15.15%
43
464
490
4866
29
223
504
5107
16
37
517
5293
—
35
33
491
5282
54
252
435
4943
84
679
296
3803
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
24357-6 [3037467]
-1.2e-01
5.5e-01
1.7e+00
—
2.1e+00
9.0e-01
2.3e-01
cases:15.57%
controls:17.19%
cases:15.01%
controls:9.25%
cases:7.50%
controls:1.46%
—
—
cases:9.13%
controls:1.19%
cases:21.47%
controls:10.01%
cases:29.74%
controls:25.15%
83
916
450
4414
80
493
453
4837
40
78
493
5252
—
48
63
478
5252
105
520
384
4675
113
1127
267
3355
Granulocytes [#/volume] in Blood
30394-1 [3035715]
30394-1 [3035715]
1.5e+00
—
—
—
—
2.6e+00
2.7e+00
cases:1.13%
controls:0.26%
—
—
—
—
—
—
—
—
cases:2.04%
controls:0.15%
cases:3.68%
controls:0.27%
6
14
527
5316
—
—
—
—
10
8
479
5187
14
12
366
4470
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
51480-2 [3031040]
-1.7e-01
3.0e-01
1.7e+00
—
1.5e+00
1.4e+00
6.7e-01
cases:13.51%
controls:15.59%
cases:11.07%
controls:8.48%
cases:6.57%
controls:1.31%
—
—
cases:4.94%
controls:1.17%
cases:28.43%
controls:8.87%
cases:37.11%
controls:23.25%
72
831
461
4499
59
452
474
4878
35
70
498
5260
—
26
62
500
5253
139
461
350
4734
141
1042
239
3440
moxifloxacin; oral, parenteral
J01MA14 [21603021]
J01MA14 [21603021]
—
1.3e+00
—
—
—
2.9e+00
2.3e+00
—
—
cases:1.13%
controls:0.30%
—
—
—
—
—
—
cases:4.50%
controls:0.27%
cases:10.00%
controls:1.07%
—
6
16
527
5314
—
—
—
22
14
467
5181
38
48
342
4434
Emergency Medicine
93 [38004510]
93 [38004510]
-9.7e-03
3.4e-01
2.0e+00
—
1.5e+00
1.2e+00
4.5e-01
cases:13.32%
controls:13.43%
cases:10.32%
controls:7.56%
cases:8.26%
controls:1.18%
—
—
cases:4.18%
controls:0.94%
cases:22.70%
controls:8.49%
cases:34.74%
controls:25.41%
71
716
462
4614
55
403
478
4927
44
63
489
5267
—
22
50
504
5265
111
441
378
4754
132
1139
248
3343
Amylase [Enzymatic activity/volume] in Serum or Plasma
1798-8 [3016771]
1798-8 [3016771]
3.2e-01
1.1e+00
2.9e+00
—
1.3e+00
1.1e+00
2.1e-01
cases:7.32%
controls:5.40%
cases:7.32%
controls:2.53%
cases:4.69%
controls:0.26%
—
—
cases:1.33%
controls:0.38%
cases:8.18%
controls:2.89%
cases:12.37%
controls:10.31%
39
288
494
5042
39
135
494
5195
25
14
508
5316
—
7
20
519
5295
40
150
449
5045
47
462
333
4020
Sodium and Potassium panel [Moles/volume] - Serum or Plasma
34548-8 [3045783]
34548-8 [3045783]
5.0e-02
2.0e-01
2.1e+00
—
2.1e+00
9.8e-01
4.6e-01
cases:4.88%
controls:4.65%
cases:2.81%
controls:2.33%
cases:3.75%
controls:0.49%
—
—
cases:3.42%
controls:0.45%
cases:5.32%
controls:2.06%
cases:6.05%
controls:3.93%
26
248
507
5082
15
124
518
5206
20
26
513
5304
—
18
24
508
5291
26
107
463
5088
23
176
357
4306
Cortisol [Moles/volume] in Serum or Plasma
14675-3 [3036481]
14675-3 [3036481]
-4.9e-02
—
—
—
2.3e+00
1.5e+00
1.3e+00
cases:1.13%
controls:1.18%
—
—
—
—
—
—
cases:1.14%
controls:0.11%
cases:2.25%
controls:0.50%
cases:6.84%
controls:2.03%
6
63
527
5267
—
—
—
6
6
520
5309
11
26
478
5169
26
91
354
4391
Complement+Immunoglobulin [Units/volume] in Red Blood Cells
4533-6 [3024403]
4533-6 [3024403]
1.5e+00
2.2e+00
1.0e+50
—
—
2.9e+00
1.3e+00
cases:1.50%
controls:0.34%
cases:1.13%
controls:0.13%
cases:2.44%
controls:0.00%
—
—
—
—
cases:2.86%
controls:0.15%
cases:2.63%
controls:0.71%
8
18
525
5312
6
7
527
5323
13
0
520
5330
—
—
14
8
475
5187
10
32
370
4450
Physiotherapy
R4110 [2001310233]
R4110 [2001310233]
-1.7e-02
1.7e-01
—
—
2.2e+00
2.1e+00
8.2e-01
cases:4.50%
controls:4.58%
cases:1.88%
controls:1.59%
—
—
—
—
cases:1.33%
controls:0.15%
cases:11.25%
controls:1.56%
cases:9.74%
controls:4.55%
24
244
509
5086
10
85
523
5245
—
—
7
8
519
5307
55
81
434
5114
37
204
343
4278
Osmolality of Urine
2695-5 [3026782]
2695-5 [3026782]
-7.9e-02
7.5e-01
1.7e+00
—
1.8e+00
1.6e+00
5.8e-01
cases:4.32%
controls:4.65%
cases:4.32%
controls:2.08%
cases:1.88%
controls:0.34%
—
—
cases:1.52%
controls:0.26%
cases:9.61%
controls:2.16%
cases:9.21%
controls:5.40%
23
248
510
5082
23
111
510
5219
10
18
523
5312
—
8
14
518
5301
47
112
442
5083
35
242
345
4240
Forced vital capacity [Volume] Respiratory system --post bronchodilation
19875-4 [3001668]
19875-4 [3001668]
1.1e+00
9.2e-01
—
—
—
2.2e+00
1.8e+00
cases:3.38%
controls:1.20%
cases:1.13%
controls:0.45%
—
—
—
—
—
—
cases:2.86%
controls:0.33%
cases:5.53%
controls:0.98%
18
64
515
5266
6
24
527
5306
—
—
—
14
17
475
5178
21
44
359
4438
FEV1 --post bronchodilation
20155-8 [3023550]
20155-8 [3023550]
1.1e+00
9.2e-01
—
—
—
2.2e+00
1.8e+00
cases:3.38%
controls:1.20%
cases:1.13%
controls:0.45%
—
—
—
—
—
—
cases:2.86%
controls:0.33%
cases:5.53%
controls:0.98%
18
64
515
5266
6
24
527
5306
—
—
—
14
17
475
5178
21
44
359
4438
FEV1/FVC --post bronchodilation
69970-2 [42868459]
69970-2 [42868459]
1.1e+00
9.2e-01
—
—
—
2.2e+00
1.8e+00
cases:3.38%
controls:1.20%
cases:1.13%
controls:0.45%
—
—
—
—
—
—
cases:2.86%
controls:0.33%
cases:5.53%
controls:0.98%
18
64
515
5266
6
24
527
5306
—
—
—
14
17
475
5178
21
44
359
4438
FVC percent change Respiratory system
69982-7 [42868471]
69982-7 [42868471]
1.1e+00
9.2e-01
—
—
—
2.2e+00
1.8e+00
cases:3.38%
controls:1.20%
cases:1.13%
controls:0.45%
—
—
—
—
—
—
cases:2.86%
controls:0.33%
cases:5.53%
controls:0.98%
18
64
515
5266
6
24
527
5306
—
—
—
14
17
475
5178
21
44
359
4438
FEV1 percent change
69983-5 [42868472]
69983-5 [42868472]
1.1e+00
9.2e-01
—
—
—
2.2e+00
1.8e+00
cases:3.38%
controls:1.20%
cases:1.13%
controls:0.45%
—
—
—
—
—
—
cases:2.86%
controls:0.33%
cases:5.53%
controls:0.98%
18
64
515
5266
6
24
527
5306
—
—
—
14
17
475
5178
21
44
359
4438
General Practice Dentistry
1223G0001X [38003675]
1223G0001X [38003675]
—
—
—
—
—
2.8e+00
2.2e+00
—
—
—
—
—
—
—
—
—
—
cases:2.25%
controls:0.13%
cases:2.89%
controls:0.33%
—
—
—
—
—
11
7
478
5188
11
15
369
4467
pH of Urine
2756-5 [3015736]
2756-5 [3015736]
1.6e-01
6.8e-01
1.6e+00
—
2.0e+00
7.9e-01
1.6e-01
cases:9.19%
controls:7.92%
cases:8.44%
controls:4.48%
cases:3.56%
controls:0.75%
—
—
cases:3.61%
controls:0.53%
cases:10.63%
controls:5.12%
cases:17.89%
controls:15.68%
49
422
484
4908
45
239
488
5091
19
40
514
5290
—
19
28
507
5287
52
266
437
4929
68
703
312
3779
Zoster without complication
B02.9 [45581143]
B02.9 [45581143]
—
1.7e+00
—
—
—
2.9e+00
2.1e+00
—
—
cases:0.94%
controls:0.17%
—
—
—
—
—
—
cases:3.07%
controls:0.17%
cases:6.32%
controls:0.83%
—
5
9
528
5321
—
—
—
15
9
474
5186
24
37
356
4445
pantoprazole; oral, parenteral
A02BC02 [21600097]
A02BC02 [21600097]
1.3e-01
5.2e-01
4.9e-01
1.6e+00
2.1e+00
1.5e+00
8.7e-01
cases:20.45%
controls:18.39%
cases:18.01%
controls:11.52%
cases:4.88%
controls:3.04%
cases:0.94%
controls:0.19%
cases:19.20%
controls:2.86%
cases:37.01%
controls:11.51%
cases:38.95%
controls:21.15%
109
980
424
4350
96
614
437
4716
26
162
507
5168
5
10
528
5320
101
152
425
5163
181
598
308
4597
148
948
232
3534
General anesthesia, balanced
WX408 [2001310808]
WX408 [2001310808]
7.2e-01
1.7e+00
—
1.0e+50
—
1.5e+00
1.1e+00
cases:5.63%
controls:2.83%
cases:3.94%
controls:0.77%
—
—
cases:3.94%
controls:0.00%
—
—
cases:3.07%
controls:0.69%
cases:5.26%
controls:1.85%
30
151
503
5179
21
41
512
5289
—
21
0
512
5330
—
15
36
474
5159
20
83
360
4399
Erythrocytes [Presence] in Urine by Automated
53292-9 [3041096]
53292-9 [3041096]
1.2e-01
5.6e-01
1.8e+00
—
2.1e+00
9.7e-01
4.3e-01
cases:5.82%
controls:5.20%
cases:5.25%
controls:3.06%
cases:2.44%
controls:0.43%
—
—
cases:2.66%
controls:0.32%
cases:7.98%
controls:3.20%
cases:14.47%
controls:9.95%
31
277
502
5053
28
163
505
5167
13
23
520
5307
—
14
17
512
5298
39
166
450
5029
55
446
325
4036
Ketones [Presence] in Urine by Test strip
2514-8 [3035350]
2514-8 [3035350]
9.2e-02
5.6e-01
1.5e+00
—
1.9e+00
8.0e-01
2.2e-01
cases:10.69%
controls:9.85%
cases:9.94%
controls:5.91%
cases:4.32%
controls:0.96%
—
—
cases:4.94%
controls:0.75%
cases:14.11%
controls:6.89%
cases:24.47%
controls:20.62%
57
525
476
4805
53
315
480
5015
23
51
510
5279
—
26
40
500
5275
69
358
420
4837
93
924
287
3558
Nitrite [Presence] in Urine by Test strip
5802-4 [3021601]
5802-4 [3021601]
1.3e-01
6.0e-01
1.5e+00
—
1.9e+00
8.2e-01
2.4e-01
cases:10.69%
controls:9.53%
cases:10.13%
controls:5.82%
cases:4.13%
controls:0.94%
—
—
cases:4.75%
controls:0.75%
cases:14.11%
controls:6.72%
cases:24.47%
controls:20.30%
57
508
476
4822
54
310
479
5020
22
50
511
5280
—
25
40
501
5275
69
349
420
4846
93
910
287
3572
Clostridioides difficile toxin genes [Presence] in Stool by NAA with probe detection
54067-4 [3051552]
54067-4 [3051552]
1.8e-01
8.9e-01
—
—
—
3.4e+00
1.4e+00
cases:0.94%
controls:0.79%
cases:1.31%
controls:0.54%
—
—
—
—
—
—
cases:13.09%
controls:0.48%
cases:6.05%
controls:1.61%
5
42
528
5288
7
29
526
5301
—
—
—
64
25
425
5170
23
72
357
4410
Glucose [Presence] in Urine by Test strip
25428-4 [3009261]
25428-4 [3009261]
8.6e-02
5.5e-01
1.5e+00
—
1.9e+00
8.1e-01
2.3e-01
cases:10.88%
controls:10.08%
cases:9.94%
controls:5.98%
cases:4.32%
controls:0.96%
—
—
cases:4.94%
controls:0.77%
cases:14.31%
controls:6.93%
cases:24.74%
controls:20.73%
58
537
475
4793
53
319
480
5011
23
51
510
5279
—
26
41
500
5274
70
360
419
4835
94
929
286
3553
Telephone prescription or other care instructions
WZB00 [2001310884]
WZB00 [2001310884]
2.7e-01
4.5e-01
—
—
2.1e+00
1.3e+00
1.3e+00
cases:5.63%
controls:4.37%
cases:1.88%
controls:1.20%
—
—
—
—
cases:1.52%
controls:0.19%
cases:4.29%
controls:1.25%
cases:12.89%
controls:3.70%
30
233
503
5097
10
64
523
5266
—
—
8
10
518
5305
21
65
468
5130
49
166
331
4316
Oral Surgery
19 [38004464]
19 [38004464]
—
1.3e+00
—
—
—
2.7e+00
2.0e+00
—
—
cases:1.13%
controls:0.30%
—
—
—
—
—
—
cases:3.27%
controls:0.23%
cases:3.68%
controls:0.51%
—
6
16
527
5314
—
—
—
16
12
473
5183
14
23
366
4459
CD3 cells [#/volume] in Blood
8122-4 [3011412]
8122-4 [3011412]
—
—
—
—
1.0e+50
—
4.6e+00
—
—
—
—
—
—
—
—
cases:2.85%
controls:0.00%
—
—
cases:12.11%
controls:0.13%
—
—
—
—
15
0
511
5315
—
46
6
334
4476
Lymphocyte T-cell and B-cell and Natural killer subsets panel - Blood
80721-4 [21493690]
80721-4 [21493690]
—
—
—
—
1.0e+50
—
4.6e+00
—
—
—
—
—
—
—
—
cases:2.47%
controls:0.00%
—
—
cases:10.00%
controls:0.11%
—
—
—
—
13
0
513
5315
—
38
5
342
4477
Treponema pallidum Ab [Presence] in Serum
22587-0 [3019832]
22587-0 [3019832]
—
1.5e+00
—
—
—
4.6e+00
8.3e-01
—
—
cases:1.13%
controls:0.24%
—
—
—
—
—
—
cases:13.09%
controls:0.15%
cases:2.37%
controls:1.05%
—
6
13
527
5317
—
—
—
64
8
425
5187
9
47
371
4435
Palliative care
Z51.5 [45547323]
Z51.5 [45547323]
—
—
—
—
—
2.9e+00
1.6e+00
—
—
—
—
—
—
—
—
—
—
cases:3.48%
controls:0.19%
cases:3.68%
controls:0.74%
—
—
—
—
—
17
10
472
5185
14
33
366
4449
IgA [Mass/volume] in Serum or Plasma
2458-8 [3007164]
2458-8 [3007164]
5.4e-01
1.7e+00
—
—
—
1.8e+00
1.1e+00
cases:3.19%
controls:1.88%
cases:4.13%
controls:0.81%
—
—
—
—
—
—
cases:6.54%
controls:1.12%
cases:11.32%
controls:4.26%
17
100
516
5230
22
43
511
5287
—
—
—
32
58
457
5137
43
191
337
4291
CD3-CD16+CD56+ (Natural killer) cells/cells in Blood
8112-5 [3027831]
8112-5 [3027831]
—
—
—
—
1.0e+50
—
4.4e+00
—
—
—
—
—
—
—
—
cases:2.09%
controls:0.00%
—
—
cases:10.26%
controls:0.13%
—
—
—
—
11
0
515
5315
—
39
6
341
4476
CD3 cells/Lymphocytes in Blood
90304-7 [1175426]
90304-7 [1175426]
—
—
—
—
1.0e+50
—
4.4e+00
—
—
—
—
—
—
—
—
cases:2.28%
controls:0.00%
—
—
cases:10.26%
controls:0.13%
—
—
—
—
12
0
514
5315
—
39
6
341
4476
Albumin [Presence] in Urine by Test strip
50949-7 [3029937]
50949-7 [3029937]
1.3e-02
6.2e-01
1.7e+00
—
1.9e+00
8.6e-01
3.8e-01
cases:6.19%
controls:6.12%
cases:6.75%
controls:3.75%
cases:3.00%
controls:0.58%
—
—
cases:3.23%
controls:0.49%
cases:9.41%
controls:4.22%
cases:15.79%
controls:11.33%
33
326
500
5004
36
200
497
5130
16
31
517
5299
—
17
26
509
5289
46
219
443
4976
60
508
320
3974
SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with probe detection
94759-8 [586526]
94759-8 [586526]
7.6e-01
1.8e+00
—
—
—
2.6e+00
8.9e-01
cases:1.31%
controls:0.62%
cases:1.31%
controls:0.23%
—
—
—
—
—
—
cases:3.68%
controls:0.27%
cases:4.74%
controls:2.01%
7
33
526
5297
7
12
526
5318
—
—
—
18
14
471
5181
18
90
362
4392
CD4 cells/Lymphocytes in Specimen
80223-1 [21494815]
80223-1 [21494815]
—
—
—
—
1.0e+50
—
4.4e+00
—
—
—
—
—
—
—
—
cases:1.14%
controls:0.00%
—
—
cases:10.00%
controls:0.13%
—
—
—
—
6
0
520
5315
—
38
6
342
4476
Extensive CT examination of arteria pulmonalis
FB1BD [2001302407]
FB1BD [2001302407]
8.6e-01
1.4e+00
—
—
—
2.4e+00
2.0e+00
cases:1.50%
controls:0.64%
cases:0.94%
controls:0.24%
—
—
—
—
—
—
cases:2.86%
controls:0.27%
cases:4.47%
controls:0.62%
8
34
525
5296
5
13
528
5317
—
—
—
14
14
475
5181
17
28
363
4454
Procalcitonin [Mass/volume] in Serum or Plasma
33959-8 [3046279]
33959-8 [3046279]
-1.0e+50
—
—
—
—
2.6e+00
1.8e+00
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
cases:4.09%
controls:0.31%
cases:6.32%
controls:1.14%
0
19
533
5311
—
—
—
—
20
16
469
5179
24
51
356
4431
Paranasal sinuses X-ray examination without contrast
DM1AA [2001301740]
DM1AA [2001301740]
1.6e+00
—
—
—
—
—
4.4e+00
cases:0.94%
controls:0.19%
—
—
—
—
—
—
—
—
—
—
cases:8.16%
controls:0.11%
5
10
528
5320
—
—
—
—
—
31
5
349
4477
Telephone, letter or other consultation without direct patient contact
ZY020 [2001311600]
ZY020 [2001311600]
6.0e-01
1.4e+00
—
—
—
3.0e+00
1.4e+00
cases:1.50%
controls:0.83%
cases:0.94%
controls:0.23%
—
—
—
—
—
—
cases:2.66%
controls:0.13%
cases:2.63%
controls:0.69%
8
44
525
5286
5
12
528
5318
—
—
—
13
7
476
5188
10
31
370
4451
rituximab
L01FA01 [955167]
L01FA01 [955167]
—
—
1.0e+50
—
—
—
4.4e+00
—
—
—
—
cases:0.94%
controls:0.00%
—
—
—
—
—
—
cases:9.47%
controls:0.13%
—
—
5
0
528
5330
—
—
—
36
6
344
4476
Gastrointestinal bacterial pathogens panel - Stool by NAA with probe detection
92695-6 [37019628]
92695-6 [37019628]
—
—
—
—
—
2.9e+00
1.4e+00
—
—
—
—
—
—
—
—
—
—
cases:3.48%
controls:0.19%
cases:2.63%
controls:0.67%
—
—
—
—
—
17
10
472
5185
10
30
370
4452
Neutrophils [#/volume] in Blood
26499-4 [3017732]
26499-4 [3017732]
3.6e-01
9.0e-01
—
—
2.7e+00
1.6e+00
4.9e-01
cases:1.69%
controls:1.18%
cases:1.88%
controls:0.77%
—
—
—
—
cases:1.71%
controls:0.11%
cases:3.89%
controls:0.83%
cases:4.74%
controls:2.97%
9
63
524
5267
10
41
523
5289
—
—
9
6
517
5309
19
43
470
5152
18
133
362
4349
dexamethasone and antiinfectives
S02CA06 [21605178]
S02CA06 [21605178]
7.7e-01
1.6e+00
—
—
—
2.7e+00
1.5e+00
cases:1.13%
controls:0.53%
cases:0.94%
controls:0.19%
—
—
—
—
—
—
cases:2.86%
controls:0.19%
cases:4.74%
controls:1.05%
6
28
527
5302
5
10
528
5320
—
—
—
14
10
475
5185
18
47
362
4435
Microscopic observation [Identifier] in Isolate by Gram stain
87975-9 [36305247]
87975-9 [36305247]
—
—
—
—
—
2.1e+00
2.1e+00
—
—
—
—
—
—
—
—
—
—
cases:1.43%
controls:0.17%
cases:4.74%
controls:0.60%
—
—
—
—
—
7
9
482
5186
18
27
362
4455
Multidisciplinary treatment meeting
WZC20 [2001310890]
WZC20 [2001310890]
—
—
1.0e+50
—
1.0e+50
—
4.2e+00
—
—
—
—
cases:0.94%
controls:0.00%
—
—
cases:3.61%
controls:0.00%
—
—
cases:7.11%
controls:0.11%
—
—
5
0
528
5330
—
19
0
507
5315
—
27
5
353
4477
Pneumocystis jirovecii DNA [Presence] in Specimen by NAA with probe detection
6521-9 [3009595]
6521-9 [3009595]
—
—
—
—
—
—
4.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.47%
controls:0.16%
—
—
—
—
—
—
36
7
344
4475
Influenza virus B RNA [Presence] in Nasopharynx by NAA with probe detection
76080-1 [46235759]
76080-1 [46235759]
—
-1.0e+50
—
—
—
2.6e+00
1.6e+00
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
cases:4.29%
controls:0.33%
cases:4.21%
controls:0.89%
—
0
14
533
5316
—
—
—
21
17
468
5178
16
40
364
4442
Bronchial lavation
TGC00 [2001303585]
TGC00 [2001303585]
—
—
—
—
—
—
4.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.16%
controls:0.13%
—
—
—
—
—
—
31
6
349
4476
Asthma, unspecified
J45.9 [45562456]
J45.9 [45562456]
-1.3e-01
2.7e-01
2.2e+00
—
2.0e+00
4.3e-01
2.4e-01
cases:3.19%
controls:3.60%
cases:2.06%
controls:1.58%
cases:1.31%
controls:0.15%
—
—
cases:1.71%
controls:0.24%
cases:2.66%
controls:1.75%
cases:5.79%
controls:4.60%
17
192
516
5138
11
84
522
5246
7
8
526
5322
—
9
13
517
5302
13
91
476
5104
22
206
358
4276
Leukocyte esterase [Presence] in Urine by Automated test strip
60026-2 [40763086]
60026-2 [40763086]
5.1e-02
5.0e-01
1.6e+00
—
1.7e+00
8.4e-01
2.5e-01
cases:9.01%
controls:8.59%
cases:8.07%
controls:5.05%
cases:3.38%
controls:0.73%
—
—
cases:3.61%
controls:0.66%
cases:11.66%
controls:5.41%
cases:19.21%
controls:15.57%
48
458
485
4872
43
269
490
5061
18
39
515
5291
—
19
35
507
5280
57
281
432
4914
73
698
307
3784
pneumococcus, purified polysaccharides antigen
J07AL01 [21601312]
J07AL01 [21601312]
—
—
—
—
—
—
4.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:12.11%
controls:0.22%
—
—
—
—
—
—
46
10
334
4472
Infectious Disease
44 [38004484]
44 [38004484]
1.6e-01
9.8e-01
—
—
—
2.3e+00
1.7e+00
cases:1.69%
controls:1.44%
cases:1.69%
controls:0.64%
—
—
—
—
—
—
cases:6.95%
controls:0.71%
cases:9.74%
controls:1.85%
9
77
524
5253
9
34
524
5296
—
—
—
34
37
455
5158
37
83
343
4399
poliomyelitis, trivalent, inactivated, whole virus
J07BF03 [21601352]
J07BF03 [21601352]
-1.0e+50
—
—
—
—
—
4.1e+00
cases:0.00%
controls:0.13%
—
—
—
—
—
—
—
—
—
—
cases:7.37%
controls:0.13%
0
7
533
5323
—
—
—
—
—
28
6
352
4476
Other minor procedure on skin
TQW99 [2001310150]
TQW99 [2001310150]
1.9e+00
—
—
—
—
—
2.2e+00
cases:1.50%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
cases:2.11%
controls:0.25%
8
12
525
5318
—
—
—
—
—
8
11
372
4471
Ileoscopy through colon
UJF30 [2001305028]
UJF30 [2001305028]
—
—
—
1.0e+50
—
2.6e+00
1.5e+00
—
—
—
—
—
—
cases:1.13%
controls:0.00%
—
—
cases:3.07%
controls:0.23%
cases:5.53%
controls:1.34%
—
—
—
6
0
527
5330
—
15
12
474
5183
21
60
359
4422
More than one and less than three hours
ZXE10 [2001311401]
ZXE10 [2001311401]
2.9e-01
1.0e+00
1.9e+00
1.0e+50
2.0e+00
1.9e+00
1.1e+00
cases:7.32%
controls:5.59%
cases:3.94%
controls:1.48%
cases:1.13%
controls:0.17%
cases:2.25%
controls:0.00%
cases:0.95%
controls:0.13%
cases:6.75%
controls:1.02%
cases:8.95%
controls:3.10%
39
298
494
5032
21
79
512
5251
6
9
527
5321
12
0
521
5330
5
7
521
5308
33
53
456
5142
34
139
346
4343
Prealbumin [Mass/volume] in Serum or Plasma
14338-8 [3013742]
14338-8 [3013742]
5.4e-01
1.4e+00
2.7e+00
—
—
1.4e+00
7.1e-01
cases:1.31%
controls:0.77%
cases:1.69%
controls:0.43%
cases:1.31%
controls:0.09%
—
—
—
—
cases:2.04%
controls:0.52%
cases:3.42%
controls:1.72%
7
41
526
5289
9
23
524
5307
7
5
526
5325
—
—
10
27
479
5168
13
77
367
4405
Polyneuropathy, unspecified
G62.9 [45566898]
G62.9 [45566898]
—
1.7e+00
—
—
—
2.4e+00
1.6e+00
—
—
cases:0.94%
controls:0.17%
—
—
—
—
—
—
cases:1.02%
controls:0.10%
cases:2.37%
controls:0.47%
—
5
9
528
5321
—
—
—
5
5
484
5190
9
21
371
4461
Influenza virus B Ag [Presence] in Nasopharynx by Immunoassay
46083-2 [3043362]
46083-2 [3043362]
—
—
—
—
—
2.2e+00
1.7e+00
—
—
—
—
—
—
—
—
—
—
cases:1.23%
controls:0.13%
cases:2.37%
controls:0.42%
—
—
—
—
—
6
7
483
5188
9
19
371
4463
Influenza virus A Ag [Presence] in Nasopharynx by Immunoassay
46082-4 [3046524]
46082-4 [3046524]
—
—
—
—
—
2.2e+00
1.7e+00
—
—
—
—
—
—
—
—
—
—
cases:1.23%
controls:0.13%
cases:2.37%
controls:0.42%
—
—
—
—
—
6
7
483
5188
9
19
371
4463
Enterovirus RNA [Presence] in Specimen by NAA with probe detection
29591-5 [3016881]
29591-5 [3016881]
—
—
—
—
—
—
4.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.53%
controls:0.11%
—
—
—
—
—
—
21
5
359
4477
CD3-CD16+CD56+ (Natural killer) cells [#/volume] in Blood
9728-7 [3025271]
9728-7 [3025271]
—
—
—
—
1.0e+50
1.0e+50
4.0e+00
—
—
—
—
—
—
—
—
cases:2.28%
controls:0.00%
cases:5.52%
controls:0.00%
cases:5.53%
controls:0.11%
—
—
—
—
12
0
514
5315
27
0
462
5195
21
5
359
4477
Rhinovirus RNA [Presence] in Specimen by NAA with probe detection
7993-9 [3025023]
7993-9 [3025023]
—
—
—
—
—
—
4.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.53%
controls:0.11%
—
—
—
—
—
—
21
5
359
4477
CD3+CD8+ (T8 suppressor) cells [#/volume] in Blood
14135-8 [3001405]
14135-8 [3001405]
—
—
—
—
1.0e+50
1.0e+50
4.0e+00
—
—
—
—
—
—
—
—
cases:2.28%
controls:0.00%
cases:5.11%
controls:0.00%
cases:5.53%
controls:0.11%
—
—
—
—
12
0
514
5315
25
0
464
5195
21
5
359
4477
25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma
68438-1 [40771025]
68438-1 [40771025]
-3.4e-01
4.5e-01
1.5e+00
1.0e+50
2.4e+00
1.0e-01
1.2e-01
cases:4.88%
controls:6.70%
cases:5.82%
controls:3.77%
cases:2.25%
controls:0.51%
cases:0.94%
controls:0.00%
cases:5.70%
controls:0.55%
cases:4.91%
controls:4.45%
cases:15.79%
controls:14.28%
26
357
507
4973
31
201
502
5129
12
27
521
5303
5
0
528
5330
30
29
496
5286
24
231
465
4964
60
640
320
3842
Chronic apical periodontitis
K04.5 [45586691]
K04.5 [45586691]
9.1e-03
-1.1e-01
—
—
2.8e+00
1.1e+00
4.7e-01
cases:4.32%
controls:4.28%
cases:1.31%
controls:1.46%
—
—
—
—
cases:2.09%
controls:0.13%
cases:4.29%
controls:1.44%
cases:7.89%
controls:5.06%
23
228
510
5102
7
78
526
5252
—
—
11
7
515
5308
21
75
468
5120
30
227
350
4255
amoxicillin and beta-lactamase inhibitor; oral, parenteral
J01CR02 [21602863]
J01CR02 [21602863]
2.0e-01
9.0e-01
—
—
1.7e+00
1.8e+00
1.1e+00
cases:9.76%
controls:8.11%
cases:4.69%
controls:1.97%
—
—
—
—
cases:1.14%
controls:0.21%
cases:12.68%
controls:2.25%
cases:21.05%
controls:7.81%
52
432
481
4898
25
105
508
5225
—
—
6
11
520
5304
62
117
427
5078
80
350
300
4132
Bicarbonate [Moles/volume] standard in Capillary blood
19231-0 [3004490]
19231-0 [3004490]
—
—
—
—
—
2.6e+00
1.2e+00
—
—
—
—
—
—
—
—
—
—
cases:4.09%
controls:0.31%
cases:3.68%
controls:1.09%
—
—
—
—
—
20
16
469
5179
14
49
366
4433
Laceration/cut
S18 [2002000983]
S18 [2002000983]
1.2e-01
3.2e-01
—
—
2.6e+00
7.5e-01
4.9e-01
cases:9.57%
controls:8.61%
cases:3.94%
controls:2.89%
—
—
—
—
cases:4.94%
controls:0.38%
cases:6.13%
controls:2.98%
cases:17.63%
controls:11.60%
51
459
482
4871
21
154
512
5176
—
—
26
20
500
5295
30
155
459
5040
67
520
313
3962
Human coronavirus NL63 RNA [Presence] in Specimen by NAA with probe detection
41005-0 [3040359]
41005-0 [3040359]
—
—
—
—
—
—
3.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.00%
controls:0.11%
—
—
—
—
—
—
19
5
361
4477
Human coronavirus 229E RNA [Presence] in Specimen by NAA with probe detection
41003-5 [3041642]
41003-5 [3041642]
—
—
—
—
—
—
3.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.00%
controls:0.11%
—
—
—
—
—
—
19
5
361
4477
Human coronavirus OC43 RNA [Presence] in Specimen by NAA with probe detection
41009-2 [3038546]
41009-2 [3038546]
—
—
—
—
—
—
3.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.00%
controls:0.11%
—
—
—
—
—
—
19
5
361
4477
Blood transfusion
WW500 [2001310603]
WW500 [2001310603]
1.5e+00
—
—
1.0e+50
1.0e+50
—
3.8e+00
cases:0.94%
controls:0.21%
—
—
—
—
cases:0.94%
controls:0.00%
cases:1.33%
controls:0.00%
—
—
cases:7.63%
controls:0.18%
5
11
528
5319
—
—
5
0
528
5330
7
0
519
5315
—
29
8
351
4474
CD3+CD4+ (T4 helper) cells/cells in Blood
8123-2 [3014037]
8123-2 [3014037]
—
—
1.0e+50
—
1.0e+50
1.0e+50
3.8e+00
—
—
—
—
cases:1.69%
controls:0.00%
—
—
cases:4.18%
controls:0.00%
cases:5.73%
controls:0.00%
cases:4.74%
controls:0.11%
—
—
9
0
524
5330
—
22
0
504
5315
28
0
461
5195
18
5
362
4477
Operative extraction of tooth
EBA10 [2001301925]
EBA10 [2001301925]
5.0e-01
1.4e+00
—
—
—
2.5e+00
1.3e+00
cases:1.69%
controls:1.03%
cases:0.94%
controls:0.24%
—
—
—
—
—
—
cases:2.45%
controls:0.21%
cases:3.68%
controls:1.03%
9
55
524
5275
5
13
528
5317
—
—
—
12
11
477
5184
14
46
366
4436
Pathology report gross observation
24419-4 [3002256]
24419-4 [3002256]
8.6e-01
1.3e+00
—
1.0e+50
—
2.1e+00
1.6e+00
cases:2.06%
controls:0.88%
cases:1.31%
controls:0.36%
—
—
cases:1.88%
controls:0.00%
—
—
cases:2.04%
controls:0.25%
cases:6.84%
controls:1.45%
11
47
522
5283
7
19
526
5311
—
10
0
523
5330
—
10
13
479
5182
26
65
354
4417
Morphology [Interpretation] in Bone marrow Narrative
51628-6 [3042111]
51628-6 [3042111]
1.5e+00
—
1.0e+50
1.0e+50
1.0e+50
1.0e+50
3.7e+00
cases:0.94%
controls:0.21%
—
—
cases:1.88%
controls:0.00%
cases:3.94%
controls:0.00%
cases:11.60%
controls:0.00%
cases:13.70%
controls:0.00%
cases:8.42%
controls:0.22%
5
11
528
5319
—
10
0
523
5330
21
0
512
5330
61
0
465
5315
67
0
422
5195
32
10
348
4472
Streptococcus pneumoniae DNA [Presence] in Specimen by NAA with probe detection
49672-9 [3032699]
49672-9 [3032699]
—
—
—
—
—
—
3.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.21%
controls:0.11%
—
—
—
—
—
—
16
5
364
4477
Examination and observation for other specified reasons
Z04.8 [45552063]
Z04.8 [45552063]
-1.1e-01
8.7e-01
2.7e+00
—
—
1.2e+00
1.0e+00
cases:1.31%
controls:1.46%
cases:0.94%
controls:0.39%
cases:1.31%
controls:0.09%
—
—
—
—
cases:1.64%
controls:0.52%
cases:4.74%
controls:1.76%
7
78
526
5252
5
21
528
5309
7
5
526
5325
—
—
8
27
481
5168
18
79
362
4403
Remote contact by phone
ZYC01 [2001311579]
ZYC01 [2001311579]
—
—
—
—
—
2.2e+00
1.5e+00
—
—
—
—
—
—
—
—
—
—
cases:1.64%
controls:0.19%
cases:3.68%
controls:0.85%
—
—
—
—
—
8
10
481
5185
14
38
366
4444
Fungus identified in Specimen by Culture
580-1 [3000494]
580-1 [3000494]
3.8e-01
5.6e-01
—
—
—
1.9e+00
1.7e+00
cases:3.00%
controls:2.08%
cases:1.50%
controls:0.86%
—
—
—
—
—
—
cases:4.50%
controls:0.71%
cases:13.16%
controls:2.57%
16
111
517
5219
8
46
525
5284
—
—
—
22
37
467
5158
50
115
330
4367
Cytomegalovirus DNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection
72493-0 [43055120]
72493-0 [43055120]
—
—
1.0e+50
—
1.0e+50
—
3.6e+00
—
—
—
—
cases:1.13%
controls:0.00%
—
—
cases:2.09%
controls:0.00%
—
—
cases:10.79%
controls:0.33%
—
—
6
0
527
5330
—
11
0
515
5315
—
41
15
339
4467
antibiotics in combination with corticosteroids
D01AA20 [21601918]
D01AA20 [21601918]
4.9e-01
1.2e+00
—
—
—
2.3e+00
1.2e+00
cases:1.88%
controls:1.16%
cases:1.50%
controls:0.45%
—
—
—
—
—
—
cases:3.27%
controls:0.33%
cases:5.00%
controls:1.54%
10
62
523
5268
8
24
525
5306
—
—
—
16
17
473
5178
19
69
361
4413
Bicarbonate [Moles/volume] in Serum or Plasma
1963-8 [3016293]
1963-8 [3016293]
—
1.5e+00
—
—
—
2.0e+00
9.4e-01
—
—
cases:2.06%
controls:0.45%
—
—
—
—
—
—
cases:2.66%
controls:0.37%
cases:3.95%
controls:1.58%
—
11
24
522
5306
—
—
—
13
19
476
5176
15
71
365
4411
Haemophilus influenzae DNA [Presence] in Specimen by NAA with probe detection
61366-1 [40764127]
61366-1 [40764127]
—
—
—
—
—
—
3.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.68%
controls:0.11%
—
—
—
—
—
—
14
5
366
4477
Bordetella parapertussis DNA [Presence] in Specimen by NAA with probe detection
29723-4 [3037875]
29723-4 [3037875]
—
—
—
—
—
—
3.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.68%
controls:0.11%
—
—
—
—
—
—
14
5
366
4477
Troponin I.cardiac [Mass/volume] in Serum or Plasma
10839-9 [3021337]
10839-9 [3021337]
-1.4e-01
4.0e-01
9.2e-01
—
2.4e+00
1.1e+00
9.3e-02
cases:3.38%
controls:3.86%
cases:4.13%
controls:2.81%
cases:0.94%
controls:0.38%
—
—
cases:2.85%
controls:0.26%
cases:7.36%
controls:2.60%
cases:7.37%
controls:6.76%
18
206
515
5124
22
150
511
5180
5
20
528
5310
—
15
14
511
5301
36
135
453
5060
28
303
352
4179
Respiratory syncytial virus RNA [Presence] in Specimen by NAA with probe detection
40988-8 [3044254]
40988-8 [3044254]
—
-1.0e+50
—
—
—
1.9e+00
1.6e+00
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
cases:2.25%
controls:0.33%
cases:3.68%
controls:0.80%
—
0
15
533
5315
—
—
—
11
17
478
5178
14
36
366
4446
pneumococcus, purified polysaccharides antigen conjugated
J07AL02 [21601313]
J07AL02 [21601313]
2.9e-01
—
—
—
—
1.5e+00
2.0e+00
cases:2.44%
controls:1.84%
—
—
—
—
—
—
—
—
cases:2.66%
controls:0.64%
cases:12.11%
controls:1.76%
13
98
520
5232
—
—
—
—
13
33
476
5162
46
79
334
4403
Gas panel - Capillary blood
24337-8 [3022313]
24337-8 [3022313]
—
—
—
—
—
2.4e+00
1.0e+00
—
—
—
—
—
—
—
—
—
—
cases:4.29%
controls:0.40%
cases:4.21%
controls:1.56%
—
—
—
—
—
21
21
468
5174
16
70
364
4412
Folate [Moles/volume] in Serum or Plasma
14732-2 [3021960]
14732-2 [3021960]
2.0e-01
5.4e-01
2.6e+00
—
9.8e-01
8.0e-01
4.0e-01
cases:3.19%
controls:2.63%
cases:3.19%
controls:1.88%
cases:3.00%
controls:0.23%
—
—
cases:0.95%
controls:0.36%
cases:5.52%
controls:2.56%
cases:14.21%
controls:10.02%
17
140
516
5190
17
100
516
5230
16
12
517
5318
—
5
19
521
5296
27
133
462
5062
54
449
326
4033
hydrocortisone; oral, parenteral
H02AB09 [21602737]
H02AB09 [21602737]
2.3e-01
8.8e-01
—
—
2.0e+00
1.4e+00
8.8e-01
cases:2.25%
controls:1.80%
cases:1.88%
controls:0.79%
—
—
—
—
cases:1.14%
controls:0.15%
cases:2.25%
controls:0.58%
cases:3.42%
controls:1.45%
12
96
521
5234
10
42
523
5288
—
—
6
8
520
5307
11
30
478
5165
13
65
367
4417
Mycobacterium sp identified in Specimen by Organism specific culture
543-9 [3005702]
543-9 [3005702]
—
—
—
—
—
—
3.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.32%
controls:0.22%
—
—
—
—
—
—
24
10
356
4472
Shigella sp [Presence] in Stool by Culture
82300-5 [42529406]
82300-5 [42529406]
—
—
—
—
—
3.4e+00
—
—
—
—
—
—
—
—
—
—
—
cases:3.89%
controls:0.13%
—
—
—
—
—
—
—
19
7
470
5188
—
Yersinia sp identified in Stool by Organism specific culture
28549-4 [3014765]
28549-4 [3014765]
—
—
—
—
—
3.4e+00
—
—
—
—
—
—
—
—
—
—
—
cases:3.89%
controls:0.13%
—
—
—
—
—
—
—
19
7
470
5188
—
Campylobacter sp identified in Tissue by Organism specific culture
20740-7 [3006418]
20740-7 [3006418]
—
—
—
—
—
3.4e+00
—
—
—
—
—
—
—
—
—
—
—
cases:3.89%
controls:0.13%
—
—
—
—
—
—
—
19
7
470
5188
—
sulfadiazine and trimethoprim
J01EE02 [21602962]
J01EE02 [21602962]
-3.1e-02
8.7e-01
—
—
—
2.4e+00
1.0e+00
cases:2.44%
controls:2.51%
cases:1.69%
controls:0.71%
—
—
—
—
—
—
cases:6.34%
controls:0.64%
cases:6.58%
controls:2.45%
13
134
520
5196
9
38
524
5292
—
—
—
31
33
458
5162
25
110
355
4372
fluconazole; oral, parenteral
J02AC01 [21603080]
J02AC01 [21603080]
3.9e-01
1.3e+00
—
—
—
2.1e+00
6.6e-01
cases:5.25%
controls:3.60%
cases:3.19%
controls:0.92%
—
—
—
—
—
—
cases:6.75%
controls:0.87%
cases:5.26%
controls:2.79%
28
192
505
5138
17
49
516
5281
—
—
—
33
45
456
5150
20
125
360
4357
Hemodialysis
TK800 [2001305768]
TK800 [2001305768]
-1.0e+50
-1.0e+50
—
—
—
3.4e+00
—
cases:0.00%
controls:0.11%
cases:0.00%
controls:0.11%
—
—
—
—
—
—
cases:3.27%
controls:0.12%
—
—
0
6
533
5324
0
6
533
5324
—
—
—
16
6
473
5189
—
LabWAS
↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
387
475
27.09
307.65
10.1
1.9
247.50
240.51
u/l
0.42
378
446
183
50
55.21
307.28
2.1
1.2
—
—
—
0
0
143
61
31.67
206.61
4.4
5.2
396.80
143.70
iu/ml
—
15
10
94
14
81.31
175.11
2.7
2.1
—
—
—
0
0
113
42
33.87
170.17
2.6
2.2
3190.63
324.57
u/ml
—
8
7
213
281
11.96
164.67
5.4
1.9
8.49
11.34
g/l
9.07
202
262
120
102
14.89
122.81
2.3
1.4
—
—
—
0
0
119
103
14.59
120.38
2.2
1.4
—
—
—
0
0
83
39
25.02
113.61
1.7
1.6
—
—
—
0
0
97
67
17.48
111.17
2.4
1.5
—
—
—
0
0
65
17
43.41
107.19
4.0
1.7
0.42
0.80
e9/l
1.70
58
17
355
1214
6.76
104.07
6.8
2.5
341.53
366.15
umol/l
3.93
347
1042
80
57
16.34
89.68
1.3
1.3
145.91
164.02
au/ml
0.55
34
20
251
706
5.83
89.11
7.6
2.5
0.81
0.83
mmol/l
1.94
246
653
143
236
7.91
87.92
3.2
1.3
1.06
1.24
g/l
0.40
132
223
59
22
30.03
87.41
5.7
2.0
28.21
47.24
%
4.57
43
13
203
489
6.09
85.28
3.9
1.9
67.29
66.27
e9/l
0.14
165
369
88
85
12.20
82.00
1.7
1.3
—
—
—
0
0
91
95
11.35
80.39
1.8
1.3
—
—
—
0
0
218
633
5.14
72.28
6.7
5.1
1.10
1.02
mmol/l
3.09
213
578
410
1970
5.69
70.67
10.4
3.8
34.31
35.36
g/l
3.09
394
1818
443
2270
6.64
70.50
36.6
5.8
3.30
4.45
e9/l
17.68
419
1958
438
2224
6.44
70.45
21.7
3.9
10.05
12.91
umol/l
11.93
431
2104
56
32
19.44
69.74
2.9
1.7
—
—
—
0
0
433
2192
6.20
69.46
14.4
5.3
0.16
0.21
e9/l
10.56
403
1897
54
30
19.92
68.10
2.9
1.7
—
—
—
0
0
65
53
13.83
67.05
1.8
1.4
—
—
—
0
0
65
55
13.32
65.53
1.7
1.5
—
—
—
0
0
246
844
4.56
64.80
3.1
1.8
—
—
—
0
0
76
83
10.51
64.63
1.7
1.3
—
—
—
0
0
142
312
5.84
64.35
2.3
1.4
—
—
—
0
0
71
71
11.38
64.22
1.7
1.3
—
—
—
0
0
83
107
9.00
62.13
1.7
1.6
—
—
—
0
0
191
606
4.35
54.46
2.5
1.8
—
—
—
0
0
47
31
16.53
54.32
3.0
1.1
—
—
—
0
0
47
31
16.53
54.32
3.0
1.1
—
—
—
0
0
47
31
16.53
54.32
3.0
1.1
—
—
—
0
0
94
167
6.62
52.58
2.3
3.4
—
—
—
0
0
48
35
14.97
52.55
5.4
2.7
48.03
56.93
%
1.18
48
28
196
649
4.19
52.46
2.5
1.8
—
—
—
0
0
413
2313
4.49
50.13
13.9
6.1
1.21
1.21
mmol/l
0.15
357
1994
43
28
16.62
49.95
1.2
1.1
—
—
—
0
0
58
68
9.45
46.44
3.2
1.4
32.83
32.91
pg
0.04
58
68
375
2065
3.75
44.25
12.8
5.7
1.21
1.20
mmol/l
0.38
365
1880
297
1458
3.34
41.31
9.6
2.0
2.33
2.35
mmol/l
1.29
283
1257
46
8
62.71
39.98
4.0
1.5
1.41
1.38
%
—
46
8
130
383
4.17
39.77
2.6
1.6
64.75
66.48
g/l
1.49
125
350
61
92
7.36
39.50
1.6
1.5
—
—
—
0
0
52
66
8.62
39.00
1.3
1.1
342.22
256.45
u/ml
0.44
23
33
36
32
11.99
34.80
1.7
1.4
—
—
—
0
0
330
1879
2.99
32.79
25.4
10.5
0.01
0.00
e9/l
0.59
296
1542
179
742
3.13
31.57
2.5
1.3
1.89
2.90
g/l
7.58
145
432
87
229
4.35
30.50
3.4
1.5
20.31
2.82
ug/l
0.53
68
177
39
47
8.87
30.35
1.3
1.3
—
—
—
0
0
31
27
12.13
30.28
1.8
1.4
—
—
—
0
0
326
1917
2.80
29.21
6.0
2.5
—
—
estimate
—
0
0
31
30
10.91
28.25
1.8
1.4
—
—
—
0
0
36
11
34.97
28.14
1.3
1.5
—
—
—
0
0
457
3265
3.80
28.13
27.8
5.6
82.43
77.76
u/l
1.56
448
3032
199
938
2.79
27.09
6.9
2.1
2.45
2.44
mmol/l
0.79
189
818
34
40
9.01
26.91
1.9
1.4
—
—
—
0
0
36
46
8.32
26.70
1.1
1.1
—
—
—
0
0
124
463
3.19
25.60
7.6
2.2
7.38
7.75
umol/l
0.07
113
407
30
33
9.57
24.95
1.1
1.2
—
—
—
0
0
60
145
4.54
23.28
1.9
1.2
—
—
—
0
0
236
1301
2.46
22.35
4.0
3.0
0.27
0.48
e6/l
1.52
192
952
200
1023
2.53
22.27
6.0
2.2
—
—
—
0
0
261
1515
2.42
21.91
4.2
3.1
22.68
111.61
e6/l
1.21
214
1158
53
123
4.67
21.59
1.6
1.7
—
—
—
0
0
436
3223
2.94
21.30
8.0
4.2
15.98
12.40
mm/h
3.87
416
2962
201
1058
2.44
20.76
3.1
2.4
4.41
4.55
e6/l
0.04
184
960
347
2328
2.41
20.36
16.7
18.4
1.26
1.36
inr
2.71
301
1959
75
235
3.55
20.27
2.0
1.7
1.59
1.55
g/l
0.14
62
210
28
12
24.54
20.15
3.7
1.1
—
—
—
0
0
28
12
24.54
20.15
3.7
1.1
—
—
—
0
0
28
12
24.54
20.15
3.7
1.2
—
—
—
0
0
79
257
3.43
20.15
1.6
1.4
—
—
—
0
0
127
552
2.71
19.43
4.9
3.0
1.89
2.03
mmol/l
0.18
112
476
272
1672
2.28
19.23
5.1
3.7
85.79
119.23
e6/l
0.40
220
1189
92
339
3.07
19.07
10.0
3.5
1.23
1.22
mmol/l
0.97
87
283
29
17
17.96
18.91
3.7
1.1
—
—
—
0
0
29
17
17.96
18.91
3.7
1.1
—
—
—
0
0
29
17
17.96
18.91
3.7
1.1
—
—
—
0
0
29
17
17.96
18.91
3.7
1.1
—
—
—
0
0
24
9
27.83
17.96
3.9
1.2
27.16
22.59
u/l
—
24
9
390
2840
2.39
17.69
6.5
4.5
2.25
2496.77
e6/l
—
8
52
382
2772
2.33
17.23
9.4
4.7
6.54
6.85
mmol/l
3.07
375
2641
25
13
20.11
17.02
1.4
1.0
—
—
—
0
0
51
141
3.89
16.48
2.0
1.3
2.81
1.41
ratio
1.36
23
85
54
158
3.69
16.09
2.1
1.3
30.42
36.57
mg/l
0.58
43
136
53
158
3.61
15.35
2.1
1.3
56.72
50.46
mg/l
0.26
44
135
36
82
4.64
14.95
3.1
2.1
232.48
73.56
u/ml
0.32
31
65
135
676
2.34
14.89
3.0
2.6
25.77
23.11
%
0.78
129
627
26
45
6.02
14.59
3.2
2.3
—
—
—
0
0
54
169
3.44
14.52
2.9
1.3
0.76
0.24
g/l
0.74
45
150
141
728
2.27
14.43
3.0
2.6
2.06
2.23
g/l
3.27
133
669
40
107
3.96
13.51
2.6
1.2
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
50
157
3.41
13.37
2.8
2.4
0.45
0.37
iu/ml
0.62
29
90
204
1255
2.01
13.02
2.3
2.3
2.99
2.74
mg/l
0.92
178
1062
28
60
4.87
12.49
1.1
1.2
85.60
169.65
miu/ml
—
5
20
50
166
3.22
12.23
1.7
2.1
39.38
38.13
u/l
0.15
45
141
16
6
27.42
12.11
2.1
1.0
—
—
—
0
0
44
136
3.44
12.05
2.8
1.3
0.00
0.00
g/l
-0.00
39
124
76
321
2.60
11.98
2.4
1.6
—
—
—
0
0
21
18
12.09
11.91
1.2
1.1
—
—
—
0
0
312
2266
1.91
11.78
4.6
3.8
0.00
0.00
estimate
-0.00
88
467
144
810
2.07
11.55
3.6
2.8
1.01
1.03
e6/l
0.03
79
431
100
489
2.29
11.42
5.9
3.4
—
—
—
0
0
314
2304
1.88
11.28
4.7
3.8
0.00
0.00
estimate
-0.00
91
475
313
2310
1.86
10.88
4.8
3.8
0.00
0.01
estimate
0.65
87
446
132
744
2.03
10.41
3.8
3.0
1.11
1.52
e6/l
0.51
66
361
21
41
5.29
10.39
3.5
1.2
—
—
—
0
0
21
42
5.16
10.12
3.5
1.2
—
—
—
0
0
21
42
5.16
10.12
3.5
1.2
—
—
—
0
0
248
1737
1.80
9.91
3.6
3.3
1478.28
1637.25
ng/l
0.34
231
1507
17
14
12.50
9.91
3.0
1.2
—
—
—
0
0
17
14
12.50
9.91
3.0
1.2
—
—
—
0
0
81
384
2.31
9.88
2.0
1.7
393.54
366.95
nmol/l
0.57
76
348
209
1401
1.81
9.60
2.8
2.3
59.30
61.61
u/l
0.12
198
1299
18
18
10.31
9.58
1.7
1.6
—
—
—
0
0
18
18
10.31
9.58
2.9
1.2
—
—
—
0
0
18
18
10.31
9.58
2.9
1.2
—
—
—
0
0
18
18
10.31
9.58
1.7
1.6
—
—
—
0
0
9
0
+∞
9.40
1.8
0.0
—
—
—
0
0
33
100
3.45
9.32
1.3
1.3
240.17
305.98
ug/g
0.80
18
62
262
1895
1.75
9.14
3.8
3.0
376.79
145.60
ug/l
8.19
243
1745
21
46
4.71
9.13
3.6
1.2
—
—
—
0
0
21
46
4.71
9.13
3.6
1.2
—
—
—
0
0
21
46
4.71
9.13
3.6
1.2
—
—
—
0
0
66
300
2.37
8.84
4.9
3.6
2.09
2.22
mmol/l
0.11
61
219
32
99
3.37
8.76
1.4
1.3
—
—
—
0
0
278
2061
1.73
8.75
3.2
2.4
—
—
—
0
0
192
1291
1.76
8.50
5.0
3.8
0.00
0.01
estimate
0.50
78
425
73
355
2.22
8.35
4.9
3.7
4.94
5.20
kpa
2.33
73
340
13
9
14.76
8.24
1.1
1.0
—
—
—
0
0
13
9
14.76
8.24
1.2
1.2
—
—
—
0
0
34
114
3.12
8.19
1.5
1.1
—
—
—
0
0
34
114
3.12
8.19
1.5
1.1
—
—
—
0
0
145
927
1.78
7.49
2.1
1.6
2.51
1.40
mg/l
0.82
129
721
46
191
2.54
7.48
4.6
1.6
—
—
—
0
0
29
95
3.17
7.27
1.5
1.3
—
—
—
0
0
29
95
3.17
7.27
1.5
1.3
—
—
—
0
0
106
623
1.88
7.18
10.1
6.6
1.14
1.03
mmol/l
0.09
86
509
72
375
2.06
6.90
2.0
2.0
0.19
0.20
g/l
0.15
66
340
14
17
8.42
6.86
1.1
1.4
—
—
—
0
0
18
45
4.10
6.67
1.2
1.7
27.20
23.44
u/ml
—
5
9
192
1372
1.62
6.39
6.9
2.7
40.11
37.92
u/l
0.15
186
1287
15
23
6.68
6.37
2.1
6.6
—
34.17
—
0
6
13
16
8.30
6.36
3.0
2.1
19.72
3.98
nmol/l
0.43
13
16
70
372
2.02
6.34
3.0
2.1
35.92
35.90
u/l
0.00
53
296
37
153
2.52
6.09
1.5
1.2
—
—
—
0
0
14
21
6.81
6.07
5.4
1.4
—
—
—
0
0
229
1724
1.58
6.04
4.7
3.8
0.00
0.01
estimate
0.78
76
375
31
118
2.73
6.01
1.4
1.5
0.09
0.19
iu/ml
—
9
24
65
345
2.01
5.91
3.0
2.5
59.88
61.51
ml/min/173m2
0.13
26
145
40
176
2.38
5.78
2.7
1.5
—
—
—
0
0
54
272
2.10
5.65
4.0
2.8
25.29
25.23
mmol/l
0.06
54
264
463
4159
1.86
5.60
52.9
15.6
23.68
27.17
mg/l
2.11
448
3414
254
1988
1.53
5.47
4.6
4.3
31.98
92.63
ng/l
1.25
223
1568
16
43
3.81
5.40
1.3
1.2
—
—
—
0
0
17
48
3.63
5.36
1.6
1.3
42215.83
171495.23
e6/l
0.53
12
30
5
0
+∞
5.21
1.2
0.0
—
—
—
0
0
27
104
2.68
5.14
1.8
1.7
—
—
—
0
0
12
19
6.43
5.10
1.7
3.0
1276.42
1344.05
u/ml
0.03
12
19
27
109
2.56
4.70
1.1
1.7
—
—
—
0
0
64
366
1.85
4.68
4.0
2.7
116.92
131.29
g/l
4.05
64
357
75
453
1.76
4.58
1.4
1.4
—
—
—
0
0
17
54
3.22
4.52
1.3
2.0
90.55
89.58
%
0.41
17
54
143
1022
1.55
4.51
3.6
4.3
118.66
351.34
ng/l
2.70
127
879
21
78
2.76
4.30
1.2
1.3
—
—
—
0
0
239
1921
1.44
4.14
2.4
2.4
80.15
78.04
nmol/l
0.51
223
1677
16
52
3.14
4.11
3.1
4.2
—
—
—
0
0
21
80
2.69
4.11
1.1
1.1
—
4.06
—
0
10
14
42
3.40
4.07
1.1
1.1
—
1.16
—
0
5
55
314
1.84
4.05
11.4
8.2
24.41
24.13
mmol/l
0.28
55
307
159
1204
1.46
3.70
4.4
3.3
0.03
0.00
estimate
0.49
69
359
11
25
4.47
3.64
1.2
1.0
—
—
—
0
0
6
6
10.09
3.50
1.2
1.2
—
—
—
0
0
13
42
3.15
3.39
1.0
1.2
—
17.00
—
0
12
9
18
5.07
3.38
3.6
4.3
—
—
—
0
0
145
1853
0.70
3.27
2.2
2.0
1.39
1.32
mmol/l
0.51
116
1523
379
4143
0.71
3.20
6.4
7.4
39.92
40.44
mmol/mol
0.57
350
3846
7
11
6.43
3.19
3.3
1.2
144.71
76.45
nmol/l
—
7
11
13
41
3.22
3.07
1.3
1.6
—
475.00
—
0
6
13
41
3.22
3.07
2.5
1.6
2952.84
95.08
u/ml
0.45
13
41
8
16
5.06
3.06
1.0
1.0
753.50
1939.62
miu/ml
—
8
16
308
2676
1.36
3.00
4.2
3.2
66.42
51.10
u/l
1.49
290
2481
7
14
5.05
2.73
13.3
3.6
11.07
10.13
kpa
—
7
14
7
14
5.05
2.73
13.3
3.6
4.96
5.43
kpa
—
7
14
6
10
6.05
2.70
1.0
1.0
—
—
—
0
0
10
30
3.38
2.61
1.0
1.7
1.00
13249.64
u/l
—
5
7
9
25
3.64
2.58
1.2
1.0
—
—
—
0
0
43
265
1.68
2.50
1.3
1.3
657.90
271.39
u/ml
0.39
38
246
15
63
2.42
2.48
3.9
2.4
1.20
1.19
mmol/l
0.34
15
63
6
12
5.04
2.41
1.0
1.0
—
—
—
0
0
8
22
3.68
2.37
1.7
1.4
—
—
—
0
0
15
65
2.35
2.33
3.9
2.4
105.73
105.25
mmol/l
0.16
15
65
15
65
2.35
2.33
3.9
2.4
4.18
4.14
mmol/l
0.20
15
65
152
1839
0.76
2.20
4.3
4.2
24.48
8.11
mg/mmol
0.53
91
1201
23
122
1.93
2.19
4.3
3.1
7.14
7.40
mmol/l
0.24
23
117
8
24
3.37
2.18
1.0
1.1
—
—
—
0
0
402
4288
0.75
2.17
5.4
6.5
2.59
2.53
mmol/l
0.59
358
3938
9
30
3.03
2.15
1.0
1.0
—
—
—
0
0
435
4074
1.37
2.10
44.6
15.3
74.88
74.64
ml/min/173m2
0.09
422
3784
121
956
1.34
2.09
1.8
1.8
1359.75
1153.59
nmol/l
1.31
94
738
153
1838
0.76
2.08
3.4
3.4
6.39
7.87
mmol/l
5.52
128
1549
19
96
2.02
2.08
2.2
2.4
254.37
195.04
%
1.34
19
89
7
20
3.53
2.06
3.9
2.2
0.86
1.05
index
—
7
20
7
20
3.53
2.06
1.0
1.1
—
—
—
0
0
466
4422
1.43
2.00
49.7
19.9
139.28
139.76
mmol/l
3.62
461
4337
7
21
3.36
1.97
2.7
1.6
0.22
0.26
nmol/l
—
7
14
390
4159
0.77
1.92
4.6
5.5
1.32
1.40
mmol/l
3.61
350
3808
466
4430
1.41
1.90
50.4
20.0
4.03
4.02
mmol/l
0.16
461
4339
6
17
3.56
1.84
1.0
1.3
—
—
—
0
0
182
1548
1.27
1.80
2.0
1.7
18.48
19.97
nmol/l
0.76
168
1297
395
4195
0.77
1.78
4.8
5.6
4.40
4.39
mmol/l
0.08
360
3867
5
13
3.87
1.72
1.0
1.1
—
15.42
—
0
6
5
13
3.87
1.72
1.0
1.1
—
—
—
0
0
74
562
1.37
1.66
13.4
7.4
—
—
—
0
0
105
845
1.30
1.60
1.2
1.3
0.90
1.54
u/ml
0.90
23
230
50
357
1.44
1.59
4.3
4.0
92.83
98.46
ng/l
0.13
39
308
8
33
2.45
1.54
1.3
1.2
9.87
10.61
u/l
—
8
28
22
136
1.64
1.34
2.4
2.4
115.45
133.39
g/l
4.55
22
112
43
583
0.71
1.31
4.7
5.5
31.66
31.97
%
0.07
35
374
25
161
1.58
1.31
1.0
1.0
—
—
—
0
0
378
3991
0.82
1.29
4.2
4.7
1.32
1.28
mmol/l
0.36
340
3623
254
2307
1.19
1.24
2.2
2.2
91.36
94.40
pmol/l
0.47
155
1212
13
71
1.85
1.20
4.4
1.6
15.74
28.61
u/ml
0.48
13
71
19
117
1.65
1.19
3.9
3.2
2.82
1.68
index
0.53
11
63
6
26
2.32
1.19
1.3
1.4
262.50
260.10
mu/l
—
6
21
130
1115
1.22
1.16
1.7
1.8
474.22
27223254.65
pmol/l
0.97
109
911
67
533
1.29
1.14
1.9
2.6
6.50
7.58
ug/l
0.20
61
471
27
184
1.49
1.13
1.1
1.2
58.57
126.94
u/ml
—
9
67
467
4511
1.28
1.12
58.2
21.0
89.27
85.24
umol/l
0.98
462
4450
7
32
2.20
1.08
1.0
1.2
138.29
98.59
pmol/l
—
7
32
7
34
2.07
1.03
1.4
1.2
90.57
37.30
u/l
—
7
27
14
220
0.63
0.94
1.6
1.9
3.19
3.44
mmol/l
—
9
175
336
3170
1.16
0.92
4.4
3.8
15.03
14.96
pmol/l
0.17
311
2842
11
63
1.76
0.90
1.6
1.4
—
—
—
0
0
176
1592
1.16
0.84
2.3
2.2
153.22
295.53
u/l
1.88
169
1492
53
650
0.80
0.84
1.4
1.3
27.56
11.36
u/ml
0.41
24
230
8
48
1.68
0.79
4.8
1.8
1511.50
1205.40
mg
—
8
48
119
1053
1.17
0.76
5.3
4.1
1.02
1.02
kg/l
1.01
81
699
16
109
1.48
0.71
1.3
1.2
—
—
—
0
0
7
40
1.76
0.71
1.1
1.1
—
295.00
—
0
6
467
4560
1.19
0.66
70.0
23.4
194.56
236.04
e9/l
30.96
461
4450
467
4562
1.19
0.65
69.9
23.4
4.05
4.49
e12/l
43.81
459
4430
467
4562
1.19
0.65
71.1
23.9
36.86
40.54
%
38.27
462
4494
0
20
0.00
0.60
0.0
1.1
—
—
—
0
0
5
86
0.58
0.56
1.2
1.3
1.39
1.48
g/l
—
5
86
9
60
1.51
0.54
1.3
1.4
—
—
—
0
0
5
31
1.62
0.43
1.0
1.2
—
—
—
0
0
382
3920
0.91
0.42
5.6
4.8
2.14
2.00
mu/l
1.05
357
3554
6
93
0.64
0.42
1.8
1.3
0.94
0.91
g/l
—
6
93
5
33
1.52
0.41
1.2
1.8
19.40
15.61
umol/l
—
5
28
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
0
16
0.00
0.41
0.0
1.1
—
—
—
0
0
0
18
0.00
0.40
0.0
1.1
—
226.89
—
0
18
413
4214
0.91
0.37
5.5
5.6
5.92
6.13
mmol/l
3.54
377
3816
14
108
1.30
0.35
2.6
2.9
35.57
37.11
umol/l
0.10
14
96
22
181
1.22
0.35
1.5
1.9
—
—
—
0
0
65
709
0.91
0.29
1.5
1.3
29.30
39.28
iu/ml
0.49
20
203
189
1967
0.94
0.27
5.2
4.0
21.17
24.07
%
2.38
106
948
11
138
0.79
0.26
1.2
1.3
—
—
—
0
0
5
39
1.28
0.23
1.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
7.5
—
10.35
—
0
11
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
8
101
0.79
0.21
1.9
1.5
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
6.6
—
5.94
—
0
13
32
292
1.10
0.16
2.0
1.4
—
—
—
0
0
145
1402
1.05
0.16
3.3
2.9
0.74
0.74
ug/l
0.01
101
954
15
130
1.16
0.16
2.7
3.3
0.86
0.83
nmol/l
—
8
106
18
159
1.14
0.15
1.6
1.9
—
—
—
0
0
5
47
1.06
0.09
1.2
1.2
—
70.29
—
0
7
5
61
0.82
0.08
1.0
1.4
—
—
—
0
0
5
63
0.79
0.08
1.2
1.1
—
11.50
—
0
10
7
66
1.06
0.08
1.3
2.2
—
—
—
0
0
241
2432
0.98
0.05
5.7
4.3
3.13
2.04
ug/l
0.60
218
2179
18
170
1.06
0.04
2.3
2.1
45.83
43.00
nmol/l
0.21
18
161
46
450
1.02
0.02
1.8
1.8
1.68
1.60
%
0.21
40
380
37
363
1.02
0.01
1.5
1.5
—
—
—
0
0
6
65
0.92
-0.00
1.2
1.3
0.62
28.98
nmol/l
—
6
60
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
25.98
—
0
5
0
7
0.00
-0.00
0.0
1.0
—
0.19
—
0
7
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
6
63
0.95
-0.00
1.0
1.0
1.65
1.55
g/l
—
6
56
0
7
0.00
-0.00
0.0
1.3
—
8.30
—
0
7
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded (different definition than used in FinnGen).
Relationships between endpoints
↥Index endpoint: C3_MANTLE_CELL_LYMPHOMA_WIDE – Mantle cell lymphoma, including Hilmo
GWS hits: 1
This endpoint is excluded (different definition than used in FinnGen).